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Amino	  Acids:	  Progress	  toward	  “Fauxteins”	  
	  Matthew	  F.	  L.	  Parker,	  PhD	  University	  of	  Pittsburgh,	  2015	  	  	  Proteins	   are	   in	   a	   category	   all	   their	   own	   as	   supramolecular	   entities	   enriched	   with	   both	  chirality	   and	   functionality.	   	   Inspired	   by	   them,	   we	   have	   created	   a	   new	   class	   of	   building	  blocks,	   called	   Bis-­‐Amino	   Acids,	   for	   making	   molecules	   several	   kilodaltons	   in	   size	   that	  possess	  high	  degrees	  of	  both	  functionality	  and	  chirality.	  	  Bis-­‐amino	  acids	  can	  assemble	  into	  shape-­‐programmable	  macromolecules,	  called	  Spiroligomers	  that	  connect	   through	  pairs	  of	  amide	  bonds.	  	  They	  serve	  as	  water-­‐soluble,	  rigid	  scaffolds	  capable	  of	  presenting	  collections	  of	  functional	  groups	  in	  different	  spatial	  orientations	  by	  virtue	  of	  their	  sequence,	  shape	  and	  stereochemistry	  of	  each	  chiral	  building	  block.	  This	  dissertation	  utilizes	  these	  unique	  building	  block	  as	  scaffolding	  for	  the	  presentation	  of	  functional	  groups	  in	  localized	  domains.	  	  A	  short	  spiroligomer	  sequence	  is	  used	  to	  presents	  a	  donor	  and	  acceptor	  pair	  facially	  for	  measuring	  electron-­‐transfer	  in	  water.	  	  The	  same	  cleft	  motif	  is	  used	  to	  present	  a	  pair	  of	  hydrogen	  bonding	  donors	  to	  catalyze	  an	  aromatic	  Claisen	  rearrangement.	  	  Methods	  are	  developed	  to	  improve	  and	  expand	  the	  chemistry	  to	  make	  the	  bis-­‐amino	   acids	   as	   well	   as	   their	   assembly	   into	   spiroligomers.	   	   Lastly,	   spiroligomers	   are	  utilized	  as	  intermediate	  building	  materials	  forming	  sequences	  of	  two	  and	  three	  connected	  by	   short,	   flexible	   linkers	   and	   cross-­‐linked	   them	   into	   assemblies.	   	  We	   envision	   the	   use	   of	  these	  macromolecules,	  called	  “Fauxteins”	  to	  position	  multiple	  functional	  groups	  over	  large	  surface	  areas	  for	  mimicry	  of	  protein-­‐protein	  interactions,	  recreation	  of	  complex	  active	  sites	  of	  enzymes,	  and	  form	  unique,	  chiral	  pockets	  for	  host-­‐guest	  molecular	  recognition.	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1.0	  Introduction	  






























































	  Figure	  1-­‐1.	  	  2D	  structures	  of	  α-­‐helix	  (A)	  and	  two	  methods	  of	  α-­‐helix	  stabilization:	  	  stapled	  peptides	  (B)	  and	  hydrogen	  bonding	  surrogates	  (C).	  	   Several	   research	   efforts	   are	   concerned	   with	   emulating	   the	   functional	   group	  organizing	   capabilities	   and	   functions	   of	   proteins.	   	   Such	   efforts	   include	   stabilization	   of	  peptides	  via	  stapled	  peptides	  and	  hydrogen	  bonding	  surrogates,	  shown	  in	  Figure	  1-­‐1.	  [4,5]	  Both	   of	   these	   examples	   utilize	   alkene-­‐derived	   peptide	   sequences	   and	   olefin	  methasis	   to	  
	  2	  

















































	  Figure	  1-­‐2.	  	  2D	  structures	  of	  small	  peptides	  used	  as	  asymmetric	  catalysts.	  	  (A)	  and	  (B)	  are	  acylation	  catalysts.	  	  (C)	  is	  an	  epoxidation	  catalyst.	  (D)	  is	  an	  aldol	  catalyst.	  	  Alternatively,	   the	  use	  of	   smaller	  peptide	   scaffolds	  have	  been	   invoked	   to	  direct	   the	  presentation	  of	  chemical	  reactive	   functional	  groups,	  hydrogen	  bonding	  groups,	  and	  steric	  bias	   to	  effect	  asymmetric	   catalysis.	   [6-­‐8]	  Figure	  1-­‐2	   illustrates	   some	  examples	  of	  peptide	  ranging	  in	  size	  from	  three	  to	  eight	  residues	  that	  have	  demonstrated	  to	  successfully	  perform	  asymmetric	   acylation	   reactions	   (Figure	   1-­‐2A	   and	   B),	   asymmetric	   epoxidation	   reactions	  (Figure	  1-­‐2C)	  and	  asymmetric	  aldol	  reactions	  (Figure	  1-­‐2D)	  as	  just	  a	  few	  examples.	  	  Based	  on	  these	  catalysts	  ability	  to	  demonstrate	  asymmetric	  induction,	  it	  is	  reasonable	  to	  suggest	  that	  a	  strong	  conformational	  preference	  exists.	  	  However,	  non-­‐polar	  solvents	  and,	  in	  some	  cases,	   subzero	   temperatures	   are	   required	   in	   order	   to	   achieve	   and	   stabilize	   the	  conformation	  necessary	  to	  provide	  asymmetric	  induction.	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  Figure	  1-­‐3.	  	  2-­‐D	  structures	  of	  general	  representations	  of	  various	  foldamers.	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1.2	  Spiroligomers	  Spiroligomers	   offer	   a	   dramatic	   departure	   from	   these	   protein-­‐inspired	   research	  directions.	  [19]	  The	  key	  element	  that	  separates	  spiroligomers	  from	  everything	  else	  is	  that	  spiroligomers	  are	  connected	  through	  pairs	  of	  amide	  bonds,	  as	  their	  name	  entails,	  providing	  a	  more	  conformationally	  restricting,	  polycyclic	  backbone.	   	  The	  shape	  and	  presentation	  of	  functional	  groups	  are	  not	  formed	  via	  folding	  and	  stabilized	  by	  noncovalent	  interactions,	  but	  instead	  are	  a	   result	  of	   the	  monomer	  structure,	   connectivity	  and	   the	   rich	   stereochemistry	  installed	   in	   each	  building	   block.	   	   Figure	   1-­‐4	   shows	   the	   general	   concept	   of	   spiroligomers.	  	  There	  are	  4	  monomer	  classes	  synthesized	  to	  date:	  	  Pro4	  class,	  Pip4	  class,	  Pip5	  class	  and	  the	  Hin	  class	  (shown	  in	  Figure	  1-­‐4).	  	  The	  Pro4	  class	  is	  most	  developed	  so	  only	  its	  synthesis	  will	  be	  discussed	  in	  detail.	  
	  	  Figure	   1-­‐4.	   	   General	   concepts	   of	   spiroligomers	   including	   example	   of	   monomer	   and	  previously	  synthesized	  oligomers.	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Each	  member	  of	  the	  Pro4	  monomer	  class	  has	  two	  stereocenters	  and	  thus	  the	  Pro4	  class	   contains	   four	  stereoisomers.	   	  All	   four	   stereoisomers	  have	  been	  synthesized	   from	  4-­‐trans-­‐hydroxyproline	   (compound	  5)	   as	   shown	   in	   Scheme	  1-­‐1.	   	   Compound	  5	   is	   protected	  with	  a	  benzyl	  carbamate	  using	  Cbz-­‐Cl	  and	  NaHCO3	  in	  1:10	  dioxane/water	  mixture.	  	  The	  C-­‐4	  hydroxyl	  group	  is	  then	  oxidized	  to	  the	  corresponding	  ketone	  with	  Jones	  reagent	  in	  AcMe.	  	  The	   C-­‐2	   carboxylic	   acid	   is	   then	   converted	   to	   the	   tert-­‐butyl	   ester	   with	   isobutylene	   and	  catalytic	  H2SO4	   in	  DCM	   to	   yield	   compound	  6.	   	   Compound	  6	   is	   subjected	   to	   the	  Bucherer	  Berg’s	  reaction	  using	  KCN,	  (NH4)2CO3	  in	  1:1	  EtOH/water	  mixture	  to	  convert	  the	  ketone	  to	  a	  5:1	   diastereomeric	  mixture	   of	   hydantoins	   (compounds	  7a	   and	  7b).	   	   The	   hydantoins	   are	  separated	  with	  column	  chromatography.	  	  	  
	  Scheme	  1-­‐1.	  	  Synthesis	  of	  Pro4	  class	  of	  monomers.	  	  (a)	  NaHCO3,	  Cbz-­‐Cl,	  1:10	  Diox/	  H2O;	  (b)	  Jones	  reagent,	  AcMe;	  (c)	  isobutylene,	  H2SO4	  (cat.),	  DCM;	  (d)	  (NH4)2CO3,	  KCN,	  1:1	  EtOH/H2O;	  (e)	  i.	  (Boc)2O,	  DMAP,	  THF	  ;	  ii.	  2	  M	  KOH;	  (f)	  Fmoc-­‐OSu,	  DIPEA,	  DCM;	  (g)	  MeOH,	  DIC,	  DMAP,	  DCM,	  0	  °C	  to	  rt;	  (h)	  1:2	  TFA/DCM;	  (j)	  H2,	  10%	  Pd/C,	  (Boc)2O,	  THF	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Each	  pure	  stereoisomer	   is	  converted	   to	   its	  amino	  acid	   form	  via	  base	  hydrolysis	   in	  two	   steps.	   	   First	   the	   hydantoin	   imide	   and	   amide	   are	   converted	   to	   tert-­‐butyl	   carbamates	  using	   Boc2O	   and	   catalytic	   DMAP	   in	   THF	   followed	   by	   base	   hydrolysis	   of	   the	   bis-­‐Boc	  hydantoin	  via	  addition	  of	  2M	  KOH	  (aq).	   	  The	  amino	  acid	   is	  recovered	  after	  neutralization	  and	  precipitation	  of	  the	  basic	  aqueous	  solution	  to	  provide	  compounds	  8	  and	  9	  from	  7a	  and	  
7b,	  respectively.	  	  Compound	  8	  is	  protected	  with	  a	  fluorenylmethyl	  carbamate	  using	  Fmoc-­‐OSu	  and	  DIPEA	   in	  DCM	  and	  esterified	  with	  MeOH,	  DIC,	  and	  catalytic	  DMAP	   in	  DCM.	   	  The	  tert-­‐butyl	  ester	   is	  cleaved	  using	  1:2	  TFA/DCM	  mixture	  and	  the	  benzyl	  carbamate	  (Cbz)	   is	  converted	   to	   a	   tert-­‐butyl	   carbamate	   (Boc)	   using	   Boc2O	   and	   Pd/C	   in	   THF	   under	   a	   H2	  atmosphere	  to	  yield	  compound	  1.	  	  Similar,	  Compound	  9	  is	  converted	  to	  compound	  2.	  The	   other	   two	   stereoisomers	   of	   Pro4	   are	   synthesized	   from	   4-­‐cis-­‐hydroxyproline	  (compound	  10),	   which	   is	   obtained	   from	   epimerization	   of	   compound	  5	   in	   three	   steps	   as	  shown	   in	  Scheme	  1-­‐2.	   	  Compound	  5	   is	   refluxed	   in	  a	  2:1	  Ac2O/AcOH	  mixture	   followed	  by	  reflux	  in	  2M	  HCl	  (aq).	  	  Compound	  10	  is	  isolated	  via	  freebasing	  with	  TEA	  and	  recrystallized	  from	  EtOH/water.	  	  Compound	  10	  is	  then	  converted	  to	  compounds	  3	  and	  4	  using	  the	  same	  protocols	  described	  for	  compounds	  1	  and	  2.	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  Scheme	  1-­‐2.	  	  Synthesis	  of	  Pro4	  class	  of	  monomers.	  	  (a)	  Ac2O,	  AcOH,	  reflux;	  (b)	  2	  M	  HCl	  (aq),	  reflux;	  (c)	  (i)	  free	  base	  with	  TEA;	  (ii)	  recryst.	  from	  EtOH/H2O.	  	  Compounds	  1-­‐4	   are	  now	  able	   to	  be	   assembled	   into	  oligomers	  using	   solid	   support	  and	  are	  designed	  to	  be	  amenable	  touse	  in	  Fmoc	  solid	  phase	  synthesis.	  	  Scheme	  1-­‐3	  shows	  the	   overall	   strategy	   for	   oligomer	   assembly	   and	   rigidification.	   	   Each	   building	   block	   is	  attached	  through	  a	  single	  amide	  bond	  with	  the	  C-­‐2	  carboxylic	  acid	  and	  the	  C-­‐4	  amino	  group	  after	  the	  Fmoc	  is	  cleaved.	  	  Once	  the	  oligomer	  is	  assembled,	  the	  remaining	  protecting	  groups	  are	  cleaved	  and	  the	  oligomer	  is	  liberated	  from	  the	  solid	  support.	  	  The	  oligomer	  	  is	  then	  rigidified	  via	  a	  methanolysis	  reaction	  in	  which	  each	  available	  amine	  forms	  an	  amide	  bond	   with	   the	   C-­‐4	   carboxy	   methyl	   ester	   of	   the	   proceeding	   building	   block	   to	   yield	   a	  diketopiperazine	  (DKP)	  ring.	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  Scheme	  1-­‐3.	  	  Solid	  phase	  oligomers	  assembly	  and	  rigidification.	  	  Many	  examples	  of	   these	  oligomers	  have	  been	  synthesized	  and	  characterized	  using	  multiple	  building	  blocks	   to	  create	  unique	  shapes	  and	  different	   techniques	  to	  characterize	  these	   structures.	   Among	   these	   techniques	   are	   multi-­‐dimensional	   NMR,	   Fluorescence	  Resonance	   Energy	   Transfer	   (FRET),	   and	   double	   electron-­‐electron	   resonance	   (DEER).	   All	  have	   contributed	   to	   our	   growing	   knowledge	   of	   the	   global	   structure	   and	   conformational	  preferences	  of	  the	  spiroligomers.	  [19]	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2.0	  Spiroligomer	  Donor-­‐Bridge-­‐Acceptor	  (DBA)	  Molecular	  Scaffolds	  for	  Probing	  
Electron	  Transfer	  Processes	  	  	  	  Chapter	  2	  details	  our	  use	  of	  bis-­‐amino	  acids	  for	  presenting	  a	  dimethylaniline	  donor	  and	  pyrene	   acceptor	  moiety	   that	   is	  water-­‐soluble	   for	   probing	   electron-­‐transfer	   in	  water.	  	  Highlights	  of	  this	  work	  are	  the	  first	  electron	  transfer	  measurements	  performed	  in	  water	  at	  ambient	   conditions.	   	   A	   3-­‐fold	   rate	   enhancement	   was	   observed	   for	   the	   cleft	   forming	  molecule	   in	   water.	   	   This	   interesting	   finding	   has	   resulted	   in	   the	   synthesis	   of	   additional	  molecules	  with	  the	  intent	  to	  further	  probe	  this	  electron-­‐transfer	  process.	  	  	   	  	  	  	  	   	  	  A	  portion	  of	  this	  work	  was	  published	  in:	  
J.	  Am.	  Chem.	  Soc.,	  2009,	  131	  (6),	  pp	  2044–2045	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2.1	  Introduction	  	   Organic	   Scaffolds,	   peptides,	   and	   oligomers	   continue	   to	   play	   an	   important	   role	   for	  understanding	   how	   positioning	   of	   chemical	   functionalities	   in	   space	   control	   chemical	  reactivity	   and	  how	   functional	   groups	   communicate	   through	  energy	  and	  electron	   transfer	  processes.	   [1-­‐5]	   Figure	   2-­‐1	   illustrates	   a	   few	   examples	   of	   Donor-­‐Bridge-­‐Acceptor	   (DBA)	  molecular	   scaffolds	   used	   to	   probe	   energy	   and	   electron	   transfer	   processes.	   	   Figure	   2-­‐1A	  shows	   a	   bis-­‐steroid	   DBA	   scaffold	   that	   was	   used	   to	   test	   the	   distance	   dependence	   of	  coulombic	   energy	   transfer.	   [1]	   The	   fused	   poly-­‐ring	   system	   provided	   a	   rigid	   backbone	   to	  position	   an	   anthracyl	   (energy	   donor)	   and	   a	   naphthyl	   (energy	   acceptor)	   groups	  approximately	  20	  Å	  apart.	  	  Figure	  2-­‐1B	  shows	  an	  example	  of	  probing	  distance	  dependence	  of	  singlet-­‐singlet	  energy	  transfer	  by	  the	  Förster	  mechanism	  using	  a	  series	  of	  poly-­‐proline	  peptides	   of	   varying	   length.	   [2]	   Poly-­‐prolines	   adopt	   a	   PPII	   helix,	  which	   is	   relatively	  more	  rigid	  than	  other	  polypeptides.	  	  Furthermore,	  the	  PPII	  helices	  containing	  different	  numbers	  of	  prolines	  act	  as	  a	  series	  of	  molecular	  rulers,	  which	  separate	  the	  naphthyl	  (energy	  donor)	  and	   a	   dansyl	   (energy	   acceptor)	   groups	   and	   enabled	   the	   observation	   of	   the	   relationship	  between	  intergroup	  distance	  and	  the	  efficiency	  of	  energy	  transfer	  between	  groups.	  	  Figure	  2-­‐1C	   shows	   an	   example	   of	   a	   poly-­‐norborane	   DBA	   scaffold	   that	   was	   used	   to	   investigate	  solvent-­‐mediated	   electronic	   coupling	   and	   electron	   transfer	   processes.	   [3-­‐5]	   The	   cis-­‐conformations	  of	  the	  norborane	  ring	  systems	  provide	  an	  inherent	  curvature	  in	  the	  scaffold,	  ultimately	   forming	   a	   cleft	   between	   and	   providing	   facial	   presentation	   of	   the	   anthracyl	  (electron	  donor)	  and	  the	  maleate	  (electron	  acceptor).	  	  These	   three	   examples	   of	   organic	   scaffolds	   represent	   two	   extremes	   of	   organic	  scaffolding	   and	   both	   offer	   benefits	   as	   well	   as	   restrictions.	   	   The	   bis-­‐steroid	   and	   poly-­‐
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RDA~6.9Å 	  Figure	   2-­‐1.	   	   Examples	   of	   organic	   scaffold	   possessing	   donor	   and	   acceptor	   moieties	   to	  measure	  energy	  transfer.	  	  (A)	  shows	  a	  bis-­‐steroid	  bridge	  for	  energy	  transfer.	  	  (B)	  shows	  a	  poly-­‐proline	  bridge	  used	  for	  energy	  transfer.	  	  (C)	  shows	  a	  poly-­‐norborane	  bridge	  used	  for	  electron	  transfer.	  	  
	  13	  
The	  importance	  of	  water	  in	  determining	  the	  activation	  energy	  for	  election	  transfer	  (ET)	   reactions	   is	   well	   appreciated.	   	   Water	   molecules	   influence	   electron	   transport	   in	  biomolecules	  and	  play	  a	  key	  role	  in	  biologically	  vital	  processes	  in	  living	  cells.	  [6-­‐8]	  Recent	  theoretical	  work	  shows	  that	  placement	  of	  a	   few	  water	  molecules	  between	  electron	  donor	  and	  acceptor	  moieties	  can	  change	  the	  electronic	  tunneling	  probabilities	  between	  them.	  [9-­‐11]	   Prior	   to	   our	   work,	   there	   have	   only	   been	   studies	   that	   probed	   electron	   tunneling	   in	  frozen	  water.	  [12,13]	  We	  demonstrate	  the	  first	  example	  of	  water	  mediated	  ET	  in	  ambient	  aqueous	  conditions.	  	   Spiroligomers	  offer	  a	  unique	  scaffold	  that	  combines	  the	  benefits	  of	  preorganization,	  like	  the	  bis-­‐steroid	  and	  poly-­‐norborane,	  and	  the	  water	  solubility	  of	  poly-­‐proline.	  As	  shown	  in	  Chapter	  1,	  the	  structure	  and	  presentation	  of	  groups	  on	  sprioligomers	  are	  controlled	  by	  the	   stereochemistry	   and	   number	   of	   component	   monomers.	   	   This	   chapter	   describes	   the	  design	   and	   synthesis	   of	   spiroligomers	   containing	   a	   pyrene	   (electron	   acceptor)	   and	  dimethylaniline	   (electron	   donor)	   for	   studying	   the	   photoinduced	   ET	   rates	   through	  water.	  [14,15]	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2.2	  	  Results	  &	  Discussion	  We	   set	   out	   to	   develop	   a	   water-­‐soluble	   DBA	  molecule	   that	   we	   could	   use	   to	   study	  electron	  transfer	  in	  water.	  	  We	  developed	  a	  small	  spiroligomer	  that	  bears	  a	  cleft	  that	  holds	  a	   pyrene	   donor	   ~4.5	   Å	   away	   from	   a	   dimethylaniline	   acceptor.	   	   Previous	   studies	   with	  spiroligomers	  as	  molecular	  rulers	  have	  provided	  evidence	  that	  the	  separation	  between	  two	  functional	   groups	   on	   a	   bis-­‐amino	   acid	   monomer	   is	   ~	   5	   Å,	   therefore	   only	   a	   single	   Pro4	  monomer	  was	  used	  to	  present	  the	  donor	  and	  acceptor	  moieties.	  [16]	  	  The	   general	   design	   is	   shown	   in	   Figure	   2-­‐2.	   	   The	   dimethylaniline	   (DMA)	  chromophore	  is	  displayed	  on	  a	  diketopiperazine	  (DKP)	  ring	  with	  the	  C-­‐4	  quaternary	  amino	  acid	  of	   the	  Pro4	  monomer.	   	  The	  DMA	  chromophore	  can	  be	  synthetically	  accessed	   from	  a	  commercially	  available	  substituted	  phenylalanine	  derivative.	  	  Figure	  2-­‐2B	  and	  C	  shows	  3D	  and	  2D	  structures,	   respectively,	  of	   the	  DBA	  scaffold	  using	   the	  2S4S	  stereoisomer	  of	  Pro4	  (compound	   11).	   	   Although,	   the	   Spiroligomer	   DBA	   design	   possesses	   several	   degrees	   of	  freedom	  and	  can	  adopt	  several	  conformations,	  the	  Amber94	  minimumized	  structure	  of	  this	  DBA	   scaffold	   shows	   that	   D-­‐SSS-­‐A	   (11)	   can	   display	   a	   cleft	   (Figure	   2-­‐2B).	   	   As	   shown,	   the	  closed	  DKP	  and	  the	  stereochemistry	  of	  the	  C-­‐4	  of	  the	  Pro4	  monomer	  and	  the	  DMA	  amino	  acid	  orient	  the	  chromophore	  on	  the	  same	  face	  as	  the	  pyrrolidine	  nitrogen	  where	  the	  pyrene	  chromophore	   was	   installed	   via	   a	   carboxamide	   linkage	   using	   commercially	   available	  pyrene-­‐1-­‐carboxylic	   acid.	   	   Lastly,	   the	   C-­‐2	   carboxylic	   acid	  was	  modified	  with	   a	   lysine	   tri-­‐peptide	   to	   enhance	   the	  water-­‐solubility	   of	   the	   system.	   	  When	   the	   2R4R	   stereoisomer	   of	  Pro4	  was	  used	   (Figure	  2-­‐2D	  and	  E),	   the	  DMA	  chromophore	  orients	   to	   the	  C-­‐2	   carboxylic	  acid	  and	  no	  distinct	  cleft	   is	  observed	   in	   the	  Amber94	  minimized	  structure	  (Figure	  2-­‐2D).	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The	   DBA	   scaffold	   using	   the	   2R4R	   stereoisomer	   of	   Pro4	   was	   synthesized	   and	   used	   as	   a	  control	  molecule	  (compound	  12).	  	  
	  






























































require	  that	  three	  different	  sets	  of	  amines	  be	  orthogonally	  protected.	  	  All	  of	  the	  amino	  acids	  were	  Fmoc	  protected	  as	  well	  as	  the	  C-­‐4	  amino	  group	  on	  Pro4	  (highlighted	  green	  in	  Figure	  2-­‐2C	  and	  E).	  	  The	  epsilon	  amino	  groups	  on	  the	  lysines	  were	  Boc	  protected	  so	  that	  side	  chain	  deprotection	  would	  accompany	  liberation	  from	  the	  solid	  support	  (highlighted	  red	  in	  Figure	  2-­‐2C	   and	   E).	   	   The	   pyrrolidine	   amine	   on	   Pro4	   was	   protected	   with	   an	   allyl	   carbamate	  (highlighted	   blue	   in	   Figure	   2-­‐2C	   and	   E).	   	   The	   Alloc	   group	   was	   chosen	   because	   it	   is	  orthogonal	   to	   both	   Fmoc	   and	   Boc	   protecting	   groups	   and	   can	   be	   easy	   cleaved	   on	   solid	  support.	  




















































formaldehyde	   and	   Pd/C	   in	   THF/MeOH	   with	   H2.	   	   The	   Pro4	   monomer	   was	   modified	   via	  removal	  of	  the	  Boc	  group	  with	  TFA/DCM	  1:2	  followed	  by	  Alloc	  protection	  with	  the	  Alloc-­‐Cl	  and	  TEA	   in	  DCM.	   	  Both	   the	  2S4S	  and	  2R4R	  stereoisomers	  of	  Pro4	  were	  converted	   to	   the	  Alloc	  protected	  derivative	  (14	  and	  ent-­‐14).	  	  





















































piperdine	   in	   DMF.	   	   The	   second	   lysine	   was	   attached	   via	   HATU	   coupling	   using	   Fmoc-­‐Lysine(Boc)-­‐OH,	   HATU	   and	   DIPEA	   in	   NMP.	   	   The	   Fmoc	   group	  was	   cleaved	   and	   the	   third	  lysine	  was	  introduced	  in	  identical	  fashion	  followed	  by	  Fmoc	  cleavage.	  	  The	  Alloc	  protected	  Pro4	  monomer	   (14	   or	  ent-­‐14)	  was	   then	   attached	   via	   HATU	   coupling	   followed	   by	   Fmoc	  cleavage.	  	  The	  DMA	  amino	  acid	  (13)	  was	  then	  attached	  and	  an	  extended	  Fmoc	  deprotection	  resulted	  in	  the	  spontaneous	  closure	  to	  the	  DKP	  ring.	  The	   Alloc	   group	   was	   removed	   using	   (PPh3)4Pd	   and	   BH3:DMA	   in	   DCM	   and	   the	  pyrene-­‐1-­‐carboxylic	   acid	  was	   attached	  using	  HATU	   coupling.	   	   The	  Boc	  protecting	   groups	  were	  removed	  and	  the	  resin	  cleavage	  was	  affected	  using	  48:1:1	  TFA/H2O/TIPS	  to	  yield	  the	  DBA	  scaffolds	  D-­‐SSS-­‐A	  (11)	  from	  compound	  (14)	  and	  D-­‐SRR-­‐A	  (12)	  from	  (ent-­‐14),	  which	  were	  purified	  using	  reverse	  phase	  HPLC.	  NMR	  analyses	  of	  the	  DBA	  spiroligomers	  (11)	  and	  (12)	  were	  performed	  in	  D2O	  and	  deuterated	   DMSO,	  which	  was	   used	   as	   a	   control	   solvent	   for	   the	   ET	   experiments.	   	   At	   low	  temperature,	   significant	   broadening	   was	   observed	   due	   to	   aggregated	   states	   and	   slow	  exchanging	   among	   conformations.	   	   However,	   as	   the	   temperature	   was	   increased,	  coalescence	  was	  observed	  to	   two	  distinct	  conformations	  which	  were	  attributed	  to	   the	  cis	  and	   trans	   amide	   rotamers	   of	   pyrenyl	   amide.	   	   This	   along	   with	   overlap	   in	   the	   aliphatic	  regions	   due	   to	   the	   lysine	   side	   chains,	   made	   full	   assignment	   impractical.	   	   The	   aromatic	  region	   of	   the	   NMR	   was	   easy	   to	   interpret	   and	   provided	   detailed	   information	   about	   the	  presence	  and	  absence	  of	   the	  molecular	   cleft	   (Figure	  2-­‐3).	   	  Two	  different	   sets	  of	  doublets	  can	  be	  observed	  for	  each	  of	  the	  two	  sets	  of	  protons	  on	  the	  DMA	  ring.	  	  Integration	  of	  these	  two	  distinct	   sets	  of	  doublets	   suggested	   that	   these	   two	  conformations	  exist	   in	   a	  2:1	   ratio.	  	  This	  was	  consistent	  for	  each	  solvent	  for	  D-­‐SSS-­‐A	  and	  D-­‐SRR-­‐A.	   	  Even	  more	  intriguing	  was	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that	  for	  the	  cleft-­‐bearing	  D-­‐SSS-­‐A,	  one	  set	  of	  doublets	  were	  shifted	  further	  up	  field	  than	  the	  other	  and	  further	  up	  field	  than	  expected	  for	  this	  particular	  type	  of	  aromatic	  proton.	  
	  	  Figure	  2-­‐3.	   	  1H	  NMR	  spectra	  for	  D-­‐SSS-­‐A	  (11)	  in	  D2O	  and	  DMSO,	  (A)	  and	  (B)	  respectively,	  and	  D-­‐SRR-­‐A	  (12)	  in	  D2O	  (C)	  at	  333K.	  	  Only	  aromatic	  region	  is	  shown	  for	  visual	  clarity.	  	   	  	   The	  two	  conformations	  observed	  by	  NMR	  were	  attributed	  to	  the	  cis	  and	  trans	  amide	  rotamers	   about	   the	   pyrrolidine-­‐pyrene	   carboxamide	   bond,	   which	   would	   be	   expected	   to	  exchange	  slowly	  on	  the	  NMR	  time	  scale	  even	  at	  elevated	  temperatures.	  	  Closer	  inspection	  of	  the	   cleft-­‐bearing	   D-­‐SSS-­‐A	   showed	   that	   a	   cleft	   is	   only	   present	   in	   the	   trans-­‐amide	  conformation	   and	   no	   clear-­‐defined	   cleft	   is	   present	   in	   the	   cis-­‐amide	   conformation.	   	   The	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conformations	   of	   the	   cis	   and	   trans	   amide	   rotamers	   and	   their	   presentation	   of	   donor	   and	  acceptor	  moieties	  are	   illustrated	   in	  Figure	  2-­‐4.	   	  Also	   illustrated	   is	   the	  shielding	  cone	  and	  deshielding	  torus,	  highlighted	  in	  green	  and	  red	  respectively.	  	  In	  the	  trans	  rotamer,	  the	  DMA	  moiety	  is	  presented	  to	  the	  shielding	  cone,	  which	  would	  cause	  an	  upfield	  shift	   in	  the	  NMR	  spectra	   for	   the	   proton	   lying	   in	   the	   shielding	   cone.	   	   This	   is	   consistent	   with	   what	   was	  observed	  for	  the	  higher	  populated	  conformer	  in	  both	  D2O	  and	  deuterated	  DMSO	  for	  D-­‐SSS-­‐A.	  	  The	  cis	  rotamer,	  the	  DMA	  moiety	  is	  presented	  to	  the	  deshielding	  torus	  and	  is	  attributed	  to	  the	  lower	  populated	  conformer	  observed	  in	  the	  NMR	  spectra.	  	  NMR	  Analyses	  of	  the	  DBA	  spiroligomers	   confirm	   that	   a	   cleft	   is	   formed	   and	   that	   similar	   conformational	   preference	  was	  exhibited	  in	  both	  D2O	  and	  deuterated	  DMSO.	  
	  Figure	  2-­‐4.	  	  3D	  model	  of	  two	  rotameric	  conformers	  of	  compound	  D-­‐SSS-­‐A	  (11).	  	  The	  pyrene	  shielding	   cone	   is	   highlighted	   in	   green	   and	   the	   pyrene	   deshielding	   torus	   is	   highlighted	   in	  red.	   	  	  Time-­‐resolved	  fluorescence	  was	  used	  to	   investigate	  electron	  transfer	  properties	  of	  the	  DBA	  spiroligomers	  D-­‐SSS-­‐A	  (11)	  and	  D-­‐SRR-­‐A	  (12).	   	  The	   fluorescence	  decay	   for	  both	  molecules	  in	  DMSO	  and	  H2O	  possess	  two	  time	  components,	  which	  we	  attributed	  to	  the	  two	  
 trans-amide cis-amide
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rotamer	   species	   observed	   from	   NMR:	   	   the	   shorter	   decay	   for	   the	   cleft-­‐forming,	   higher	  populated	  conformer	  and	  the	  longer	  decay	  for	  the	  less	  populated	  conformer.	  	  The	  ET	  rate	  constants,	  kET,	  were	  derived	  for	  each	  DBA	  spiroligomer	  in	  both	  DMSO	  and	  H2O	  over	  a	  range	  of	  temperatures.	  	  A	  proportional	  temperature	  dependence	  was	  observed	  for	  each	  trial	  and	  a	  ~3	   fold	   increase	  of	   kET	  was	  observed	   for	   the	   cleft-­‐forming	  DBA	  D-­‐SSS-­‐A	   (11)	   in	  water.	  	  This	  is	  attributed	  to	  an	  enhancement	  from	  tunneling	  mediated	  by	  water	  molecules.	  
	  Figure	   2-­‐5.	   	   Photophysical	   Data	   for	   D-­‐SSS-­‐A	   (11)	   and	   D-­‐SRR-­‐A	   (12).	   	   Decay	   law	   fitting	  parameters	  for	  D-­‐SSS-­‐A	  and	  the	  ET	  rate	  plotted	  versus	  temperature.	  	   	  The	   presence	   of	   two	   time	   components	   in	   the	   lifetime	   data	   as	   well	   as	   two	   states	  found	   in	   the	  NMR	  prompted	   further	   interest	   in	  DBA	  scaffold	  using	  sing	  photon	  counting.	  	  However,	   these	   experiments	   required	   the	   use	   of	   laser	   equipment	   with	   an	   excitation	  wavelength	  of	  375	  nm.	  	  The	  current	  DBA	  scaffold	  does	  not	  absorb	  at	  375	  nm	  and	  therefore	  is	   unsuitable	   for	   this	   analysis.	   	   In	   order	   to	   shift	   the	   excitation	   wavelength,	   a	   chemical	  modification	   was	   made	   to	   the	   pyrene	   moiety	   to	   affect	   a	   bathochromic	   shift	   of	   its	  absorbance	   spectra.	   	   Previously,	   a	   series	   of	   pyrene-­‐bridged	  peptides	   and	  pyrene-­‐peptide	  macrocycles	  have	  been	  shown	  to	  possess	  a	  sufficient	  absorbance	  at	  375	  nm.	  [17]	  Figure	  2-­‐6	  shows	   the	   absorbance	   spectra	   and	   structure	   of	   these	   compounds.	   	   According	   to	   this	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precedent,	  an	  additional	  carboxamide	  functionality	  appended	  to	  the	  pyrene	  moiety	  on	  the	  DBA	  scaffold	  will	  cause	  the	  desired	  bathochromic	  shift.	  








































15b 16 	  Scheme	  2-­‐3.	   	  Synthesis	  of	  modified	  pyrene.	   	  a)	  Na2CO3,	  MeI,	  DMF;	  b)	  HNO3,	  Ac2O;	  c)	  Pd/C,	  H2,	  THF;	  d)	  Ac2O,	  DIPEA,	  DCM;	  e)	  KOTMS,	  DCM	  	   Full	  NMR	  analysis,	  shown	  in	  Figure	  2-­‐7,	  was	  conducted	  on	  fractions	  1	  and	  3	  in	  order	  to	  assign	  unknown	  compounds	  X,	  Y,	   and	  Z.	   	   From	   the	  1H	  spectrum,	   it	  was	  apparent	   that	  unknown	  Y	  was	  the	  1,3	  disubstituted	  pyrene	  (15a).	  	  The	  C-­‐2	  of	  the	  1,3	  disubstituted	  pyrene	  would	  provide	  a	  characteristic	  singlet	  that	  was	  not	  observed	  in	  either	  1H	  spectra.	  	  The	  Cosy	  spectrum	  provided	  assignment	  of	  each	  signal	  to	  the	  four	  spin	  systems	  of	  pyrene;	  labeled	  A,	  B,	   C,	   and	   D	   (shown	   in	   Figure	   2-­‐7).	   	   The	   aniline	   carbon,	   which	   has	   a	   very	   characteristic	  chemical	  shift	  range	  at	  140-­‐150	  ppm,	  was	  an	  excellent	  NMR	  handle	  to	  aid	  in	  differentiating	  between	  the	  remaining	  pyrene	  regioisomers.	  	  The	  HMBC	  spectrum	  showed	  that	  the	  aniline	  carbon	  coupled	  into	  different	  spins	  systems	  of	  the	  pyrene	  in	  each	  fraction.	  	  For	  unknown	  X,	  the	  aniline	  carbon	  clearly	  coupled	  into	  the	  C	  and	  D	  spin	  systems.	  	  This	  was	  consistent	  with	  the	  1,6	  disubstituted	  pyrene	  (15b).	  	  For	  unknown	  Z,	  the	  aniline	  carbon	  clearly	  coupled	  into	  the	  C	  and	  B	  spin	  systems.	  	  This	  was	  consistent	  with	  the	  1,8	  disubstituted	  pyrene	  (15c).	  	  The	  summary	   of	   the	   final	   assignments	   is	   compound	   15a	   is	   unknown	   Y,	   compound	   15b	   is	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unknown	  X,	   and	   compound	  15c	   is	   unknown	  Z.	   	   Compound	  15b	  was	   isolated	   in	   greatest	  quantity	  and	  was	  used	  for	  the	  remainder	  of	  the	  synthesis.	  	  	  
	  	  

















































































2.3	  Conclusion	  	   Two	   DBA	   scaffolds	   were	   synthesized,	   one	   of	   which	   possessed	   a	   cleft	   that	   could	  accommodate	   a	   water	   molecule	   for	   photoinduced	   electron	   transfer	   studies.	   	   A	   3-­‐fold	  enhancement	  of	  electron	  transfer	  rate	  was	  observed	  for	  the	  cleft	  forming	  DBA	  in	  water	  but	  not	   in	   DMSO	   and	   no	   water-­‐mediated	   rate	   enhancement	   was	   observed	   for	   the	   non-­‐cleft	  forming	  DBA.	   	  However,	  all	  DBA	  scaffolds	  showed	  two	  time	  components	  in	  both	  solvents.	  	  In	   the	   NMR	   characterization,	   two	   distinct	   conformations	   were	   observed	   for	   both	   DBA	  scaffolds	  in	  both	  water	  and	  DMSO	  that	  could	  be	  attributed	  to	  two	  amide	  rotamers.	  	  Further	  studies	   of	   this	   duality	   can	   now	  be	   conducted	  with	   the	   synthesis	   of	   a	   new	  modified	  DBA	  scaffolds	  designed	  to	  be	  suitable	  for	  single	  photon	  counting	  experiments.	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2.4	  Eperimental	  Details	  















13 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Fmoc-­‐4-­‐nitrophenylalanine	  a)	  	  CH2O(n),	  Pd/C,	  H2,	  THF,	  MeOH	  
(S)-­‐2-­‐(((9H-­‐fluoren-­‐9-­‐yl)methoxy)carbonylamino)-­‐3-­‐(4-­‐(dimethylamino)	  









































ent-14 	  a) TFA,	  DCM	  (1:2);	  b)	  	  Alloc-­‐Cl,	  DIPEA,	  DCM	  
(2S,4S)-­‐4-­‐(((9H-­‐fluoren-­‐9-­‐yl)methoxy)carbonylamino)-­‐1-­‐(allyloxycarbonyl)-­‐4-­‐
(methoxycarbonyl)pyrrolidine-­‐2-­‐carboxylic	  acid	  (14):	  To	  a	  solution	  of	  Pro4ss	  (1)	  (1g,	  1.96mmoles)	  in	  DCM	  (14mL)	  was	  added	  TFA	  (7mL).	   	  The	  reaction	  mixture	  was	  stirred	  for	  4	  hours	  then	  concentrated	  under	  reduced	  pressure.	   	  The	  residue	  was	  diluted	  with	  PhMe	  and	  concentrated	  under	  reduced	  pressure	  and	  further	  dried	  over	   night	   under	   high	   vacuum.	   	   The	   residue	   was	   dissolved	   in	   DCM	   (20mL)	   and	   DIPEA	  (1.03mL,	   5.88mmoles,	   3equiv)	   was	   added	   followed	   by	   Alloc-­‐Cl	   (230uL,	   2.15mmoles,	  1.1equiv).	   	   The	   reaction	   mixture	   was	   stirred	   overnight	   then	   diluted	   with	   EtOAc.	   	   The	  solution	  was	  washed	  with	  sat.	  NH4Cl	  (aq)	  x	  3,	  sat.	  NaCl	  (aq)	  x	  2,	  dried	  over	  Na2SO4,	  filtered,	  and	   concentrated	   under	   reduced	   pressure.	   	   The	   residue	  was	   chromatographed	   on	   silica	  (gradient	   elution	   over	   16	   column	   volumes	   from	   0-­‐5%	   MeOH	   in	   DCM).	   	   The	   desired	  fractions	  were	   combined	   and	   concentrated	   to	   yield	   a	   yellow	   solid	   (914mg,	   1.85mmoles,	  94%yield).	   	   1H	  NMR	  (500	  MHz,	  365K,	  DMSO-­‐d6):	  δ	  8.49	  (bs,	  1H),	  8.11	  (d,	   J	  =	  7.5	  Hz,	  2H),	  7.92	  (d,	  J	  =	  7.1	  Hz,	  2H),	  7.64	  (t,	  J	  =	  7.3	  Hz,	  7.4	  Hz,	  2H),	  7.56	  (t,	  J	  =	  7.3	  Hz,	  7.2	  Hz,	  2H),	  6.17	  (m,	  1H),	  5.52	  (t,	  J	  =	  16.7	  Hz,	  16.7	  Hz,	  1H),	  5.43	  (dd,	  J	  =	  10.5	  Hz,	  17.9	  Hz,	  10.5	  Hz,	  1H),	  4.77	  (m,	  2H),	  4.54	  (m,	  4H),	  4.29	  (dd,	   J	  =	  11.2	  Hz,	  24.2	  Hz,	  11.2	  Hz,	  1H),	  3.82	  (s,	  3H),	  3.80	  (m,	  1H),	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3.11	   (m,	  1H);	   );	   13C	  NMR	  (125MHz,	  365K,	  DMSO-­‐d6):	  δ	   174.8,	  171.8,	  157.6,	  155.6,	  155.6,	  143.6,	  141.0,	  133.5,	  128.7,	  128.4,	  128.2,	  126.8,	  116.4,	  67.3,	  65.1,	  55.0,	  54.8,	  52.2,	  50.9,	  37.2;	  LRESIQMS	  calcd	  for	  C132H138N10O40	  (M	  +	  H+)	  494.1689,	  measured	  494.2.	  
(2R,4R)-­‐4-­‐(((9H-­‐fluoren-­‐9-­‐yl)methoxy)carbonylamino)-­‐1-­‐(allyloxycarbonyl)-­‐4-­‐















15c15b15a 	  Pyrene-­‐1-­‐carboxylic	  acid	  a)	  Na2CO3,	  MeI,	  DMF;	  b)	  HNO3,	  Ac2O;	  c)	  Pd/C,	  H2,	  THF	  d)	  Ac2O,	  DIPEA,	  DCM;	  e)	  KOTMS,	  DCM	  
Methyl	  6-­‐aminopyrene-­‐1-­‐carboxylate	  (15b):	  To	  a	  solution	  of	  Pyrene-­‐1-­‐carboxylic	  acid	  (250mg,	  1.02mmoles)	  in	  DMF	  (10mL)	  was	  added	  Na2CO3	  (215mg,	  2.04mmoles,	  2equiv)	  followed	  by	  MeI	  (70uL,	  1.12mmoles,	  1.1equiv).	  	  The	  reaction	  mixture	  was	  stirred	  overnight	  then	  added	  dropwise	  to	  a	  stirring	  solution	  of	  water	  (100mL)	  at	  0oC.	  	  The	  precipitate	  was	  collected	  and	  washed	  with	  cold	  water.	  	  The	  resulting	  solid	   was	   suspended	   in	   Ac2O	   (10mL)	   and	   a	   0.4	   M	   HNO3	   solution	   in	   Ac2O	   (5mL,	  2.04mmoles,	   2equiv)	   was	   added.	   	   The	   reaction	  mixture	   was	   heated	   to	   70oC	   and	   stirred	  overnight	  then	  concentrated	  under	  reduced	  pressure.	  	  The	  residue	  was	  suspended	  in	  THF	  (20mL)	  and	  Pd/C	  (30mg)	  was	  added.	  	  The	  reaction	  mixture	  was	  then	  degassed	  and	  charged	  with	   H2	   (g)	   and	   stirred	   overnight	   then	   chromatographed	   on	   silica	   (isocratic	   elution	   of	  PhMe).	  	  The	  desired	  fractions	  were	  combined	  and	  concentrated	  to	  yield	  a	  red	  solid	  (118mg,	  429umoles,	  42%).	  	  1H	  NMR	  (500	  MHz,	  rt,	  CDCl3):	  δ	  9.03	  (d,	  J=9.1	  Hz,	  1H),	  8.56	  (d,	  J=8.3	  Hz,	  1H),	  8.07	  (m,	  3H),	  8.01	  (d,	  J=8.3	  Hz,	  1H),	  7.98	  (d,	  J=9.1	  Hz,	  1H),	  7.41	  (d,	  J=8.3	  Hz,	  1H),	  4.08	  (s,	   3H);	   13C	   NMR	   (125MHz,	   rt,	   CDCl3):	   δ	   168.8,	   141.8,	   135.2,	   134.9,	   132.3,	   128.6,	   126.3,	  125.7,	  125.3,	  124.5,	  123.0,	  122.6,	  122.2,	  121.1,	  117.1,	  116.1,	  114.3,	  52.2;	  LRESIQMS	  calcd	  for	  C18H13NO2	  (M	  +	  H+)	  276.0946,	  measured	  276.2.	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Methyl	  3-­‐aminopyrene-­‐1-­‐carboxylate	  (15a):	  Isolated	  as	  a	  mixture	  of	  15a,	  15b,	  and	  15c	  from	  purification	  of	  15b.	  










15b 16 	  d)	  Ac2O,	  DIPEA,	  DCM;	  e)	  KOTMS,	  DCM	  
6-­‐acetamidopyrene-­‐1-­‐carboxylic	  acid	  (16):	  To	  a	  solution	  of	  15b	  (110mg,	  400umoles)	  in	  DCM	  (8mL)	  was	  added	  Ac2O	  (1mL)	  followed	  by	   TEA	   (1mL).	   	   The	   reaction	   was	   stirred	   overnight	   then	   concentrated	   under	   reduced	  pressure.	  	  The	  residue	  was	  diluted	  in	  THF	  (20mL)	  and	  KOTMS	  (513mg,	  4mmoles,	  10equiv)	  was	  added.	  	  The	  reaction	  mixture	  was	  stirred	  overnight	  then	  chromatographed	  by	  reverse-­‐phase	  chromatography	  (gradient	  elution	  over	  18	  column	  volumes	  from	  water	  (0.1%	  formic	  acid)	  to	  MeCN	  in	  water	  (0.1%	  formic	  acid).	   	  Desired	  fractions	  were	  combined	  and	  freeze-­‐dried	  to	  a	  white	  powder	  (910mg,	  300umoles,	  75%).	   	   1H	  NMR	  (500	  MHz,	  rt,	  DMSO-­‐D6):	  δ	  10.41	  (s,	  1H),	  9.18	  (d,	  J=9.0	  Hz,	  1H),	  8.59	  (d,	  J=9.0	  Hz,	  1H),	  8.46	  (d,	  J=9.0,	  1H),	  8.33	  (m,	  5H),	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2.26	  (s,	  3H);	  13C	  NMR	  (125MHz,	  rt,	  CDCl3):	  δ	  167.7,	  133.6,	  130.4,	  128.9,	  128.7,	  127.4,	  126.8,	  126.1,	  124.9,	  124.4,	  123.9,	  123.7,	  123.0;	  LRESIQMS	  calcd	  for	  C19H13NO3	  (M	  +	  H+)	  304.0895,	  measured	  305.1.	  
Solid	  Phase	  Synthesis	  
General	  procedure	  (A):	  Attachment	  to	  Trityl	  resin	  To	   a	   solution	   of	   the	   amino	   acid	   (10	   equivalents	   based	   on	   resin	   loading)	   in	   DCM	  (3mL/mmole	  of	  amino	  acid)	  was	  added	  DIPEA	  (5	  equivalents	  based	  on	  resin	  loading).	  The	  reaction	  mixture	  was	   added	   to	   a	   portion	   of	   resin	   in	   a	   solid	   phase	   reactor.	   The	   reaction	  mixture	  was	  stirred	   for	  4	  hours.	  The	  resin	  was	   filtered	  and	  washed	  with	  DMF,	  DCM,	   IPA,	  DCM	  and	  DMF.	  
General	  procedure	  (B):	  HATU	  coupling	  To	  a	  solution	  of	  amino	  acid	  (3	  equivalents	  based	  on	  resin	  loading)	  and	  HATU	  (3	  equivalents	  based	   on	   resin	   loading	   in	   NMP	   (5mL/mmole	   of	   amino	   acid)	   was	   added	   DIPEA	   (6	  equivalents	  based	  on	  resin	  loading).	  The	  reaction	  mixture	  was	  agitated	  for	  5	  minutes	  then	  added	  to	  a	  pre-­‐swelled	  (with	  DMF)	  portion	  of	  resin	  in	  a	  solid	  phase	  reactor	  and	  stirred	  for	  45	  minutes.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  IPA,	  DCM	  and	  DMF.	  
General	  procedure	  (C):	  Fmoc	  deprotection	  A	  solution	  of	  20%	  of	  piperidine	  in	  DMF	  (15mL/mmole	  based	  on	  resin	  loading)	  was	  added	  to	   a	   pre-­‐swelled	   (with	  DMF)	   portion	   of	   resin	   in	   a	   solid	   phase	   reactor	   and	   stirred	   for	   15	  minutes.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  IPA,	  DCM	  and	  DMF.	  
General	  procedure	  (D):	  Alloc	  deprotection	  A	   solution	   of	   borane:dimethylamine	   complex	   (6	   equivalents	   based	   on	   resin	   loading)	   in	  DCM	   (10mL/mmole	   based	   on	   resin	   loading)	   was	   added	   to	   a	   pre-­‐swelled	   (with	   DMF)	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portion	   of	   resin	   in	   a	   solid	   phase	   reactor	   and	   stirred	   for	   5	  minutes.	   To	   this	   solution	  was	  added	   a	   solution	   of	   tetrakis(triphenylphosphine)palladium(0)	   (0.1	   equivalents	   based	   on	  resin	   loading)	   in	  DCM	   (10mL/mmole	   based	   on	   resin	   loading).	   The	   reaction	  mixture	  was	  stirred	  for	  1	  hour.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  IPA,	  DCM	  and	  DMF.	  





















































D-­‐SSS-­‐A	  (11)	  Trityl	  resin	  (100mg,	  100umoles	  loading)	  was	  placed	  in	  a	  4mL	  solid	  phase	  reactor.	   	  Fmoc-­‐Lys(Boc)-­‐OH	  (703mg,	  1.5mmoles)	  	  was	  attached	  according	  to	  general	  procedure	  (A)	  using	  DCM	   (4.5mL)	   and	   DIPEA	   (116uL,	   750umoles).	   	   The	   terminal	   Fmoc	   group	   was	   removed	  according	  to	  general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  Fmoc-­‐Lys(Boc)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	  (B)	  using	   HATU	   (171mg,	   450umoles),	   NMP	   (2.25mL),	   and	   DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  	  Fmoc-­‐Lys(Boc)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	  (B)	  using	  HATU	   (171mg,	   450umoles),	  NMP	   (2.25mL),	   	   and	  DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  
14	   (223mg,	   450umoles)	   was	   coupled	   according	   to	   general	   procedure	   (B)	   using	   HATU	  (171mg,	  450umoles),	  NMP	  (2.25mL),	  and	  DIPEA	  (156uL,	  900umoles).	  	  The	  terminal	  Fmoc	  group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	   piperidine	   in	   DMF	  (2.25mL).	  	  	  	  Fmoc-­‐DMA-­‐OH	  (194mg,	  450umoles)	  was	  coupled	  according	  to	  general	  procedure	  (B)	  using	  HATU	  (171mg,	  450umoles),	  NMP	  (2.25mL),	  and	  DIPEA	  (156uL,	  900umoles).	  	  The	  terminal	  Fmoc	  group	  was	  removed	  according	  to	  general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL)	  and	  the	  reaction	  time	  was	  extended	  to	  2	  hour.	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The	   Alloc	   group	   was	   removed	   according	   to	   general	   procedure	   (D)	   using	  borane:dimethylamine	   complex	   (53mg,	   900umoles)	   in	   DCM	   (2.5mL)	   and	  tetrakis(triphenylphosiphine)palladium(0)	   (17mg,	   15umoles)	   in	   DCM	   (2mL).	   	   Pyrene-­‐1-­‐carboxylic	  acid	  (111mg,	  450umoles)	  was	  coupled	  according	  to	  general	  procedure	  (B)	  using	  HATU	  (171mg,	  450umoles),	  NMP	  (2.25mL),	  and	  DIPEA	  (156uL,	  900umoles).	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D-­‐SRR-­‐A	  (12):	  Trityl	  resin	  (100mg,	  100umoles	  loading)	  was	  placed	  in	  a	  4mL	  solid	  phase	  reactor.	   	  Fmoc-­‐Lys(Boc)-­‐OH	  (703mg,	  1.5mmoles)	  	  was	  attached	  according	  to	  general	  procedure	  (A)	  using	  DCM	   (4.5mL)	   and	   DIPEA	   (116uL,	   750umoles).	   	   The	   terminal	   Fmoc	   group	   was	   removed	  according	  to	  general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL).	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Fmoc-­‐Lys(Boc)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	  (B)	  using	   HATU	   (171mg,	   450umoles),	   NMP	   (2.25mL),	   and	   DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  Fmoc-­‐Lys(Boc)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	  (B)	  using	  HATU	   (171mg,	   450umoles),	  NMP	   (2.25mL),	   	   and	  DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  
Ent-­‐14	  (223mg,	  450umoles)	  was	  coupled	  according	  to	  general	  procedure	  (B)	  using	  HATU	  (171mg,	  450umoles),	  NMP	  (2.25mL),	  and	  DIPEA	  (156uL,	  900umoles).	  	  The	  terminal	  Fmoc	  group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	   piperidine	   in	   DMF	  (2.25mL).	  	  	  	  Fmoc-­‐DMA-­‐OH	  (194mg,	  450umoles)	  was	  coupled	  according	  to	  general	  procedure	  (B)	  using	  HATU	  (171mg,	  450umoles),	  NMP	  (2.25mL),	  and	  DIPEA	  (156uL,	  900umoles).	  	  The	  terminal	  Fmoc	  group	  was	  removed	  according	  to	  general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL)	  and	  the	  reaction	  time	  was	  extended	  to	  2	  hour.	  	  	  The	   Alloc	   group	   was	   removed	   according	   to	   general	   procedure	   (D)	   using	   borane:	  dimethylamine	   complex	   (53mg,	   900umoles)	   in	   DCM	   (2.5mL)	   and	   tetrakis	  (triphenylphosiphine)	  palladium(0)	  (17mg,	  15umoles)	  in	  DCM	  (2mL).	  	  Pyrene-­‐1-­‐carboxylic	  acid	   (111mg,	   450umoles)	   was	   coupled	   according	   to	   general	   procedure	   (B)	   using	   HATU	  (171mg,	  450umoles),	  NMP	  (2.25mL),	  and	  DIPEA	  (156uL,	  900umoles).	  	  	  
12	  was	   liberated	   from	  the	  resin	  according	  to	  general	  procedure	  (E)	  using	  3.75	  mL	  of	   the	  cleavage	  cocktail.	  	  The	  residue	  was	  reconstituted	  in	  50%	  MeCN	  in	  water	  (0.1%	  formic	  acid)	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D-­‐SSS-­‐A*	  (17):	  Trityl	  resin	  (100mg,	  100umoles	  loading)	  was	  placed	  in	  a	  4mL	  solid	  phase	  reactor.	   	  Fmoc-­‐Lys(Boc)-­‐OH	  (703mg,	  1.5mmoles)	  	  was	  attached	  according	  to	  general	  procedure	  (A)	  using	  DCM	   (4.5mL)	   and	   DIPEA	   (116uL,	   750umoles).	   	   The	   terminal	   Fmoc	   group	   was	   removed	  according	  to	  general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  Fmoc-­‐Lys(Boc)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	  (B)	  using	   HATU	   (171mg,	   450umoles),	   NMP	   (2.25mL),	   and	   DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  Fmoc-­‐Lys(Boc)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	  (B)	  using	  HATU	   (171mg,	   450umoles),	  NMP	   (2.25mL),	   	   and	  DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL).	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14	   (223mg,	   450umoles)	   was	   coupled	   according	   to	   general	   procedure	   (B)	   using	   HATU	  (171mg,	  450umoles),	  NMP	  (2.25mL),	  and	  DIPEA	  (156uL,	  900umoles).	  	  The	  terminal	  Fmoc	  group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	   piperidine	   in	   DMF	  (2.25mL).	  Fmoc-­‐DMA-­‐OH	  (194mg,	  450umoles)	  was	  coupled	  according	  to	  general	  procedure	  (B)	  using	  HATU	  (171mg,	  450umoles),	  NMP	  (2.25mL),	  and	  DIPEA	  (156uL,	  900umoles).	  	  The	  terminal	  Fmoc	  group	  was	  removed	  according	  to	  general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL)	  and	  the	  reaction	  time	  was	  extended	  to	  2	  hour.	  	  	  The	   Alloc	   group	   was	   removed	   according	   to	   general	   procedure	   (D)	   using	  borane:dimethylamine	   complex	   (53mg,	   900umoles)	   in	   DCM	   (2.5mL)	   and	  tetrakis(triphenylphosiphine)palladium(0)	  (17mg,	  15umoles)	  in	  DCM	  (2mL).	   	  16	  (111mg,	  450umoles)	   was	   coupled	   according	   to	   general	   procedure	   (B)	   using	   HATU	   (171mg,	  450umoles),	  NMP	  (2.25mL),	  and	  DIPEA	  (156uL,	  900umoles).	  	  	  




















D-­‐SRR-­‐A*	  (18):	  Trityl	  resin	  (100mg,	  100umoles	  loading)	  was	  placed	  in	  a	  4mL	  solid	  phase	  reactor.	   	  Fmoc-­‐Lys(Boc)-­‐OH	  (703mg,	  1.5mmoles)	  	  was	  attached	  according	  to	  general	  procedure	  (A)	  using	  DCM	   (4.5mL)	   and	   DIPEA	   (116uL,	   750umoles).	   	   The	   terminal	   Fmoc	   group	   was	   removed	  according	  to	  general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  Fmoc-­‐Lys(Boc)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	  (B)	  using	   HATU	   (171mg,	   450umoles),	   NMP	   (2.25mL),	   and	   DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  Fmoc-­‐Lys(Boc)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	  (B)	  using	  HATU	   (171mg,	   450umoles),	  NMP	   (2.25mL),	   	   and	  DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  
Ent-­‐14	  (223mg,	  450umoles)	  was	  coupled	  according	  to	  general	  procedure	  (B)	  using	  HATU	  (171mg,	  450umoles),	  NMP	  (2.25mL),	  and	  DIPEA	  (156uL,	  900umoles).	  	  The	  terminal	  Fmoc	  group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	   piperidine	   in	   DMF	  (2.25mL).	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Fmoc-­‐DMA-­‐OH	  (194mg,	  450umoles)	  was	  coupled	  according	  to	  general	  procedure	  (B)	  using	  HATU	  (171mg,	  450umoles),	  NMP	  (2.25mL),	  and	  DIPEA	  (156uL,	  900umoles).	  	  The	  terminal	  Fmoc	  group	  was	  removed	  according	  to	  general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL)	  and	  the	  reaction	  time	  was	  extended	  to	  2	  hour.	  	  	  The	   Alloc	   group	   was	   removed	   according	   to	   general	   procedure	   (D)	   using	  borane:dimethylamine	   complex	   (53mg,	   900umoles)	   in	   DCM	   (2.5mL)	   and	  tetrakis(triphenylphosiphine)palladium(0)	  (17mg,	  15umoles)	  in	  DCM	  (2mL).	   	  16	  (111mg,	  450umoles)	   was	   coupled	   according	   to	   general	   procedure	   (B)	   using	   HATU	   (171mg,	  450umoles),	  NMP	  (2.25mL),	  and	  DIPEA	  (156uL,	  900umoles).	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3.0	  Acceleration	  of	  an	  aromatic	  Clasien	  rearrangement	  via	  a	  designed	  spiroligozyme	  
catalyst	  that	  mimics	  the	  ketosteroid	  isomerase	  catalytic	  dyad	  	  	  	  Chapter	  3	  details	  our	  use	  of	  bis-­‐amino	  acids	  for	  presenting	  a	  phenol	  and	  a	  benzoic	  acid	  moiety	   on	   for	   catalysis	   of	   an	   aromatic	   Claisen	   rearrangement	   of	   a	   prenyl	   coumarin.	  	  Highlights	  of	  this	  work	  are	  the	  first	  demonstration	  of	  a	  synthetic	  Claisen	  catalyst	  based	  on	  oxygen	   hydrogen	   bonding.	   	   A	   58-­‐fold	   reactivity	   enhancement	  was	   observed	   for	   the	   best	  computational	   design.	   	   Several	   catalysts	   were	   investigated	   experimentally	   and	  computationally	  for	  structure	  function	  analysis.	  	  	  	  	  	  	  	   	  	  A	  portion	  of	  this	  work	  was	  published	  in:	  
J.	  Am.	  Chem.	  Soc.,	  2014,	  136	  (10),	  pp	  3817-­‐3827	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3.1	  Introduction	  One	  century	  after	  its	  discovery,[2]	  the	  [3,3]-­‐sigmatropic	  rearrangement	  of	  allyl	  vinyl	  ethers	  (i.e.	  the	  Claisen	  rearrangement)	  continues	  to	  be	  extensively	  investigated	  and	  applied	  in	  the	  synthesis	  of	  natural	  products	  and	  complex	  organic	  molecules.[3,4]	  Many	  efforts	  have	  been	  devoted	  to	  develop	  small	  molecule-­‐	  and	  bio-­‐catalysts	   for	  this	  synthetically	  powerful	  reaction.[5,6]	   Attractive	   non-­‐covalent	   interactions	   are	   responsible	   for	   much	   of	   the	   rate	  accelerations	  and	  stereoselectivities	  observed	  in	  enzyme	  catalysis,	  and	  active	  site	  residues	  can	  stabilize	  the	  transition	  state	  by	  electrostatic	  and	  non-­‐covalent	  interactions.[7]	  A	  variety	  of	   dual	   hydrogen-­‐bond	   donor	   organocatalysts	   such	   as	   ureas,	   thio-­‐ureas,	   guanidinium	  groups	   and	   bis-­‐imidazoliums	   have	   been	   reported	   in	   the	   literature	   for	   Claisen	  rearrangements.[6,8-­‐13]	  Some	  biological	  catalysts	  have	  also	  been	  identified,[14-­‐16]	  and	  de	  novo	  computational	  design	  strategies	  for	  developing	  an	  aromatic	  Claisen	  biocatalyst	  have	  been	   carried	   out.[17]	   We	   are	   developing	   a	   new	   approach	   to	   the	   development	   of	  organocatalysts	   called	   “spiroligozymes”	   wherein	   we	   use	   transition	   state	   modeling	   to	  identify	  constellations	  of	  reactive	  functional	  groups	  and	  then	  build	  those	  functional	  groups	  onto	   a	   spiroligomer	   scaffold	   to	   see	   if	   they	   can	   act	   as	   organocatalysts.[18]	   In	   this	  manuscript,	  we	  describe	  the	  design	  and	  synthesis	  of	  a	  series	  of	  bis-­‐amino	  acid	  monomers	  fused	  to	  amino	  acids	  through	  diketopiperazines,	  that	  accelerate	  the	  Claisen	  rearrangement	  of	   1,1-­‐dimethylallyl	   coumarin.	   This	   paper	   reports	   the	   successful	  mimicry	   of	   the	   catalytic	  dyad	  of	  bacterial	  ketosteroid	  isomerase	  (KSI)	  in	  a	  small	  spiroligozyme	  and	  the	  catalysis	  of	  an	  aromatic	  Claisen	  rearrangement	  of	  a	  1,1-­‐dimethylallyl	  coumarin.	  	  Aromatic	  Claisen	  rearrangements	  are	  typically	  performed	  in	  the	  temperature	  range	  of	   180-­‐225ºC,[19]	   and	   proceed	   through	   a	   concerted	   pericyclic	   pathway	   followed	   by	   a	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keto/enol	   tautomerization	   that	   restores	   aromaticity.	   The	   cyclic	   transition	   state	   of	   the	  Claisen	  rearrangement	  is	  key	  for	  understanding	  a	  number	  of	  phenomena.	  These	  include	  the	  effect	   of	   solvent	   on	   the	   rate	   of	   the	   reaction,[20-­‐27]	   substituent	   effects,	   and	  stereoselectivity.[4]	   There	   is	   one	   well-­‐established	   enzyme-­‐catalyzed	   Claisen	  rearrangement,	   the	   chorismate	   to	   prephenate	   transformation	   catalyzed	   by	   chorismate	  mutase.[28-­‐33]	   The	   Claisen	   rearrangement	   of	   O-­‐prenylated	   tyrosines	   in	   a	  prenyltransferase	  from	  the	  TruF	  enzyme	  family	  has	  also	  been	  proposed,[16]	  and	  catalytic	  antibodies	  have	  been	  developed	  for	  the	  chorismate	  to	  prephenate	  conversion.[34-­‐36]	  Considerable	  acceleration	  of	  the	  Claisen	  rearrangement	  can	  be	  achieved	  employing	  hydrogen-­‐bonding	   solvents,	   especially	   water.[25,26,28,37-­‐40]	   In	   1987,	   Carpenter	   and	  coworkers	   first	   reported	   the	  acceleration	  of	   the	  Claisen	   rearrangement	  of	   chorismic	  acid	  and	   related	   compounds	   in	   aqueous	   media.[28]	   The	   rate	   of	   the	   aromatic	   Claisen	  rearrangement	  of	  allyl	  naphthyl	  ether	  was	  also	  increased	  in	  aqueous	  suspensions	  relative	  to	   other	   organic	   solvents	   such	   as	   toluene,	   dimethylformamide,	   acetonitrile	   and	  methanol.[41]	   Sharpless	   reported	   “on-­‐water”	   catalysis	   of	   a	   Diels-­‐Alder	   reaction	   and	  aromatic	  Claisen	  rearrangement.	  Several	  examples	  from	  his	   lab	  illustrated	  the	  substantial	  rate	   acceleration	   of	   the	   reactions	   when	   insoluble	   reactants	   were	   stirred	   in	   aqueous	  suspension.	   This	   “on	   water”	   catalysis	   has	   prompted	   several	   computational	   studies	   to	  unravel	   the	   origin	   of	   the	   rate	   acceleration	   in	   water	   and	   hydrogen-­‐bonding	  solvents.[20,21,26,28,38,42]	   It	   was	   found	   that	   the	   aqueous	   acceleration	   of	   the	   Claisen	  rearrangement	   is	   due	   to	   a	   greater	   stabilization	   of	   the	   transition	   state	   by	   specific	  interactions	   with	   first	   shell	   solvent	   molecules.[17,38,43-­‐45]	   Jorgensen	   and	   coworkers	  computationally	  studied	  the	  acceleration	  of	  the	  Claisen	  rearrangement	  in	  water.	  The	  model	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consisted	   of	   two	   explicit	   water	  molecules	   around	   the	   core	   heteroatom	   of	   the	   allyl	   vinyl	  ether.[21]	  	  Curran	   et	   al.	   discovered	   that	   dual	   hydrogen-­‐bonding	   catalysts	   such	   as	   ureas	   and	  thioureas	   accelerate	   the	   Claisen	   rearrangement	   and	  measured	  modest	   rate	   accelerations	  using	   NMR	   experiments.[9]	   In	   addition,	   protonated	   catalysts	   including	   those	   based	   on	  guanidinium,[11]	  quinolinium	  thioamide,[46]	  and	  ammonium[26,47]	  structures	  were	  also	  studied.	  The	  latter	  positively	  charged	  catalysts	  tend	  to	  activate	  electrophiles	  more	  strongly	  than	   the	   neutral	   compounds.[10]	   Jacobsen	   and	   co-­‐workers	   have	   developed	  diphenylguanadinium	  salts	  as	  stereoselective	  Claisen	  rearrangement	  catalysts	  for	  a	  variety	  of	   substituted	   allyl	   vinyl	   ethers	   and	   β-­‐ketoester	   derivatives.[11,13]	   The	   mechanism	   by	  which	  the	  guanidinium	  catalysts	  promote	  the	  Claisen	  rearrangement	  was	  also	  studied	  both	  experimentally	  and	  theoretically.[6,12]	  The	  catalysis	  is	  mainly	  achieved	  by	  stabilization	  of	  the	   developing	   negative	   charge	   on	   the	   oxallyl	   fragment,	   and	   by	   a	   secondary	   attractive	  interaction	   between	   the	   π-­‐system	   of	   the	   catalyst	   and	   the	   partially	   positive	   allyl	   cation	  fragment.[12]	   Kozlowski	   and	   co-­‐workers	   designed	   a	   bisamidinium	   catalyst	   salt	   able	   to	  catalyze	  the	  Claisen	  rearrangement	  through	  a	  two-­‐point	  hydrogen	  bonding	  stabilization	  of	  the	  negatively	  charged	  ether	  oxygen	  in	  the	  transition	  state.[8]	  	  The	  most	  prominent	  biological	  example	  of	  a	  Claisen	  rearrangement	   is	   the	  enzyme	  Chorismate	   mutase,	   which	   catalyzes	   the	   Claisen	   rearrangement	   of	   chorismate	   to	  prephenate	  more	  than	  a	  million	  fold	  relative	  to	  the	  uncatalyzed	  process.[15]	  Hilvert	  and	  co-­‐workers	  have	  also	  studied	  the	  enzyme-­‐catalyzed	  Cope	  rearrangement	  of	  carbachorismate	  to	   carbaprephenate	   in	   the	   enzyme	  Bacillus	   subtilis	   chorismate	  mutase	   (BsCM).[14]	  They	  showed	  that	  a	  positively	  charged	  residue	  at	  position	  88	  or	  90	  is	  essential	  for	  stabilization	  of	  
	  46	  
the	   transition	   state	   of	   the	   enzymatic	   chorismate	   rearrangement.	   [14]	   Borden	   and	   Houk	  studied	  models	   for	   this	   rearrangement	  and	   tested	  differents	   theozymes	   to	  determine	   the	  effect	  of	  different	  side	  chains	  in	  chorismate	  mutase.[48]	  Bertran	  et	  al.	  performed	  a	  QM/MM	  study	  where	  two	  different	  transition	  states	  were	  located	  for	  the	  chorismate	  conversion	  to	  prephenate.	   It	  was	   found	   that	   the	   enzyme	   stabilizes	   one	   of	   the	   transition	   states	   (TS)	   by	  means	  of	  hydrogen	  bonding	  interactions,	  while	  the	  other	  TS	  located,	  corresponded	  to	  the	  preferred	  one	   in	  vacuum	  and	   in	  water.	   [49]	  They	   found	   that	  aqueous	  solution	  and	  BsCM	  active	   site	   environments	   reduce	   the	   free	   energy	  barriers	  more	   than	   in	   the	   gas	  phase	   for	  both	   reactions.	   The	   catalytic	   effect	   was	   mainly	   attributed	   to	   the	   enhanced	   electrostatic	  stabilization	   of	   the	   transition	   state	   relative	   to	   the	   starting	   substrate	   in	   the	   Claisen	  rearrangement.[50]	  	  Very	   recently,	   LynF,	   a	   prenyltransferase	   from	   the	   TruF	   enzyme	   family	   was	  characterized.	  [16]	  This	  enzyme	  performs	  O-­‐prenylation	  of	  tyrosine,	  serine	  and	  threonine	  in	  cyclic	  peptides.	  It	  was	  found	  that	  at	  physiological	  temperature	  and	  in	  aqueous	  buffer,	  O-­‐prenylated	  tyrosine	  derivatives	  undergo	  spontaneous	  Claisen	  rearrangements.	  	  	  In	   recent	   years,	   novel	   enzyme	   catalysts	   for	   the	   Kemp	   elimination,[51,52]	   retro-­‐aldol[53]	   and	  Diels-­‐Alder[54]	   reactions	   have	   been	   designed,	  making	   use	   of	   the	   so-­‐called	  “Inside-­‐Out”	   approach.	   The	   first	   step	   of	   this	   protocol	   involves	   quantum	   mechanical	  calculations	   of	   the	   ideal	   arrangement	   of	   catalytic	   groups	   around	   the	   transition	   state	   of	   a	  reaction;	   these	   computed	   complexes	   are	   called	   theozymes	   (short	   for	   theoretical	  enzymes).[55-­‐57]	   Theozymes	   serve	   as	   models	   for	   active	   site	   structures	   and	   for	   the	  prediction	  of	  activation	  barriers	   relative	   to	   the	  uncatalyzed	   reaction	   in	  aqueous	  solution.	  The	  arrangement	  of	  functional	  groups	  in	  the	  theozyme	  geometry	  is	  then	  incorporated	  into	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protein	   scaffolds	   from	   the	   Protein	   Data	   Bank[58]	   using	   the	   computational	   package	  RosettaMatch.	   [59]	   The	   active	   sites	   of	   the	   generated	   proteins	   are	   then	   minimized	   and	  repacked,	  and	  amino	  acids	  in	  the	  vicinity	  of	  the	  active	  site	  are	  mutated	  to	  stabilize	  the	  ideal	  transition	   state	   geometry.	   This	   process	   is	   performed	   using	   the	   RosettaDesign	   package.	  [60,61]	   The	   Inside-­‐Out	   approach	   has	   been	   satisfactorily	   applied	   in	   the	   above-­‐mentioned	  cases	  (Kemp	  elimination,	  retro-­‐Aldol	  and	  Diels-­‐Alder	  reaction),	  but	  it	  has	  some	  important	  limitations.	   Up	   until	   now,	   most	   active	   designed	   enzymes	   still	   perform	   quite	   poorly	   in	  comparison	   with	   the	   natural	   existing	   enzymes	   (i.e.	   natural	   enzymes	   have	   average	  kcat/kuncat	   of	   ~1011	   whereas	   artificial	   enzymes	   developed	   through	   computational	  modeling	  and	  directed	  evolution	  have	  kcat/kuncat	  values	   that	  range	   from	  102	  to	  105).	   [52-­‐54,62]	   In	   part,	   this	   is	   due	   to	   the	   difficulty	   of	   designing	   a	   protein	   with	   the	   same	   ideal	  geometry	  of	  functional	  groups	  as	  present	  in	  the	  theozyme.	  The	  design	  and	  testing	  of	  small-­‐molecule	  “enzyme	  mimics”	  has	  been	  a	  tempting	  but	  frustrating	   target	   for	   organic	   chemists,[63-­‐67]	   and	   occasional	   success	   has	   been	  reported.[10,68,69]	  We	  conceived	  the	  melding	  of	  the	  Inside-­‐Out	  approach	  with	  our	  recent	  successes	   in	   spiroligozyme	   syntheses	   to	   mount	   catalytic	   groups	   from	   theozymes	   on	   a	  spiroligomer	   scaffold.[70]	   Spiroligomers	   are	   shape-­‐programmable	   macromolecules	  constructed	   by	   assembling	   stereochemically	   pure,	   cyclic,	   functionalized	   bis-­‐amino	   acids	  through	  pairs	  of	  amide	  bonds	  to	  create	  rigidified	  scaffolds	  that	  present	  functional	  groups	  in	  controlled	   three-­‐dimensional	   constellations	   by	   virtue	   of	   the	   sequence,	   shape	   and	  stereochemistry	   inherent	   in	   each	   chiral	   building	   block.[71-­‐73]	   Previously,	   spiroligomers	  have	   been	   utilized	   as	   catalysts	   for	   the	   aldol	   reaction	   and	   transesterification	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reaction.[18,70]	  We	  now	  report	  a	  combined	  computational	  and	  experimental	  approach	  to	  use	  spiroligozymes	  as	  catalysts	  for	  the	  aromatic	  Claisen	  rearrangement.	  
3.2	  Results	  and	  Discussion	  Bacterial	   Ketosteroid	   Isomerase	   (KSI)	   is	   heavily	   utilized	   as	   a	   model	   system	   for	  investigating	  fundamental	  aspects	  of	  enzyme	  catalysis.[1,74,75]	  Its	  natural	   function	  is	  the	  isomerization	   of	   the	   position	   of	   a	   double	   bond	   in	   steroids.	   	   The	   mechanism	   involves	   a	  general	   base	   that	   deprotonates	   the	   steroid	   forming	   a	   dienolate,	   which	   is	   stabilized	   via	  hydrogen	  bonding	  with	  a	  tyrosine-­‐16	  residue	  and	  a	  protonated	  aspartic	  acid-­‐104	  residue	  (see	   Figure	   1a).	   	   The	   stabilized	   intermediate	   is	   reprotonated	   and	   the	   double	   bond	  isomerized.	  	  The	  hydrogen	  bonding	  catalytic	  dyad	  was	  considered	  a	  promising	  modality	  for	  the	   stabilization	   of	   the	   growing	   negative	   charge	   in	   the	   transition	   state	   of	   the	   Claisen	  rearrangement	   (Figure	   1).	   It	   was	   proposed	   by	   Gerlt	   and	   Gassman	   that	   the	   formation	   of	  short,	   strong	   hydrogen	   bonds	   (SSHB,	   also	   called	   low-­‐barrier	   hydrogen	   bonds	   LBHB)	  between	  the	  KSI	  oxyanion	  hole	  and	  the	  reaction	  intermediate	  stabilizes	  the	  transition	  state	  of	  the	  reaction.[76,77]	  There	  has	  been	  an	  intense	  debate	  about	  the	  role	  of	  SSHBs	  in	  enzyme	  catalysis.[78,79]	  We	   designed	   a	   series	   of	   bio-­‐inspired	   spiroligozyme	   catalysts	   that	   display	   a	  carboxylic	   acid	   and	   a	   phenol	   on	   a	   spiroligomer	   backbone	   that	   resembles	   the	   hydrogen	  bonding	  catalytic	  dyad	  of	  KSI	  (see	  Figure	  1b).	  The	  use	  of	  a	  phenol	  and	  carboxylic	  acid	  is	  a	  stark	  departure	  from	  the	  currently	  utilized	  organocatalysts	  for	  the	  Claisen	  rearrangement,	  which	   generally	   rely	   on	   N-­‐H	   hydrogen-­‐bond	   donors.	   The	   optimized	   theozyme	   for	   the	  aromatic	  Claisen	  rearrangement	  using	  the	  KSI	  catalytic	  dyad	  (i.e.	  Asp/Tyr,	  see	  Figure	  1b)	  suggests	   that	   a	   105	   fold	   acceleration	   with	   respect	   to	   the	   background	   reaction	   could	   be	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achieved	  (at	  M06-­‐2X/6-­‐311+G(d,p)//M06-­‐2X/6-­‐31G(d)	  and	  in	  CPCM	  implicit	  solvation	  for	  CH2Cl2	  with	  e	  =	  4).	  	  
	  














	   Scheme	  3-­‐1.	   	   Solid	   phase	   assembly	   of	   Claisen	   catalysts	  19a-­‐j.	   	   	   a)	  HMBA	  Resin	   (1.1eq),	  MSNT	   (2eq),	  NMI	   (2eq),	  DCM	   (0.1M);	   b)	   33%	  HBr	   in	  AcOH/DCM	   (1:1,	   0.1M);	   c)	  Benzoic	  Acid	  derivative	  (3eq),	  HATU	  (3eq),	  DIPEA	  (6eq),	  NMP	  (0.2M);	  d)	  Substituted	  Amine	  (6eq),	  PyAOP	  (3eq),	  NMP	  (0.2M);	  (e)	  20%	  Piperidine	  in	  DMF	  (0.1M);	  f)	  N-­‐Boc-­‐Amino	  Acid	  (3eq),	  HATU	  (3eq),	  DIPEA	  (6eq),	  NMP	  (0.2M);	  g)	  TFA/DCM	  (1:1,	  0.1M);	  h)	  10%	  DIPEA	   in	  MeCN	  (0.05M).	  	   A	   series	   of	   molecules	   of	   this	   scaffold	   type	   were	   synthesized	   using	   solid	   phase	  synthesis	   on	   HMBA	   resin	   (Scheme	   1).[82]	   The	   bis-­‐amino	   acid[83]	   20	   was	   attached	   to	  HMBA	  resin	  with	  MSNT	  and	  NMI	  in	  DCM.	  	  The	  benzyl	  carbamate	  and	  tert-­‐butyl	  ester	  were	  then	  removed	  by	  treatment	  with	  33%	  HBr	  in	  AcOH	  as	  a	  1:1	  volumetric	  mixture	  with	  DCM.	  	  This	   treatment	   causes	   acetylation	   of	   all	   remaining	   hydroxyl	   groups	   on	   the	   resin.	   	   The	  benzoic	  acid	  derivative	  was	  introduced	  using	  HATU	  and	  DIPEA	  in	  NMP.	  	  The	  C-­‐2	  carboxylic	  acid	  was	  converted	   to	  an	  amide	  using	  PyAOP	  and	   the	  amine	  R3R4NH	   in	  NMP	  to	   form	  the	  resin	   bound	   intermediate	   21.	   	   The	   Fmoc	   group	   was	   removed	   using	   a	   20%	   solution	   of	  piperidine	   in	   DMF.	   	   The	   phenylalanine	   derivative	   was	   then	   introduced	   using	   HATU	   and	  DIPEA	  in	  NMP	  to	  produce	  intermediate	  22.	  	  The	  tert	  butyl	  carbamate,	  ester	  and	  ether	  were	  removed	   with	   treatment	   with	   a	   1:1	   volumetric	   mixture	   of	   TFA	   and	   DCM.	   The	   DKP	  was	  closed	  and	  subsequent	  cleavage	  from	  the	  resin	  was	  affected	  with	  a	  10%	  solution	  of	  DIPEA	  
	   	  




in	  MeCN.	  Purification	  with	  C18	  reverse	  phase	  HPLC	  yielded	  the	  pure	  catalysts	  19a-­‐j	  in	  60-­‐70%	  isolated	  yields	  (Table	  1).	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kinetics	  model.	  Table	  1	  lists	  relative	  rate	  constants	  for	  the	  catalysts	  as	  well	  as	  benzoic	  acid	  and	  diphenylguanidinium	  BARF	  catalyst.[11]	  The	   compound	   19a	   displayed	   a	   11-­‐fold	   rate	   enhancement	   relative	   to	   the	  background	  reaction	  (entries	  1-­‐2).	  19a	  was	  designed	  to	  display	  a	   terephthalic	  acid	  and	  a	  tyrosine	   in	   order	   to	   project	   a	   carboxylic	   acid	   and	   a	   phenol	   alcohol	   towards	   each	   other.	  Molecular	   modeling	   suggested	   that	   this	   would	   direct	   the	   terephthalic	   acid	   and	   phenol	  towards	  each	  other	  so	  that	  they	  could	  both	  simultaneously	  act	  as	  hydrogen	  bond	  donors	  to	  a	  single	  ether	  oxygen	  atom.	  This	  close	  approach	  of	  these	  two	  hydrogen-­‐bonding	  groups	  is	  promoted	  by	  the	  stereochemistry	  of	   the	  spirofused	  pyrrolidine	  and	  diketopiperazine	  ring	  onto	  which	   the	  groups	  are	  mounted	   (Figure	  1a).	  This	   close-­‐approach	   is	   analogous	   to	   the	  close-­‐approach	   that	   is	   achieved	   when	   a	   pyrene	   and	   a	   para-­‐dimethylaniline	   group	   are	  displayed	  in	  place	  of	  the	  terephthalic	  acid	  and	  phenol.[81]	  The	  C-­‐2	  amide	  was	  modified	  to	  primary	  and	  tertiary	  amides	  (entries	  3	  and	  4)	   to	  create	   the	  catalysts	  19b	  and	  19c	  which	  are	  more	   soluble	   in	  dichloroethane	  and	   this	  does	  not	   effect	   the	   catalytic	   rate,	   suggesting	  that	  the	  C2	  amide	  is	  not	  involved	  in	  hydrogen	  bond	  stabilization	  of	  the	  transition	  state.	  The	  cooperativity	   of	   the	   two	   hydrogen	   bond	   donor	   groups	   was	   probed	   by	   altering	   the	  stereochemistry	   of	   the	   bicyclic	   backbone	   to	   create	  19d,	  which	  modeling	   suggests	  would	  pull	  the	  two	  donors	  away	  from	  each	  other	  (entry	  5)	  –	  and	  the	  activity	  of	  19d	  drops	  to	  two-­‐fold	  above	  background,	  which	  is	  similar	  to	  the	  activity	  of	  benzoic	  acid	  alone	  (entry	  7).	  The	  cooperativity	  was	   further	  probed	  by	   removing	   the	  phenol	  alcohol	  using	  phenylalanine	   in	  place	  of	   tyrosine	   to	   form	  19e	   (entry	  6)	   and	   its	   activity	   is	   equivalent	   to	  19d	   and	  benzoic	  acid.	  Altering	  the	  substitution	  of	  the	  carboxylic	  acid	  on	  the	  benzoic	  acid	  derivative	  to	  meta	  (19f)	  and	  ortho	  (19g)	  leads	  to	  less	  well-­‐aligned	  hydrogen	  bond	  donor	  groups	  by	  modeling	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and	   leads	   to	   lower	   activity	   catalysts	   (entries	   8	   and	   9).	   	   Swapping	   the	   positions	   of	   the	  alcohol	   and	   the	   carboxylic	   acid	   (19h)	   brings	   the	   carboxylic	   acid	   and	   phenol	   alcohol	   in	  better	   alignment	   to	   simultaneously	   donate	   two	   hydrogen	   bonds	   to	   a	   single	   oxygen	   and	  increased	  the	  relative	  rate	  to	  30-­‐fold	  over	  background	  (entry	  10).	  	  Altering	  the	  position	  of	  the	  alcohol	  on	  the	  benzoic	  acid	  derivative	  to	  meta	  (19i)	  and	  ortho	  (19j)	  also	  leads	  to	  less-­‐well-­‐aligned	   hydrogen	   bond	   donor	   groups	   by	   modeling	   and	   led	   to	   less	   active	   catalysts	  (entries	   11	   and	   12).	   	   Diphenyl	   guanidinium	   BARF	   (DPGB;	   entry	   13)	   is	   a	   prototype	   of	   a	  series	   of	   asymmetric	   catalysts	   of	   the	   Claisen	   rearrangement	   developed	   by	   the	   Jacobsen	  group.[11]	  Under	  these	  reaction	  conditions	  DPGB	  generated	  the	  product	  24	  with	  a	  krel	  of	  14,	   however	   concomitant	   with	   product	   formation,	   significant	   amounts	   of	   side-­‐products	  were	  formed,	  as	  observed	  by	  analytical	  reverse	  phase	  C18	  HPLC	  analysis	  during	  the	  course	  of	   the	   reaction.	   	   Among	   these	   side-­‐products,	   the	   free	   coumarin	  was	   observed	   indicating	  that	  the	  guanidinium	  catalyst	  is	  effective,	  under	  these	  reaction	  conditions,	  at	  breaking	  the	  ether	   linkage	   between	   the	   coumarin	   oxygen	   and	   allylic	   carbon,	   possibly	   by	   acting	   as	   a	  Bronsted	  acid.	  Modeling	  suggests	  that	  the	  diketopiperazine	  ring	  of	  the	  BPC	  scaffold	  exists	  in	  a	  boat-­‐like	   conformation.	   The	   boat	   conformation	   and	   the	   rotamer	   preferences	   of	   the	   functional	  groups	   could	   be	   altered	   through	   N-­‐alkylation	   of	   the	   amide	   nitrogens	   within	   the	  diketopiperazine	   ring	   and	   this	   could	   alter	   the	   presentation	   of	   the	   phenol	   and	   carboxylic	  acid	   groups	   and	   change	   their	   catalytic	   activity.	   Dichloroethane	   solutions	   of	   19a-­‐j	   were	  cloudy	   at	   room	   temperature	   although	   clear	   at	   60ºC	   which	   we	   attributed	   to	  diketopiperazine-­‐tape	  formation	  at	  room	  temperature.[84]	  N-­‐alkylation	  could	  also	  improve	  the	   solubility	   of	   the	   catalysts	   in	   the	   dichloroethane	   solvent	   because	   it	   would	   disrupt	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hydrogen-­‐bonded	  tape-­‐formation.	  We	  created	  three	  N-­‐alkylated	  versions	  of	  19h,	  the	  mono	  N-­‐benzylated	  catalysts	  19k	  and	  19l,	  and	  the	  di-­‐N-­‐benzylated	  catalyst	  19m.	  	  
	   	  Scheme	  3-­‐2.	  	  Solid	  phase	  assembly	  of	  spiroligomer	  Claisen	  catalysts	  19k-­‐m.	  	  	  a)	  Substituted	  Amino	   Resin	   (1	   eq),	   HATU	   (1eq)	   DIPEA	   (2eq),	   NMP	   (0.2M);	   b)	   (P(Ph3)4)Pd(0)	   (0.3eq),	  BH3:DMA	  (6eq),	  DCM	  (0.1M);	  c)	  Benzoic	  Acid	  Derivative	  (3eq),	  HATU	  (3eq),	  DIPEA	  (6eq),	  NMP	   (0.2M);	   d)	   20%	   Piperidine	   in	   DMF	   (0.1M);	   e)	   PhCHO	   (2eq);	   NaH3BCN	   (2eq);	   DMF	  (0.1M);	  f)	  Boc-­‐Amino	  Acid	  (3eq);	  HATU	  (3eq),	  DIPEA	  (6eq);	  NMP	  (0.2M);	  g)	  TFA.	  	  In	  order	  to	  synthesize	  these,	  an	  alternative	  solid	  phase	  synthesis	  had	  to	  be	  devised	  to	  assemble	  the	  tetra	  and	  penta	  substituted	  DKP	  rings	  shown	  in	  Scheme	  2.	  The	  bis-­‐amino	  acid	  derivative	  [83]	  25	  was	  attached	  to	  an	  isobutyl	  amine	  modified	  formyl	  resin	  via	  HATU	  promoted	  acylation.	  	  The	  pyrollidine	  Alloc	  group	  was	  removed	  using	  Palladium	  catalyst	  in	  the	  presence	  of	  a	  scavenger	  and	  then	  acylated	  with	  the	  t-­‐butyl	  protected	  4-­‐hydroxy	  benzoic	  acid.	   	   The	   C-­‐4	   amino	   acid	   protecting	   group	   was	   then	   removed	   followed	   by	   reductive	  alkylation	  to	  the	  C-­‐4	  nitrogen	  with	  benzaldehyde	  to	  form	  26.	   	  The	  carboxy-­‐phenylalanine	  derivative	  was	  introduced	  via	  HATU	  promoted	  acylation	  to	  form	  27.	  Treatment	  of	  the	  resin	  with	   neat	   TFA	   was	   used	   to	   cleave	   the	   intermediate	   from	   the	   resin,	   which	   led	   to	  spontaneous	  diketopiperazine	  formation	  and	  concomitant	  removal	  of	  all	  protecting	  groups	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to	  yield	  19k-­‐m.	  	  Purification	  with	  reverse	  phase	  HPLC	  yielded	  the	  pure	  catalysts	  in	  75-­‐80%	  yields	  relative	  to	  solid	  support	  loading.	  Kinetic	  studies	  of	  catalysts	  19a,	  19h,	  and	  19k-­‐m	  are	  shown	  in	  figure	  2.	  Improvement	  in	  catalytic	  rate	  was	  observed	  over	  the	  course	  of	  each	  catalyst	  generation	  with	  19m	  (krel	  =	  58)	  providing	  the	  largest	  rate	  enhancement	  relative	  to	  the	  background	  reaction.	  	  
Figure	  3-­‐2.	  	  Claisen	  rearrangement	  product	  formation	  as	  a	  function	  of	  time	  and	  catalyst	  (0.2	  M	  substrate	  in	  dichloroethane,	  60ºC,	  0.02M	  catalyst).	  	  The	  catalyst	  19a	  was	  crystallized	  from	  water/acetonitrile	  1:1	  at	  room	  temperature	  and	   its	   crystal	   structure	  was	  determined	   (Figure	  3).	   In	   the	   crystal	   structure	   the	   tyrosine	  side	  chain	  is	  observed	  to	  fold	  back	  over	  the	  diketopiperazine	  and	  pyrrolidine	  rings	  in	  the	  conformation	   that	   was	   proposed	   for	   bifunctional	   hydrogen	   bonded	   catalysis.	   	   The	  terephthalic	   acid	   is	   rotated	   away	   from	   the	   tyrosine	   in	   one	   of	   the	   two	   available	   amide	  rotamers.	  The	  preference	  of	   this	   rotamer	  of	   the	   terephthalic	   acid	   in	   the	   crystal	   structure	  can	  be	  understood	  in	  terms	  of	  crystal	  packing	  forces	  and	  an	  intermolecular	  hydrogen	  bond	  between	   the	   amide	   carbonyl	   of	   the	   terephthalic	   acid	   and	   the	   tyrosine	   alcohol	   of	   another	  molecule	  of	  19a.	  The	  X-­‐ray	  crystal	  structure	  is	  very	  similar	  to	  the	  predicted	  conformation	  
19a’	  in	  Figure	  4b.	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  Figure	   3-­‐3.	   X-­‐ray	   crystal	   structure	   of	   19a	   illustrates	   the	   proposed	   catalytically	   active	  conformation	  of	  the	  tyrosine	  side-­‐chain	  and	  one	  of	  the	  two	  possible	  amide	  rotamers	  of	  the	  terphthalic	  acid.	  This	  X-­‐ray	  observed	  conformation	  is	  very	  similar	  to	  19a’	  (Figure	  4b),	  one	  of	  the	  lowest	  energy	  predicted	  structures	  of	  19a.	  	  We	  have	  explored	  the	  catalysis	  by	  19a,	  19h	  and	  19k-­‐m	  using	  Molecular	  Dynamics	  (MD)	   to	   explore	   the	   conformational	   space	  of	   each	   catalyst	   and	  used	  quantum	  mechanics	  (QM)	   to	   evaluate	   transition	   states.	  We	   performed	   a	   conformational	   analysis	   of	  19a,	  19h	  and	   19k-­‐m	   using	   the	   Monte	   Carlo	   (MCMM)	   method	   and	   the	   OPLS-­‐AA	   force	   field	   as	  implemented	  in	  the	  MacroModel	  computational	  package	  (see	  SI	  for	  a	  detailed	  description	  of	   the	   computational	   methods	   used).[85,86]	   In	   each	   case,	   20	   or	   more	   lower	   energy	  conformers	   were	   further	   re-­‐optimized	   using	   the	   hybrid	   meta	   exchange-­‐correlation	   DFT	  functional	  M06-­‐2X,[87,88]	  which	  includes	  medium-­‐range	  correlation,	  with	  the	  standard	  6-­‐31G(d)	  basis	  set.[89,90]	  Solvent	  effects	  were	  included	  with	  the	  Conductor-­‐like	  Polarizable	  Continuum	   Model	   (CPCM)[91]	   with	   dichloroethane	   as	   the	   solvent.	   M06-­‐2X/6-­‐31G(d)	  energies	   indicated	   that	   the	   lowest	   energy	   conformer	   for	   19h	   is	   from	   6.5	   up	   to	   18.6	  kcal/mol	  more	  stable	   than	   the	  rest	  of	   the	  computed	  conformers.	  The	  situation	   for	  19a	   is	  slightly	  different	  as	  the	  lowest	  energy	  conformer	  (BPC1a)	  is	  only	  0.6	  kcal/mol	  more	  stable	  than	  19a”,	  with	  the	  rest	  of	  the	  computed	  conformers	  being	  from	  4	  up	  to	  15	  kcal/mol	  higher	  in	   energy	   (see	   Figure	   4).	   19h	   and	   19a”	   both	   present	   close	   approaching,	   preorganized	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carboxylic	  acid	  and	  phenol	  groups	  for	  catalysis,	  while	  19a’	  has	  these	  two	  functional	  groups	  far	  separated	  (see	  Figure	  4).	  	  
	  Figure	  3-­‐4.	  M06-­‐2X/6-­‐31G(d)	   optimized	   structures	   for	   the	   lowest	   energy	   conformers	   for	  
19h,	  19a’	  and	  19a”.	  M06-­‐2X/6-­‐311+G(d,p)//M06-­‐2X/6-­‐31G(d)	  relative	  Gibbs	  free	  energies	  have	  been	  computed	  using	  the	  thermal	  corrections	  at	  M06-­‐2X/6-­‐31G(d)	  level	  (all	  distances	  are	  represented	  in	  Å).	  	   The	  optimized	  transition	  state	  structures	  with	  catalytic	  conformations	  of	  19h,	  19a’	  and	   19a”	   are	   shown	   in	   Figure	   6.	   The	   computed	   activation	   barrier	   for	   the	   Claisen	  rearrangement	   catalyzed	   by	  19h	   is	   26.0	   kcal/mol	  with	   respect	   to	   isolated	   reactants	   (i.e.	  
19h	  and	  the	  coumarin	  reactant).	  As	  a	  reference,	  the	  computed	  activation	  barrier	  in	  terms	  of	   free	   Gibbs	   energy	   for	   the	   background	   reaction	   is	   29.9	   kcal/mol	   at	   the	   M06-­‐2X/6-­‐311+G(d,p)//M06-­‐2X/6-­‐31G(d)	  level	  of	  theory	  in	  CPCM	  dichloroethane	  (see	  Figure	  5).	  	  The	  catalyzed	  reaction	  is	  bimolecular,	  and	  the	  rate	  of	  rearrangement	  is	  considerably	  faster	  than	  the	   background,	   but	   there	   is	   unfavorable	   entropy	   of	   association	   of	   the	   substrate	   and	  catalyst.	   The	   reactant	   complex	   between	  19h	   and	   the	   1,1-­‐dimethylallyl	   coumarin	   ether	   is	  2.1	   kcal/mol	   higher	   in	   Gibbs	   free	   energy	   than	   isolated	   reactants;	   that	   is,	   the	   nearly	   10	  kcal/mol	  binding	  is	  counteracted	  by	  –TΔS	  for	  the	  bimolecular	  association.	  In	  the	  transition	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state,	  both	  hydroxyl	  groups	  of	  19h	  are	  stabilizing	  the	  partial	  negative	  charge	  on	  the	  ether	  oxygen	  and	  are	  approximately	  1.7	  Å	  away	  (see	  Figure	  6).	  The	  breaking	  O-­‐C	  and	  the	  forming	  C-­‐C	  bond	  distances	  are	  2.274,	  2.416	  Å,	  respectively.	  	  	  
	  Figure	  3-­‐5.	  M06-­‐2X/6-­‐31G(d)	  optimized	  structures	   for	   the	  a)	   theozyme	  with	   the	  Asp/Glu	  and	  Tyr	  motif	  and	  b)	  the	  uncatalyzed	  reaction	  (all	  distances	  are	  represented	  in	  Å).	  	  	  For	   19a’,	   the	   catalysis	   of	   the	   aromatic	   Claisen	   rearrangement	   could	   be	   assessed	  considering	   two	  different	  approaches.	  The	  phenol	  group	  and	   the	  benzoic	  acid	  moiety	  are	  not	  in	  close	  contact.	  Instead,	  the	  hydroxyl	  group	  of	  the	  phenol	  is	  interacting	  with	  a	  carbonyl	  group	  of	  the	  bis-­‐peptide	  backbone	  (see	  Figures	  4b	  and	  6b).	  Therefore,	   the	  19a’	  catalyzed	  reaction	  was	  studied	  using	  either	  the	  phenol	  or	  the	  carboxylic	  group	  individually	  hydrogen	  bonded	   to	   the	   ether	   oxygen	   of	   the	   coumarin	   transition	   state.	   A	   lower	   energy	   transition	  state	  was	  found	  for	  the	  phenol-­‐mediated	  catalysis.	  	  This	  single	  hydrogen-­‐bonding	  TS	  has	  a	  computed	  Gibbs	  free	  activation	  barrier	  of	  28.6	  kcal/mol	  relative	  to	  isolated	  reactants,	  19a’	  and	  the	  coumarin	  ether.	  At	  the	  TS,	  the	  hydrogen	  bond	  distance	  between	  the	  ether	  oxygen	  and	  the	  hydrogen	  of	  the	  phenol	  is	  1.743	  Å,	  and	  the	  C-­‐O	  breaking	  and	  C-­‐C	  forming	  bond	  are	  2.159,	  and	  2.279	  Å,	  respectively.	  The	  coumarin	  analogue	  is	  nicely	  π-­‐stacked	  to	  the	  benzoic	  acid	  moiety	  (the	  distance	  between	  the	  center	  of	  mass	  of	  the	  benzene	  rings	  is	  approximately	  3.3	  Å).	   An	   enantiomer	   bound	   to	   the	   same	   catalyst	  was	   also	   found,	   but	  was	   0.2	   kcal/mol	  higher	  in	  energy.	  The	  transition	  state	  involving	  19a”,	  which	  has	  both	  hydroxyl	  groups	  in	  a	  closer	   disposition,	   presents	   an	   activation	   barrier	   that	   is	   0.1	   kcal/mol	   higher	   than	   the	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previous	  TS	   for	  19a’	   (the	  Gibbs	   free	   activation	  barrier	   compared	   to	   isolated	   reactants	   is	  28.7	  kcal/mol,	  see	  Figure	  6c).	  This	  slightly	  higher	  activation	  barrier	  is	  mainly	  attributed	  to	  the	  fact	  that	  only	  the	  hydroxyl	  group	  of	  the	  phenol	  moiety	  is	  stabilizing	  the	  negative	  charge	  of	   the	   ether	   oxygen,	   and	  more	   importantly	   the	   favorable	   π-­‐stacking	   interaction	   between	  the	  coumarin	  derivative	  and	  the	  benzoic	  acid	  moiety	  is	  lost	  (see	  Figure	  6c).	  	  








substituents.	   The	   difference	   in	   energy	   between	   the	   different	   conformers	   is	   less	   than	   4	  kcal/mol	  in	  all	  cases.	  	  
Figure	  3-­‐7.	  M06-­‐2X/6-­‐31G(d)	  optimized	  structures	  for	  the	  lowest	  energy	  conformers	  for	  a)	  
19k,	   b)	   19l	   and	   b)	   19m.	   The	   benzyl	   substituents	   have	   been	   marked	   in	   light	   green	   for	  clarity.	  All	  distances	  are	  represented	  in	  Å.	  	  Molecular	   Dynamics	   (MD)	   simulations	   using	   AMBER11[92]	   and	   a	   10	   Å	   truncated	  octahedral	  box	  with	  explicit	  chloroform	  molecules	  were	  performed	  in	  order	  to	  determine	  the	  relative	  free	  energies	  of	  catalytic	  and	  non-­‐catalytic	  conformers	  of	  the	  catalyst.	  In	  Figure	  8,	   the	   average	   distances	   between	   both	   oxygen	   atoms	   of	   the	   phenol	   and	   benzoic	   acid	  moieties	  of	  the	  spiroligozymes	  (dist	  OOH-­‐OOH)	  along	  the	  1	  microsecond	  MD	  simulation	  are	  represented.	   In	   Figure	   9,	   the	   histograms	   for	   the	   OOH-­‐OOH	   distance	   are	   provided.	   The	  standard	  deviation	  is	  also	  shown	  using	  a	  shaded	  area	  and	  has	  been	  computed	  every	  20	  ps.	  For	   each	   catalyst	   analyzed	   in	   this	   way	   (i.e	   19h	   and	   19k-­‐m),	   250	   superimposed	   MD	  snapshots	   have	   also	   been	   included	  where	   both	   the	   open	   and	   closed	   conformations	   have	  been	  marked	  using	  two	  different	  colors.	  The	  ideal	  arrangement	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  Figure	  3-­‐8.	  Representation	  of	  250	  superimposed	  MD	  snapshots	  for	  (a)	  19h,	  (b)	  19k,	  (c)	  19l	  and	   (d)	   19m.	   The	   plots	  monitoring	   the	   OOH-­‐OOH	   distance	   along	   the	   1	   microsecond	   MD	  trajectory	   for	   these	  catalysts	  are	  also	   included.	  The	  computed	  QM	  distance	  at	  M06-­‐2X/6-­‐31G(d)	  is	  ca.	  2.836	  Å.	  The	  standard	  deviation	  is	  also	  represented	  using	  a	  shaded	  area	  and	  has	  been	  calculated	  every	  10	  steps	  of	  the	  simulation	  (i.e.	  20	  ps)	  (all	  distances	  are	  expressed	  in	  Å).	  

























0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 

























0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 

























0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 

























0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 
5.16 ±2.61 




	   	  




	  for	  catalysis	   is	  substantially	  altered	  along	  the	  simulation	  for	  19h,	  19k	  and	  19m	  catalysts	  (see	  Figure	  8	  and	  10).	  The	  distance	  between	  the	  hydroxyl	  groups	  of	  both	  the	  phenol	  and	  benzoic	   acid	   moieties	   (d(OOH-­‐OOH))	   along	   the	   MD	   trajectory	   for	   19h	   and	   19k-­‐m	   are	  5.86±2.87,	   5.16±2.61,	   4.39±0.88,	   4.677±1.80	   Å,	   respectively.	   These	   distances	   are	  substantially	   longer	   than	   the	   optimized	  QM	   value	   of	   2.84	   Å,	   especially	   for	  19h	   and	  19k	  cases.	  The	  higher	  distance	  and	  deviation	  found	  for	  19h	  and	  19k	  is	  due	  to	  a	  conformational	  change	  that	  leads	  to	  an	  arrangement	  where	  both	  benzoic	  acid	  and	  phenol	  moieties	  are	  not	  interacting	  (see	  snapshots	   in	  Figure	  8,	  and	  histograms	  in	  Figure	  9).	   Interestingly,	   in	  most	  cases	   more	   than	   100	   ns	   of	   simulation	   is	   needed	   to	   observe	   the	   latter	   conformational	  change	   (see	  plots	   in	  Figure	  8).	  MD	  simulations	   indicate	   that	   the	   correct	   arrangement	   for	  catalysis	  is	  present	  68.5%	  of	  the	  simulation	  time	  for	  19h.	  In	  this	  suitable	  arrangement,	  the	  averaged	  OOH-­‐OOH	  distance	   is	  4.41±0.79	  Å,	  which	   is	   still	   substantially	   longer	   than	   the	  QM	  value	   of	   2.84	   Å.	   The	   distance	   between	   hydroxyl	   groups	   is	   less	   than	   3	   Å	   14.5%	   of	   the	  simulation	  time.	  The	  introduction	  of	  a	  benzyl	  substituent	  on	  the	  amide	  backbone	  leads	  to	  a	  substantial	  improvement.	  19k	  adopts	  the	  proper	  conformation	  for	  catalysis	  ca.	  74%	  of	  the	  simulation	   time,	   and	   the	   averaged	  OOH-­‐OOH	  distance	   for	   this	   arrangement	   is	   3.73±0.51	  Å.	  The	   arrangement	   stays	   close	   to	   the	  QM	  value	   (i.e.	   less	   than	  3	  Å)	   55.5%	  of	   the	   time.	   The	  benzoic	  acid	  moiety	  in	  19l	  stays	  in	  the	  proper	  orientation	  ca.	  99%	  of	  the	  time,	  however	  the	  OOH-­‐OOH	  distance	  is	  close	  to	  the	  QM	  value	  32.1%	  of	  the	  simulation	  time.	  19m,	  which	  have	  benzyl	  substituents	  on	  both	  amide	  backbone	  nitrogens,	  adopt	  the	  correct	  arrangement	  ca.	  94%	   of	   the	   time	   during	   the	  MD	   trajectory.	   The	   averaged	   OOH-­‐OOH	   distance	   for	   the	  19m	  suitable	   arrangement	   for	   catalysis	   is	   4.41±0.79	   Å;	   the	   OOH-­‐OOH	   distance	   is	   less	   than	   3	   Å	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31.9%	  of	  the	  time.	  The	  MD	  simulations	  performed	  on	  the	  free	  catalysts	  have	  shown	  that	  the	  ideal	  arrangement	   for	  catalysis	   is	  substantially	  modified,	  especially	   in	   the	  case	  of	  19h.	   In	  the	  case	  of	  19k,	  19l	  and	  19m,	  those	  conformers	  with	  the	  suitable	  arrangement	  for	  catalysis	  present	  averaged	  OOH-­‐OOH	  distances	   closer	   to	   the	  optimized	  QM	  value.	  These	   simulations	  indicate	  the	  fraction	  of	  conformers	  that	  have	  the	  catalytic	  groups	  properly	  preorganized	  for	  catalysis.	  	  	  
















































































































































































































complexes	  are	  ca.	  5-­‐6	  kcal/mol	  higher	   in	  Gibbs-­‐free	  energy	  than	   isolated	  reactants	   in	   the	  case	   of	  19k	   and	  19l,	   and	   ca.	   3	   kcal/mol	   in	  19m.	   In	   all	   cases,	   the	   breaking	   O-­‐C	   and	   the	  forming	   C-­‐C	   bond	   distances	   are	   approximately	   2.260	   and	   2.390	   Å	   (see	   Figure	   10).	   The	  hydrogen	   bonds	   formed	   between	   the	   ether	   oxygen	   and	   the	   phenol	   and	   benzoic	   acid	  moieties	  to	  stabilize	  the	  partial	  negative	  charge	  are	  1.710	  and	  1.692,	  and	  1.734	  and	  1.640	  Å	  in	  19k	   and	  19l,	   respectively.	   Interestingly,	  19m	  presents	  slightly	  shorter	  hydrogen	  bond	  distances	  of	  1.620	  and	  1.718	  Å.	  	  
	  Figure	   3-­‐10.	   M06-­‐2X/6-­‐311+G(d,p)//M06-­‐2X/6-­‐31G(d)	   optimized	   transition	   state	  structures	   for	   the	   Claisen	   rearrangement	   catalyzed	   by	   (a)	  19k,	   (b)	  19l	   and	   (c)	  19m	   in	  dichloroethane	  using	  CPCM	  implicit	  solvation	  model.	  The	  uncatalyzed	  reaction	  has	  a	  Gibbs	  free	  activation	  barrier	  of	  29.9	  kcal/mol.	  All	  distances	  are	  represented	  in	  Å.	  	  	  The	   computed	   activation	   barriers	   for	   the	   uncatalyzed,	   19a,	   19h	   and	   19k-­‐m	  catalyzed	   Claisen	   rearrangements	   are	   29.9,	   28.7,	   26.0,	   26.6,	   27.2	   and	   23.5	   kcal/mol,	  respectively.	   MD	   simulations	   have	   shown	   that	   19h	   and	   19k-­‐m	   adopt	   the	   appropriate	  conformation	   for	   catalysis	   (the	   hydroxyl	   distance	   is	   less	   than	  3	  Å)	   14.5%,	   55.5%,	   32.1%	  
	  




and	  31.9%	  of	  the	  simulation	  time,	  respectively.	  The	  latter	  fraction	  of	  conformers	  (f)	  in	  the	  catalytic	   conformation	   can	   be	   used	   to	   estimate	   the	   experimental	   rate	   constant	   (kcat	   =	  f•kcat,computed).	   This	   leads	   to	   a	   computed	   kcat/kuncat	   of	   ca.	   100	   and	   15,800	   for	  19h	   and	  
19m	  with	  respect	  to	  the	  background	  reaction,	  respectively.	  Although	  the	  fraction	  of	  active	  conformers	   from	   the	   MD	   has	   been	   included,	   the	   predicted	   values	   are	   substantially	  overestimated	  compared	  to	  the	  experimentally	  observed	  krel	  values.	  	  	  
3.3	  Conclusions	  We	  have	  developed	  a	  series	  of	  bifunctional	  hydrogen-­‐bond	  donor	  catalysts	  for	  the	  aromatic	  Claisen	  rearrangement	  modeled	  on	  the	  active	  site	  of	  Ketosteroid	  Isomerase.	  These	  catalysts	  are	   designed	   to	   present	   a	   carboxylic	   acid	   and	   a	   phenol	   alcohol	   that	   each	   simultaneously	  donates	   one	   hydrogen	   bond	   donor	   to	   a	   single	   ether	   oxygen	   of	   the	   1,1-­‐dimethylallyl	  coumarin	  substrate	  to	  stabilize	  the	  developing	  negative	  charge	  on	  the	  ether	  oxygen	  in	  the	  transition	  state	  of	  the	  Claisen	  rearrangement.	  The	  catalysts	  provide	  increasing	  reactivity	  as	  they	   better	   organize	   their	   hydrogen	   bonding	   groups	   and	   more	   closely	   approximate	   the	  functional	  group	  display	  observed	  in	  Ketosteroid	  Isomerase	  and	  as	  they	  are	  better	  able	  to	  stabilize	  the	  transition	  state	  as	  determined	  by	  transition	  state	  modeling.	  The	  first	  designed	  catalyst	  19a	  accelerates	  the	  reaction	  11-­‐fold	  relative	  to	  background	  while	  the	  best	  catalyst	  
19m,	   accelerates	   the	  reaction	  58-­‐fold.	  The	  combined	  QM	  and	  MD	  computational	  study	  of	  these	  systems	  established	   that	  19m	   gives	  a	  higher	  acceleration	  of	   the	  reaction	  due	   to	  an	  optimal	  disposition	  of	  the	  hydroxyl	  groups	  of	  both	  the	  phenol	  and	  benzoic	  acid	  moieties	  in	  both	  the	  TS	  and	  the	  reactant	  complex.	  This	  optimal	  arrangement	  is	  induced	  by	  the	  benzyl	  substituents	   of	   the	   amide	   backbone,	   which	   limit	   the	  movement	   of	   the	   benzoic	   acid	   and	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phenol	   moieties.	   MD	   simulations	   have	   determined	   that	   this	   arrangement	   is	   better	  conserved	   in	   the	   case	  of	  19m	   and	  19k	   cases.	  The	  higher	   efficiency	  of	  19m	   compared	   to	  




General	  Methods	  All	  Bis	  amino	  acid	  starting	  materials	  were	  synthesized	  according	  to	  literature	  procedure.22	  Diphenylguandidinium	  BARF	  catalyst	  was	  synthesized	  according	  to	  literature	  procedure.23	  Anhydrous	   N-­‐methylpyrrolidinone,	   anhydrous	   dimethylformamide,	   anhydrous	  dichloromethane	   were	   purchased	   from	   Acros.	   HATU	   was	   purchased	   from	   Genscript.	  	  PyAOP	  was	  purchased	  from	  Oakwood.	  	  MSNT	  and	  solid	  phase	  resins	  were	  purchased	  from	  Novabiochem.	   	   All	   amino	   acids	   were	   purchased	   from	   Bachem.	   	   Redistilled	  diisopropylethylamine,	   tetrakis(triphenylphosphine)	   palladium0	   ,borane:	   dimethyl-­‐amine	  complex,	   diisopropylcarbodiimide,	   and	   all	   other	   reagents	   were	   purchased	   from	   Aldrich.	  Flash	   Chromatography	  was	   perfored	   on	   an	   ISCO	   CombiFlash	   Companion	  with	   cartridges	  filled	   with	   Bodman	   32-­‐63	   D	   (60.)	   grade	   silica	   gel.	   	   Analytical	   HPLC-­‐MS	   analysis	   was	  performed	  on	  a	  Hewlett-­‐Packard	  Series	  1200	  with	  a	  Waters	  Xterra	  MS	  C18	  column	  (3.5um	  packing,	  4.6	  mm	  x	  100mm)	  with	  a	  solvent	  system	  of	  water/acetonitrile	  with	  0.1%	  formic	  acid	  at	  a	  flow	  rate	  of	  0.8mL/min.	  Preparatory	  Scale	  HPLC	  purification	  was	  performed	  on	  a	  Varian	  Prostar	  Prep	  HPLC	  with	  a	  Waters	  Xterra	  column	  (5um	  packing,	  19mm	  x	  100mm)	  with	   a	   solvent	   system	   of	   water/acetonitrile	   with	   0.1%	   formic	   acid	   at	   a	   flow	   rate	   of	  12mL/min.	  	  NMR	  experiments	  were	  performed	  on	  a	  Bruker	  500mHz	  NMR	  with	  a	  chemical	  shifts	   (δ)	   reported	   relative	   to	  DMSO-­‐d6	  or	  CDCl3	   residual	   solvent	  peaks.	   	  HRESIQTOFMS	  analysis	  was	  performed	  by	  Ohio	  State	  University.	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Synthesis	  of	  Claisen	  substrate	  24	  
	  
	  
	  To	   a	   solution	   of	   4-­‐methylumbelliferone	   (880.9mg,	   5	   mmoles)	   and	   1,1-­‐dimethylallyl	  isobutyl	   carbonate	   (1.86g,	   10	   mmoles)	   in	   90mL	   dichloromethane	   (DCM)	   was	   added	  tetrakis(triphenyl-­‐phosphine)palladium0	   (1.1g,	   1	  mmole)	   in	  10mL	  of	  DCM.	   	  The	   reaction	  was	   allowed	   to	   stir	   at	   room	   temperature	   for	   12	   hours	   then	   concentrated	   on	   celite	   and	  purified	  by	  silica	  gel	  chromatography	  (gradient	  elution	  from	  10%	  ethyl	  acetate	  in	  hexanes	  to	  100%	  ethyl	  acetate.	  	  The	  product	  containing	  fractions	  were	  combined	  and	  concentrated	  under	   reduced	   pressure	   to	   yield	   the	   product	   as	   a	   white	   powder	   (86%,	   1g).	   	   1H	   NMR	  (500MHz,	  CDCl3,	  273K,	  δ)	  7.4	  (d,	  1H,	  J=8.8),	  7.0	  (s,	  1H),	  6.9	  (m,	  1H),	  6.1	  (m,	  2H),	  5.2	  (dd,	  2H,	  












Solid	  Phase	  Assembly	  of	  19a-­‐j	  
	  a)	   HMBA	   Resin	   (1.1eq),	   MSNT	   (2eq),	   NMI	   (2eq),	   DCM	   (0.1M);	   b)	   33%	   HBr	   in	  AcOH/DCM	   (1:1,	   0.1M);	   c)	   Benzoic	   Acid	   Derivative	   (3eq),	   HATU	   (3eq),	   DIPEA	   (6eq),	  NMP	  (0.2M);	  d)	  Substituted	  Amine	  (6eq),	  PyAOP	  (3eq),	  NMP	  (0.2M);	  (e)	  20%	  Piperidine	  in	   DMF	   (0.1M);	   f)Boc-­‐Amino	   Acid	   (3eq),	   HATU	   (3eq),	   DIPEA	   (6eq),	   NMP	   (0.2M);	   g)	  TFA/DCM	  (1:1,	  0.1M);	  h)	  10%	  DIPEA	  in	  MeCN	  (0.05M).	  
	  



















































for	  30	  minutes	  then	  added	  to	  a	  pre-­‐swelled	  portion	  of	  HMBA	  resin	  (1.1	  equivalents).	  	  The	  reaction	  was	  stirred	  overnight	  and	  filtered	  and	  washed	  with	  DMF,	  DCM,	  and	  DMF.	  	  
General	  Procedure	  (B):	  	  tBu	  and	  Cbz	  Deprotection	  	  A	   solution	   of	   33%	  Hydrogen	   Bromide	   in	   Acetic	   Acid	  was	  mixed	   1:1	   volumetrically	  with	  dichloromethane	  (DCM)	  (10mL/mmole	  based	  on	  resin	  loading)	  was	  added	  to	  the	  resin	  and	  stirred	  for	  30	  minutes,	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF.	  	  
General	  Procedure	  (C,F):	  	  HATU	  Coupling	  	  To	  a	  solution	  of	  the	  acid	  (3	  equivalents	  based	  on	  resin	   loading)	  and	  HATU	  (3	  equivalents	  based	   on	   resin	   loading	   in	   N-­‐methylpyrrolidine	   (NMP)	   (5mL/mmole	   of	   acid)	   was	   added	  diiso-­‐propylethylamine	   (DIPEA)	   (6	   equivalents	   based	   on	   resin	   loading).	   The	   reaction	  mixture	   was	   added	   to	   a	   pre-­‐swelled	   (in	   dimethylformamide)	   portion	   of	   resin	   in	   a	   solid	  phase	   reactor	   and	   stirred	   for	   45	  minutes.	   The	   resin	  was	   filtered	   and	  washed	  with	  DMF,	  DCM,	  DMF.	  
	  
General	  Procedure	  (D):	  	  PyAOP	  Coupling	  	  To	  a	  solution	  of	  the	  amine	  (3	  equivalents	  based	  on	  resin	  loading)	  and	  PyAOP	  (3	  equivalents	  based	  on	  resin	   loading	   in	  N-­‐methylpyrrolidine	  (NMP)	  (5mL/mmole	  of	  amine)	  was	  added	  diiso-­‐propylethylamine	   (DIPEA)	   (6	   equivalents	   based	   on	   resin	   loading).	   The	   reaction	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mixture	   was	   added	   to	   a	   pre-­‐swelled	   (in	   dimethylformamide)	   portion	   of	   resin	   in	   a	   solid	  phase	   reactor	   and	   stirred	   for	   45	  minutes.	   The	   resin	  was	   filtered	   and	  washed	  with	  DMF,	  DCM,	  DMF.	  	  
General	  Procedure	  (E):	  Fmoc	  Deprotection	  	  A	  solution	  of	  of	  piperidine	  was	  mixed	  1:4	  volumetrically	  with	  dimethylformamide	  (DMF)	  (15mL/mmole	   based	   on	   resin	   loading)	  was	   added	   to	   a	   pre-­‐swelled	   (in	   DMF)	   portion	   of	  resin	  in	  a	  solid	  phase	  reactor	  and	  stirred	  for	  15	  minutes.	  The	  resin	  was	  filtered	  and	  washed	  with	  DFM,	  DCM,	  DMF.	  	  
General	  Procedure	  (G):	  	  Boc	  Deprotection	  	  A	   solution	   of	   Trifluoroacetic	   acid	   was	   mixed	   1:1	   volumetrically	   with	   dichloromethane	  (DCM)	   (10mL/mmole	   based	   on	   resin	   loading)	   was	   added	   to	   the	   resin	   and	   stirred	   for	   2	  hours,	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF.	  	  
General	  Procedure	  (H):	  	  Liberation	  from	  HMBA	  resin	  and	  DKP	  Formation	  
	  A	   solution	   of	   diisopropylethylamine	   (DIPEA)	   was	   mixed	   1:9	   volumetrically	   with	  acetonitrile	  (MeCN)	  was	  added	  to	  the	  resin	  and	  stirred	  overnight,	  filtered,	  and	  the	  filtrated	  was	  acidified	  with	  with	  a	  10%	  Formic	  acid	  solution	  in	  water	  and	  freeze-­‐dried.	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19a	  	  HMBA	  Resin	  (220mg,	  200umoles	   loading)	  was	  placed	  in	  a	  8	  mL	  solid	  phase	  reactor.	   	  The	  bis	  amino	  acid	  was	  attached	  according	  to	  general	  procedure	  (A)	  and	  modified	  according	  to	  the	   above	   scheme	   to	   yield	   BPC1	   as	   a	   white	   powder	   (72%,	   75mg)	   after	   purification	   by	  reverse-­‐phase	  chromatography	  (gradient	  elution	  over	  30	  minutes	  from	  5-­‐95%	  acetonitrile	  in	  water	  modified	  with	  0.1%	  formic	  acid.	  	  1H	  NMR	  (500MHz,	  DMSO-­‐d6,	  333K,	  δ)	  8.2	  (d,	  2H,	  
J=8.3),	  8.1	  (d,	  2H,	  J=8.2),	  7.0	  (d,	  2H,	  J=8.5),	  6.8	  (d,	  2H,	  J=8.5),	  4.5	  (t,	  1H,	  J=8.3,7.9),	  4.3	  (t,	  1H,	  














19b	  	  HMBA	  Resin	  (220mg,	  200umoles	   loading)	  was	  placed	  in	  a	  8	  mL	  solid	  phase	  reactor.	   	  The	  bis	  amino	  acid	  was	  attached	  according	  to	  general	  procedure	  (A)	  and	  modified	  according	  to	  the	   above	   scheme	   to	   yield	   BPC1	   as	   a	   white	   powder	   (79%,	   74mg)	   after	   purification	   by	  reverse-­‐phase	  chromatography	  (gradient	  elution	  over	  30	  minutes	  from	  5-­‐95%	  acetonitrile	  in	  water	  modified	  with	  0.1%	  formic	  acid.	  	  1H	  NMR	  (500MHz,	  DMSO-­‐d6,	  333K,	  δ)	  8.2	  (d,	  2H,	  
J=8.3),	  8.2	  (d,	  2H,	  J=8.2),	  7.0	  (d,	  2H,	  J=8.5),	  6.9	  (d,	  2H,	  J=8.5),	  4.5	  (t,	  1H,	  J=8.3,7.9),	  4.3	  (t,	  1H,	  













19c	  	  HMBA	  Resin	  (220mg,	  200umoles	   loading)	  was	  placed	  in	  a	  8	  mL	  solid	  phase	  reactor.	   	  The	  bis	  amino	  acid	  was	  attached	  according	  to	  general	  procedure	  (A)	  and	  modified	  according	  to	  the	   above	   scheme	   to	   yield	   BPC1	   as	   a	   white	   powder	   (70%,	   73mg)	   after	   purification	   by	  reverse-­‐phase	  chromatography	  (gradient	  elution	  over	  30	  minutes	  from	  5-­‐95%	  acetonitrile	  in	  water	  modified	  with	  0.1%	  formic	  acid.	  	  1H	  NMR	  (500MHz,	  DMSO-­‐d6,	  333K,	  δ)	  8.2	  (d,	  2H,	  
J=8.3),	  8.1	  (d,	  2H,	  J=8.2),	  7.0	  (d,	  2H,	  J=8.5),	  6.8	  (d,	  2H,	  J=8.5),	  4.5	  (t,	  1H,	  J=8.3,7.9),	  4.3	  (t,	  1H,	  
J=4.7,4.9),	  3.1	  (d,	  1H,	  J=13.8),	  2.8	  (m,	  2H),	  2.6	  (d,	  1H,	  J=7.0),	  2.5	  (d,	  2H,	  J=12.2),	  2.4	  (d,	  2H,	  













19d	  	  HMBA	  Resin	  (220mg,	  200umoles	   loading)	  was	  placed	  in	  a	  8	  mL	  solid	  phase	  reactor.	   	  The	  bis	  amino	  acid	  was	  attached	  according	  to	  general	  procedure	  (A)	  and	  modified	  according	  to	  the	   above	   scheme	   to	   yield	   BPC1	   as	   a	   white	   powder	   (70%,	   73mg)	   after	   purification	   by	  reverse-­‐phase	  chromatography	  (gradient	  elution	  over	  30	  minutes	  from	  5-­‐95%	  acetonitrile	  in	  water	  modified	  with	  0.1%	  formic	  acid.	  	  1H	  NMR	  (500MHz,	  DMSO-­‐d6,	  333K,	  δ)	  8.2	  (d,	  2H,	  
J=8.3),	  8.1	  (d,	  2H,	  J=8.2),	  7.0	  (d,	  2H,	  J=8.5),	  6.7	  (d,	  2H,	  J=8.5),	  4.5	  (t,	  1H,	  J=8.3,7.9),	  4.3	  (t,	  1H,	  









































19g	  	  HMBA	  Resin	  (220mg,	  200umoles	   loading)	  was	  placed	  in	  a	  8	  mL	  solid	  phase	  reactor.	   	  The	  bis	  amino	  acid	  was	  attached	  according	  to	  general	  procedure	  (A)	  and	  modified	  according	  to	  the	   above	   scheme	   to	   yield	   BPC1	   as	   a	   white	   powder	   (65%,	   68mg)	   after	   purification	   by	  reverse-­‐phase	  chromatography	  (gradient	  elution	  over	  30	  minutes	  from	  5-­‐95%	  acetonitrile	  in	  water	  modified	  with	  0.1%	  formic	  acid.	  	  1H	  NMR	  (500MHz,	  DMSO-­‐d6,	  333K,	  δ)	  7.9	  (d,	  1H,	  
J=7.5),	   7.8	   (d,	   1H,	   J=7.5),	   7.7	   (m,	   2H),	   7.0	   (d,	   2H,	   J=8.5),	   6.8	   (d,	   2H,	   J=8.5),	   4.5	   (t,	   1H,	  
J=8.3,7.9),	  4.3	  (t,	  1H,	  J=4.7,4.9),	  3.1	  (d,	  1H,	  J=13.8),	  2.8	  (m,	  2H),	  2.6	  (d,	  1H,	  J=7.0),	  2.5	  (d,	  2H,	  














19h	  	  HMBA	  Resin	  (220mg,	  200umoles	   loading)	  was	  placed	  in	  a	  8	  mL	  solid	  phase	  reactor.	   	  The	  bis	  amino	  acid	  was	  attached	  according	  to	  general	  procedure	  (A)	  and	  modified	  according	  to	  the	   above	   scheme	   to	   yield	   BPC1	   as	   a	   white	   powder	   (74%,	   77mg)	   after	   purification	   by	  reverse-­‐phase	  chromatography	  (gradient	  elution	  over	  30	  minutes	  from	  5-­‐95%	  acetonitrile	  in	  water	  modified	  with	  0.1%	  formic	  acid.	  	  1H	  NMR	  (500MHz,	  DMSO-­‐d6,	  333K,	  δ)	  8.2	  (d,	  2H,	  
J=8.3),	  8.1	  (m,	  6H),	  6.8	  (d,	  2H,	  J=8.5),	  4.5	  (t,	  1H,	  J=8.3,7.9),	  4.3	  (t,	  1H,	  J=4.7,4.9),	  3.1	  (d,	  1H,	  









































Solid	  Phase	  Assembly	  of	  19k-­‐m	  	  
	  	  a)	   Substituted	   Amino	   Resin	   (1	   eq),	   HATU	   (1eq)	   DIPEA	   (2eq),	   NMP	   (0.2M);	   b)	  (P(Ph3)4)Pd(0)	   (0.3eq),	   BH3:DMA	   (6eq),	   DCM	   (0.1M);	   c)	   Benzoic	   Acid	   Derivative	   (3eq),	  HATU	  (3eq),	  DIPEA	  (6eq),	  NMP	  (0.2M);	  d)	  20%	  Piperidine	  in	  DMF	  (0.1M);	  e)	  PhCHO	  (2eq);	  NaH3BCN	   (2eq);	   DMF	   (0.1M);	   f)	   Boc-­‐Amino	   Acid	   (3eq);	   HATU	   (3eq),	   DIPEA	   (6eq);	   NMP	  (0.2M);	  g)	  TFA	  	  

























































and	  washed	  with	  DMF,	  DCM,	  DMF.	  	  
General	  Procedure	  (B):	  	  Alloc	  Cleavage	  	  A	   solution	   of	   borane:dimethylamine	   complex	   (6	   equivalents	   based	   on	   resin	   loading)	   in	  dichloromethane	  (DCM)	  (10mL/mmole	  based	  on	  resin	  loading)	  was	  added	  to	  a	  pre-­‐swelled	  (in	  DMF)	  portion	  of	  resin	  in	  a	  solid	  phase	  reactor	  and	  stirred	  for	  5	  minutes.	  To	  this	  solution	  was	  added	  a	  solution	  of	  tetrakis(triphenylphosphine)palladium0	  (0.1	  equivalents	  based	  on	  resin	   loading)	   in	  DCM	   (10mL/mmole	   based	   on	   resin	   loading).	   The	   reaction	  mixture	  was	  stirred	  for	  2	  hour.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF	  	  
General	  Procedure	  (C,F):	  	  HATU	  Coupling	  	  To	  a	  solution	  of	  the	  acid	  (3	  equivalents	  based	  on	  resin	   loading)	  and	  HATU	  (3	  equivalents	  based	   on	   resin	   loading	   in	   N-­‐methylpyrrolidine	   (NMP)	   (5mL/mmole	   of	   acid)	   was	   added	  diiso-­‐propylethylamine	   (DIPEA)	   (6	   equivalents	   based	   on	   resin	   loading).	   The	   reaction	  mixture	   was	   added	   to	   a	   pre-­‐swelled	   (in	   dimethylformamide)	   portion	   of	   resin	   in	   a	   solid	  phase	   reactor	   and	   stirred	   for	   45	  minutes.	   The	   resin	  was	   filtered	   and	  washed	  with	  DMF,	  DCM,	  DMF.	  
	  
General	  Procedure	  (D):	  Fmoc	  and	  OFm	  Cleavage	  	  A	  solution	  of	  of	  piperidine	  was	  mixed	  1:4	  volumetrically	  with	  dimethylformamide	  (DMF)	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(15mL/mmole	   based	   on	   resin	   loading)	  was	   added	   to	   a	   pre-­‐swelled	   (in	   DMF)	   portion	   of	  resin	   in	  a	   solid	  phase	  reactor	  and	  stirred	   for	  2	  hours.	  The	  resin	  was	   filtered	  and	  washed	  with	  DFM,	  DCM,	  DMF.	  	  
General	  Procedure	  (E):	  	  Reductive	  Alkylation	  	  A	  solution	  of	  aldehyde	  (2	  equivalents	  based	  on	  resin	  loading)	  in	  dimethylformamide	  (DMF)	  (5mL/mmole	  based	  on	  resin	  loading)	  was	  added	  to	  a	  pre-­‐swelled	  (in	  DMF)	  portion	  of	  resin	  in	  a	  solid	  phase	  reactor	  and	  stirred	   for	  2	  hours.	  To	   this	   solution	  was	  added	  a	  solution	  of	  sodium	   cyanoborohydride	   (2	   equivalents	   based	   on	   resin	   loading)	   in	   DMF	   (5mL/mmole	  based	  on	  resin	  loading).	  The	  reaction	  mixture	  was	  stirred	  overnight.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF	  	  
General	  Procedure	  (G):	  	  Liberation	  from	  Resin	  and	  DKP	  Formation	  	  A	   solution	   of	   5%	   triisopropylsilane	   and	   5%	  water	   in	   trifluoroacetic	   acid	   (25	  mL/mmole	  based	   on	   resin	   loading	   was	   added	   to	   a	   portion	   of	   resin	   (successively	   washed	   with	  dichloromethane	   and	   methanol,	   and	   thoroughly	   dried	   under	   vacuum)	   and	   stirred	  overnight.	   The	   resin	   was	   filtered	   and	   washed	   with	   trifluoroacetic	   acid.	   The	   filtrate	   was	  concentrated,	   reconstituted	   in	  75%	  acetonitrile	   in	  water	   (0.05%	   formic	  acid)	  and	   freeze-­‐dried.	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Kinetic	  Measurements	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0.2 M DCE, 20% cat, 60oC, 84hr
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  Table	  3-­‐2.	  	  Kinetic	  Raw	  Data	  
	  90	  
	  











































HPLC of 19m @ 58 hours  
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  Figure	  3-­‐13:	  	  HPLC	  of	  19k	  @	  58	  hours	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4.2	  Results	  and	  Discussion	  	  
	  	  	  	  	  	  	  Figure	   4-­‐1.	   	   Structures	   of	   Spiroligomer	   macrocycles.	   	   Macrocycle	   28	   is	   derived	   from	   2	  oligomers	  and	  macrocycle	  29	  is	  derived	  from	  3	  oligomres.	  	  	  













































































































surrounded	  with	  functionality.	  	  These	  two	  factors	  are	  very	  protein-­‐like	  in	  essence	  and	  are	  uncommon	  features	  in	  other	  synthetic	  materials.	   	  For	  this	  reasons,	  this	  class	  of	  molecules	  are	  called	  “Fauxteins”.	  
	  
	  	  	  	  	  Figure	   4-­‐2.	   	   Structure	   of	   a	   spiroligomer	   bundle	   (called	   a	   “Fauxtein”)	   derived	   from	   3	  segments	  
	  












































































(pyrrolidine	   nitrogens	   of	   the	   green	   and	   blue	   oligomers)	   and	   two	   electrophiles	  (bromoacetates	  on	  the	  red	  and	  green	  oligomers)	  onto	  the	  open	  form	  will	  result	  in	  only	  one	  possible	   reaction	   outcome.	   	   The	   two	   electrophiles	   won’t	   cross-­‐react	   nor	   will	   the	   two	  nucleophiles.	  	  With	  the	  right	  set	  up,	  as	  shown	  in	  Figure	  4-­‐3,	  the	  green	  oligomer	  nucleophile	  can	  only	  attack	  the	  electrophile	  on	  the	  red	  oligomer	  (bromine	  atom	  is	  highlighted	  in	  green).	  	  	  The	   green	   oligomer	   cannot	   physically	   reach	   the	   other	   electrophile	   (bromine	   atom	   is	  highlighted	   in	   blue).	   	   The	   rigidity	   of	   the	   spiroligomers	   prevents	   the	   blue	   electrophile	   to	  come	  in	  contact.	   	  The	  same	  argument	  can	  be	  made	  for	  the	  second	  nucleophile	  on	  the	  blue	  oligomer.	   	   Like	   with	   other	   macrocyclization	   and	   ligations,	   polymerization	   is	   a	   very	   real	  concern.	  
	  
Figure	  4-­‐3.	  	  Crosslinking	  strategy	  for	  Fauxtein	  31	  












































































































































































































































































































































































































































































































































































































































































(m) 	  32 
31 
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Treatment	  with	  TFA	  soln	  removed	  all	   the	  BOC	  groups	  and	  cleaves	   the	  molecule	   from	  the	  resin	  to	  yield	  the	  open	  form	  32.	  	  The	  additional	  crosslinks	  can	  be	  formed	  by	  treatment	  with	  1:99	  TEA/DMF	  mixture	  (0.0015M)	  to	  provide	  31.	  
Figure	  4-­‐4.	  	  HPLC	  and	  MS	  traces	  for	  32	  and	  31.	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carry	   three	   functional	   groups	   at	   the	   internal	   DKPs.	   	   The	   stereochemistry	   was	   modeled	  using	  AMBER	  94	   force	   field	   to	  come	  up	  with	  a	  design	  that	  create	  as	  many	   inter-­‐oligomer	  functional	  group	   interactions	  as	  possible.	   	  Additonally	   the	   functional	  groups	   in	  proximity	  are	  as	  different	  as	  possible.	  Every	  aspect	  of	  it	  has	  been	  maticulously	  optimized	  for	  solution	  characterization	   by	   NMR.	   	   Lastly	   and	   most	   importantly,	   the	   building	   blocks	   will	   be	   15N	  labelled	   at	   the	   C-­‐4	   position.	   [6]	   This	  will	   bring	   an	   additional	   dimensionality	   for	   solution	  characterization.	  	  	  
	  
































































































functionalized	  and	  15N	  labeled.	  	  Both	  of	  these	  synthetic	  hurdles	  will	  need	  to	  be	  addressed.	  
	  
Scheme	  4-­‐2.	  	  Solid	  Phase	  Synthesis	  of	  Functionalized	  Spiroligomers	  [7]	  
The	   previous	   synthesis	   of	   functionized	   oligomers	   is	   shown	   in	   Scheme	   4-­‐2.	   [7]	   A	  summary	   of	   the	   approach	   is	   that	   it	   assembles	   the	   Pro4	   monomers	   together	   with	   both	  amide	   bonds	   at	   once	   forming	   a	  DKP	   after	   each	   coupling	   step.	   	   It	   requires	   strong	   acid	   at	  regular	   intervals	  to	  remove	  the	  pyrrolidine	  nitrogen	  and	  C-­‐2	  acid	  protecting	  groups.	   	  The	  use	   of	   strong	   acid	   limits	   the	   the	   scope	   of	   solid	   phase	   synthesis	   techniques	   and	   resin	  options.	  	  Previous	  mechanistic	  insight	  into	  the	  coupling	  reaction	  has	  elucidated	  a	  possible	  way	  to	  improve	  the	  synthesis.	  [8]	  
Figure	  4-­‐6	  shows	  a	   competition	  experiment	   	  of	  one	  of	   the	  activated	  Pro4	  building	  blocks	  (B)	  which	  is	  the	  activatied	  ester	  of	  Pro4	  building	  block	  (A).	   	  (B)	  is	  reacted	  with	  an	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Figure	  4-­‐6.	  Functionalized	  bis-­‐amino	  acid	  coupling	  competition	  reaction.	  [8]	  







target	   for	  deprotection	   is	   the	   reduction	  of	   the	  aryl	  nitro	  group	  down	   to	   the	  aniline.	   	  The	  aniline	   performs	   a	   spontaneous	   [1,6]	   elimination	   liberating	   a	   carboxylate	   that	   also	  eliminates	  to	  yield	  CO2	  furnishing	  the	  free	  amine.	  (Figure	  4-­‐7)	  
	  	   Figure	  4-­‐7.	  	  pNZ	  protecting	  group	  deprotection	  mechanism	  via	  nitro	  reduction.	  	  
The	  pNZ	  protecting	  group	  can	  be	  installed	  at	  the	  hydantoin	  stage	  of	  Pro4	  synthesis	  (See	  Chapter	  1).	  	  The	  Cbz	  protecting	  group	  on	  compound	  7a	  can	  be	  removed	  with	  Pd/C	  and	  H2(g)	  in	  THF.	  	  After	  sparging	  the	  reaction	  with	  Ar(g),	  pNC-­‐Cl	  and	  TEA	  can	  be	  added	  to	  make	  compound	  34.	  	  The	  hydantoin	  can	  be	  hydrolyzed	  by	  first	  reaction	  with	  Boc2O	  and	  DMAP	  in	  THF	   followed	   by	   a	   dropwise	   addition	   of	   2M	   KOH.	   	   The	   resulting	   amino	   acid	   can	   be	  reductively	   alkylated	   with	   any	   aldehyde	   and	   sodium	   cyanoborohydride	   in	   MeOH.	   	   The	  functionalized	   amino	   acid	   can	   then	   be	   activated	   with	   a	   mixture	   of	   HOAT	   and	   DIC	   in	   a	  DCM/DMF	  mixture	  to	  yield	  compound	  35.	  (Scheme	  4-­‐3)	  	  	  
	  



















































    THF
2) 2M KOH
3) RCHO, NaH3BCN
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Scheme	   4-­‐4	   Solid	   Phase	   Spiroligomer	   Synthesis	   using	   pNZ	   protecting	   group	   and	   direct	  acylation.	  	  































2) 4M SnCl2, cat HCl
    DMF
3) DIPEA, DCM/DMF
4) 4M SnCl2, cat HCl
    DMF
5) DIPEA, DCM/DMF
6) 4M SnCl2, cat HCl
    DMF
7) DIPEA, DCM/DMF
8) 4M SnCl2, cat HCl



























































followed	  by	  removal	  of	   the	  pNZ	  group	  using	  a	  4M	  tin	  (II)	  chloride	  solution	  with	  catalytic	  acid.	  	  Each	  successive	  building	  block	  (35a,	  35c,	  35e	  to	  yield	  37a	  or	  35b,	  35d,	  35f	  to	  yield	  37b)	   is	   attached	   followed	   by	   pNZ	   removal.	   	   Treatment	   with	   TFA	   provided	   a	  mixture	   of	  product	  by	  mass	  were	  identified	  as	  products	  with	  various	  combinations	  of	  open	  and	  closed	  DKPs.	  	  The	  TFA	  treatment	  and	  was	  extended	  to	  24	  hours	  to	  yield	  the	  fully	  closed	  product	  in	  50-­‐60%	  yield.	  	  Although,	  this	  initially	  surprised	  us,	  DKPs	  have	  been	  known	  to	  form	  under	  general	  acid	  catalysis	  mechanism.	  [12,13,14].	  	  The	  scope	  and	  limitations	  of	  the	  spontaneous	  DKP	   formation	   for	   rigidifying	   the	   oligomers	   is	   still	   unknown.	   	   However,	   this	   has	   been	   a	  viable	   strategy	   to	   make	   a	   variety	   of	   oligomers	   on	   cheap,	   conventional	   resins	   in	   larger	  quantities	  in	  moderate	  yields.	  
	  
Scheme	  4-­‐5.	  	  Synthesis	  of	  15N	  label	  Pro4	  building	  blocks	  for	  oligomer	  assembly	  
























































































































































































































































































































































































































With	  15N	  labeled	  building	  blocks	  and	  a	  means	  to	  assemble	  them	  into	  oligomers,	  the	  3	  oligomers	  need	  to	  assemble	  Fauxtein	  33	  were	  synthesized.	   (Figure	  4-­‐8,	  Oligomers	  37c,	  
37d,	  37e)	   Following	   the	  methods	   outlined	   for	   Fauxtein	  31,	   Fauxtein	  33	  was	   assembled.	  	  The	  setup	  for	  crosslinking	  here	  is	  different	  than	  that	  of	  Fauxtein	  31	  where	  bromoacetates	  and	   amines	   were	   used.	   	   For	   Fauxtein	   33,	   acylation	   is	   the	   reaction	   for	   crosslinking.	  	  Intermediate	  38	   possess	  2	   carboxylic	   acids	   and	  2	   amines.	   	  As	  with	  before,	   the	   acids	   and	  amines	  are	  positioned	  to	  offer	  only	  one	  competent	  reaction	  pathway	  (Figure	  4-­‐8,	  colored	  red	  and	  blue).	   	  The	  length	  and	  rigidity	  of	  the	  spiroligomer	  prevents	  the	  blue	  acid	  and	  red	  amine,	   and	   the	   red	   acid	   and	   blue	   amine	   from	   reacting	   with	   one	   another	   respectively.	  	  Intermediate	  38	  was	  dissolved	   in	   a	  DCM	   to	   a	   concentration	  of	  6	  mM.	   	  This	   solution	  was	  added	  dropwise	  at	  a	  rate	  of	  12.5	  uL/min	  from	  a	  syringe	  pump	  to	  a	  stirring	  DCM	  solution	  of	  equal	   volume	   of	   PyAOP	   and	   DIPEA.	   	   Figure	   4-­‐8	   shows	   the	   HPLC	   and	   MS	   traces	   for	   the	  intermediate	  38	  and	  Fauxtein	  33.	  	  A	  very	  large	  change	  of	  retention	  time	  is	  observed	  which	  is	   consistent	   with	   lose	   of	   two	   free	   acids	   and	   two	   free	   amines.	   (Figure	   4-­‐9,	   peaks	   are	  highlighted	   in	   yellow)	   	   The	   observed	   change	   in	  mass	   is	   consistent	   with	   the	   loss	   of	   two	  water	  molecules.	  	  The	  (m+2)/2	  masses	  are	  observed	  for	  both	  compounds.	  	  The	  recovery	  of	  Fauxtein	  33	  on	  small	   scale	  was	  encouraging,	  however,	   scale	  up	  attempts	  did	  not	  provide	  sufficient	  quantities.	   	   Efforts	   to	   increase	   the	  quantity	   of	   Fauxtein	  33	   are	   currently	  under	  way.	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Figure	  4-­‐9.	  	  HPLC	  and	  MS	  traces	  for	  Fauxtein	  33	  and	  Intermediate	  38.	  






















































































4.4	  Experimental	  Details	  
General	  Methods:	  All	   Bis-­‐amino	   acids	   were	   synthesized	   according	   to	   established	   literature	   procedure.	   	   All	  amino	  acids	  including	  diamines	  were	  purchased	  from	  either	  Novabiochem	  or	  Bachem.	  	  O-­‐(7-­‐Azabenzotriazole-­‐1-­‐yl)-­‐N,	  N,N’N’-­‐tetramethyluronium	  hexafluorophosphate	  (HATU)	  and	  1-­‐Hydroxy-­‐7-­‐azabenzotriazole	  (HOAT)	  were	  purchased	  from	  Genscript.	   	  All	  other	  reagent	  were	   purchased	   from	   Aldirch.	   	   Flash	   Chromatography	   was	   performed	   on	   an	   ISCO	  CombiFlash	   Rf	   with	   ISCO	   prepackaged	   silica	   gel	   or	   C	   18	   columns.	   Analytical	   HPLC-­‐MS	  analysis	   was	   performed	   on	   a	   Agilent	   Series	   1200	   HPLC	   attached	   to	   an	   Agilent	   Single	  Quadrole	  ESI	  Mass	  Spec	  with	  a	  Waters	  Xterra	  MS	  C18	  column	  (3.5um	  packing,	  4.6	  mm	  x	  150mm)	  with	  a	  solvent	  system	  of	  water/acetonitrile	  with	  0.1%	  formic	  acid	  at	  a	  flow	  rate	  of	  0.8mL/min.	  	  Preparatory	  Scale	  HPLC	  purification	  was	  performed	  on	  a	  Agilent	  Series	  1100	  HPLC	  with	  a	  Waters	  Xterra	  column	  (5um	  packing,	  7.8mm	  x	  150mm)	  with	  a	  solvent	  system	  of	  water/acetonitrile	  with	  0.1%	  formic	  acid	  at	  a	  flow	  rate	  of	  3mL/min.	  
	  
General	  procedure	  (A):	  	  Attachment	  to	  Trityl	  Resin	  To	  a	  solution	  of	  trityl	  resin	  and	  the	  amino	  acid	  (0.9	  equivalents	  based	  on	  resin	  loading)	  in	  DCM	   (10mL/g	   of	   resin)	   was	   added	   DIPEA	   (4	   equivalents	   based	   on	   resin	   loading).	   The	  reaction	  mixture	  was	   stirred	   overnight.	   	   The	   solution	  was	   poured	   through	   a	   solid	   phase	  reactor	   to	   remove	   the	   resin	   from	   solution	   and	  washed	  with	   DMF,	   DCM,	   DMF,	   IPA,	   DMF,	  DCM	  and	  DMF.	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General	  Procedure	  (B):	  	  Attachment	  to	  Brominated	  Wang	  Resin	  To	  a	  solution	  of	  brominated	  Wang	  resin	  and	  the	  amino	  acid	  (0.9	  equivalents	  based	  on	  resin	  loading)	   in	   DCM	   (10mL/g	   of	   resin)	   was	   added	   DIPEA	   (4	   equivalents	   based	   on	   resin	  loading).	  The	  reaction	  mixture	  was	  stirred	  overnight.	   	  The	  solution	  was	  poured	  through	  a	  solid	  phase	  reactor	   to	  remove	  the	  resin	   from	  solution	  and	  washed	  with	  DMF,	  DCM,	  DMF,	  IPA,	  DMF,	  DCM	  and	  DMF.	  	  
General	  procedure	  (C):	  Attachment	  to	  NovaPEG	  Rink	  Amide	  Resin	  To	  a	  solution	  of	  amino	  acid	  (3	  equivalents	  based	  on	  resin	  loading)	  and	  HATU	  (3	  equivalents	  based	   on	   resin	   loading	   in	   NMP	   (5mL/mmole	   of	   amino	   acid)	   was	   added	   DIPEA	   (6	  equivalents	  based	  on	  resin	  loading).	  The	  reaction	  mixture	  was	  agitated	  for	  5	  minutes	  then	  added	  to	  a	  pre-­‐swelled	  (with	  DMF)	  portion	  of	  resin	  in	  a	  solid	  phase	  reactor	  and	  stirred	  for	  4	  hours.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF,	  IPA,	  DMF,	  DCM	  and	  DMF.	  
	  
General	  Procedure	  (D):	  	  Coupling	  of	  Functionalized	  Bis-­‐amino	  acid	  To	  a	  solution	  of	  the	  functionalized	  bis-­‐amino	  acid	  (3	  equivalents	  relative	  to	  resin	  loading)	  and	  HOAT	  (6	  equivalents	  relative	  to	  bis-­‐amino	  acid)	  in	  1:2	  DMF/DCM	  (18mL/mmole)	  was	  added	   DIC	   (1equivalent	   relative	   to	   bis-­‐amino	   acid).	   	   The	   reaction	   was	   stirred	   for	   90	  minutes	  then	  added	  to	  a	  pre-­‐swelled	  (with	  DMF)	  portion	  of	  resin	  in	  a	  solid	  phase	  reactor.	  	  A	  solution	  of	  DIPEA	  (2	  equivalents	  based	  on	  resin	  loading)	  in	  DMF	  (6mL/mmole)	  and	  stirred	  for	   3	   hours.	   	   An	   additional	   aliquiot	   of	   DIC	   (3	   equivalents	   relative	   to	   resin	   loading)	   was	  added	  and	  stirred	  for	  1	  hour.	  	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF,	  IPA,	  DMF,	  DCM	  and	  DMF.	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General	  Procedure	  (E):	  	  Solution	  Coupling	  of	  Functionalized	  Bis-­‐amino	  acid	  To	  a	  solution	  of	  the	  functionalized	  bis-­‐amino	  acid	  (1	  equivalent)	  and	  HOAT	  (6	  equivalents)	  in	  1:2	  DMF/DCM	  (18mL/mmole)	  was	  added	  DIC	  (1equivalent).	   	  The	  reaction	  was	  stirred	  for	   90	  minutes	   then	   added	   to	   a	   second	   bis-­‐amino	   acid	   (0.8	   equivalents)	   and	  DIPEA	   (1.6	  equivalents)	   in	   DMF	   (6mL/mmole).	   	   The	   reaction	   was	   stirred	   for	   7.5	   hours	   and	   an	  additional	   aliquiot	   of	   DIC	   (2	   equivalents	  was	   added	   and	   stirred	   overnight.	   	   The	   reaction	  was	  diluted	  with	  EtOAc	  then	  washed	  with	  sat.	  NH4Cl	  (aq)	  x	  3,	  sat.	  NaCl	  (aq)	  x	  1,	  sat.	  NaHCO3	  (aq)	   x	   3,	   NaCl	   (aq)	   x	   2,	   dried	   over	   Na2SO4,	   filtered,	   and	   concentrated	   under	   reduced	  pressure.	  
	  
General	  procedure	  (F):	  HATU	  Coupling	  To	  a	  solution	  of	  amino	  acid	  (3	  equivalents	  based	  on	  resin	  loading)	  and	  HATU	  (3	  equivalents	  based	   on	   resin	   loading	   in	   NMP	   (5mL/mmole	   of	   amino	   acid)	   was	   added	   DIPEA	   (6	  equivalents	  based	  on	  resin	  loading).	  The	  reaction	  mixture	  was	  agitated	  for	  5	  minutes	  then	  added	  to	  a	  pre-­‐swelled	  (with	  DMF)	  portion	  of	  resin	  in	  a	  solid	  phase	  reactor	  and	  stirred	  for	  4	  hours.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF,	  IPA,	  DMF,	  DCM	  and	  DMF.	  	  
General	  procedure	  (G):	  PyAOP	  Coupling	  To	   a	   solution	   of	   amino	   acid	   (3	   equivalents	   based	   on	   resin	   loading)	   and	   PyAOP	   (3	  equivalents	  based	  on	  resin	  loading	  in	  NMP	  (5mL/mmole	  of	  amino	  acid)	  was	  added	  DIPEA	  (6	   equivalents	   based	  on	   resin	   loading).	   The	   reaction	  mixture	  was	   agitated	   for	   5	  minutes	  then	  added	  to	  a	  pre-­‐swelled	  (with	  DMF)	  portion	  of	  resin	  in	  a	  solid	  phase	  reactor	  and	  stirred	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for	  12	  hours.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF,	  IPA,	  DMF,	  DCM	  and	  DMF.	  
	  
General	  Procedure	  (H):	  	  Boc	  and	  tert-­‐Butyl	  Ester	  Deprotection	  A	  solution	  of	  5%	  TIPS	  in	  TFA	  (10mL/mmole	  based	  on	  resin	  loading)	  was	  added	  to	  a	  pre-­‐swelled	  (with	  DMF)	  portion	  of	  resin	  in	  a	  solid	  phase	  reactor	  and	  stirred	  for	  30	  minutes.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF,	  IPA,	  DMF,	  DCM	  and	  DMF.	  	  This	  process	  was	  repeated	  in	  duplicate	  to	  ensure	  complete	  deprotection.	  	  
General	  Procedure	  (I):	  	  Cbz	  and	  tert-­‐Butyl	  Ester	  Deprotection	  A	  solution	  of	  the	  Spiroligomer	  and	  1:2	  HBr/AcOH	  (5mL/mmole)	  in	  DCM	  (5mL/mmole)	  was	  stirred	  for	  4	  hours.	  The	  reaction	  mixture	  was	  concentrated	  under	  reduced	  pressure.	  
	  
General	  procedure	  (J):	  Fmoc	  Deprotection	  A	  solution	  of	  20%	  of	  piperidine	  in	  DMF	  (10mL/mmole	  based	  on	  resin	  loading)	  was	  added	  to	   a	   pre-­‐swelled	   (with	  DMF)	   portion	   of	   resin	   in	   a	   solid	   phase	   reactor	   and	   stirred	   for	   15	  minutes.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF,	  IPA,	  DMF,	  DCM	  and	  DMF.	  	  This	  process	  was	  repeated	  in	  duplicate	  to	  ensure	  complete	  deprotection.	  	  	  	  
General	  procedure	  (K):	  Alloc	  Deprotection	  A	   solution	   of	   borane:dimethylamine	   complex	   (6	   equivalents	   based	   on	   resin	   loading)	   in	  DCM	   (10mL/mmole	   based	   on	   resin	   loading)	   was	   added	   to	   a	   pre-­‐swelled	   (with	   DMF)	  portion	   of	   resin	   in	   a	   solid	   phase	   reactor	   and	   stirred	   for	   5	  minutes.	   To	   this	   solution	  was	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added	   a	   solution	   of	   tetrakis(triphenylphosphine)palladium(0)	   (0.1	   equivalents	   based	   on	  resin	   loading)	   in	  DCM	   (10mL/mmole	   based	   on	   resin	   loading).	   The	   reaction	  mixture	  was	  stirred	  for	  2	  hour.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF,	  IPA,	  DMF,	  DCM	  and	  DMF.	  	  
General	  procedure	  (L):	  IvDde	  Deprotection	  A	  solution	  of	  2%	  of	  hydrazine	  in	  DMF	  (10mL/mmole	  based	  on	  resin	  loading)	  was	  added	  to	  a	   pre-­‐swelled	   (with	   DMF)	   portion	   of	   resin	   in	   a	   solid	   phase	   reactor	   and	   stirred	   for	   20	  minutes.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF,	  IPA,	  DMF,	  DCM	  and	  DMF.	  	  This	  process	  was	  repeated	  in	  triplicate	  to	  ensure	  complete	  deprotection.	  
	  
General	  procedure	  (M):	  	  Bromoacetate	  Acylation	  To	   a	   solution	   of	   bromoacetic	   anhydride	   (3	   equivalents	   based	   on	   resin	   loading)	   in	   NMP	  (5mL/mmole	  of	  amino	  acid)	  was	  added	  DIPEA	  (6	  equivalents	  based	  on	  resin	  loading).	  The	  reaction	   mixture	   was	   agitated	   for	   5	   minutes	   then	   added	   to	   a	   pre-­‐swelled	   (with	   DMF)	  portion	  of	  resin	  in	  a	  solid	  phase	  reactor	  and	  stirred	  for	  4	  hours.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF,	  DCM,	  DMF,	  DCM	  and	  DMF	  
	  
General	  Procedure	  (N):	  	  Alloc	  Protection	  To	   a	   solution	   of	   the	   oligomer	   (1	   equivalent)	   and	   Alloc-­‐Cl	   (1.1	   equivalents)	   in	   DCM	  (10mL/mmole)	   was	   added	   DIPEA	   (3	   equivalents).	   	   The	   reaction	   mixture	   was	   stirred	  overnight	  then	  diluted	  with	  EtOAc.	  	  The	  solution	  was	  washed	  with	  sat.	  NH4Cl	  (aq)	  x	  3,	  sat.	  NaCl	  (aq)	  x	  2,	  dried	  over	  Na2SO4,	  filtered,	  and	  concentrated	  under	  reduced	  pressure.	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General	  Procedure	  (O):	  	  Safety	  Catch	  Cleavage	  from	  HMBA	  resin	  A	  solution	  of	  10%	  DIPEA	   in	  DMF	   (10	  mL/mmole	  based	  on	   resin	   loading	  was	  added	   to	   a	  portion	  of	  resin	  and	  stirred	  overnight.	  The	  resin	  was	  filtered.	  The	  filtrate	  was	  concentrated,	  reconstituted	  in	  50%	  MeCN	  in	  water	  (0.1%	  formic	  acid)	  and	  freeze-­‐dried.	  
	  
General	  procedure	  (P):	  	  Liberation	  from	  Trityl	  or	  Rink	  Amide	  Solid	  Phase	  Resins	  A	   solution	  of	  5%	  TIPS	   and	  5%	  water	   in	  TFA	   (20	  mL/mmole	  based	  on	   resin	   loading	  was	  added	   to	   a	   portion	   of	   resin	   (successively	   washed	   with	   DCM	   and	  MeOH,	   and	   thoroughly	  dried	  under	  vacuum)	  and	  stirred	  for	  4	  hours.	  The	  resin	  was	  filtered	  and	  rinsed	  with	  TFA.	  The	  filtrate	  was	  concentrated,	  reconstituted	  in	  50%	  MeCN	  in	  water	  (0.1%	  formic	  acid)	  and	  freeze-­‐dried.	  
	  
General	  Procedure	  (Q):	  	  Rigidification	  of	  Spiroligomers:	  
A	   solution	   of	   the	   spiroligomer	   in	   0.5	  M	  NH4OAc	   in	  MeCN/water	   1:1	   (20mL/umole)	  was	  heated	  to	  60oC	  and	  stirred	  overnight	  and	  freeze-­‐dried.	  
	  
General	  Procedure	  (R):	  	  Cross-­‐linking	  in	  Aqueous	  Solution:	  
A	  solution	  of	  the	  spiroligomer	  linear	  assembly	  in	  50%	  MeCN	  in	  water	  (22mL/umole)	  was	  added	  dropwise	  to	  a	  solution	  of	  0.05M	  pH	  7	  Phosphate	  Buffer	  (44ml/umole)	  and	  stirred	  for	  60	  hours	  and	  freeze-­‐dried.	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General	  Procedure	  (S):	  	  Cross-­‐linking	  in	  Organic	  Solution:	  
A	  solution	  of	  the	  spiroligomer	  linear	  assembly	  in	  DMF	  (22mL/umole)	  was	  added	  dropwise	  to	  a	  solution	  of	  1.5%	  TEA	  in	  DMF	  (44mL/umole)	  and	  stirred	  overnight.	  The	  solution	  was	  added	   dropwise	   to	   a	   solution	   of	   diethyl	   ether	   (666mL/umole,	   chilled	   to	   –20oC)	   and	  centrifuged.	   	  The	  solvent	  was	  decanted	  and	  the	  pellet	  was	  reconstituted	   in	  50%	  MeCN	  in	  water	  (0.1%	  formic	  acid)	  and	  freeze-­‐dried.	  
	  
	  
General	  procedure	  (T):	  pNZ	  Deprotection	  A	   4M	   solution	   of	   tin	   (II)	   chloride	  with	   64	   uM	  HCl	   in	  DMF	   (10mL/mmole	   based	   on	   resin	  loading)	  was	  added	  to	  a	  pre-­‐swelled	  (with	  DMF)	  portion	  of	  resin	   in	  a	  solid	  phase	  reactor	  and	  stirred	  for	  30	  minutes.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  DMF,	  IPA,	  DMF,	   DCM	   and	   DMF.	   	   This	   process	   was	   repeated	   in	   triplicate	   to	   ensure	   complete	  deprotection.	  	  




Spiroligomer	  30:	  	  Pro4ssAHFM	  (494.5mg,	  1mmole)	  was	  attached	  to	  Trityl	  resin	  (1g,	  1.1mmole)	  according	  to	  general	  procedure	  (A)	  using	  DCM	  (10mL)	  and	  DIPEA	  (696.8uL,	  4mmoles).	  	  The	  terminal	  Fmoc	  group	  was	  removed	  according	  to	  general	  procedure	  (J)	  using	  20%	  piperidine	  in	  DMF	  (900uL).	  	  	  



















	  	   Figure	  4-­‐10.	  	  HPLC	  of	  Spiroligomer	  30	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NovaPEG	  Rink	  Amide	  Resin	  (81.1mg,	  30umoles	  loading)	  was	  placed	  in	  an	  8mL	  solid	  phase	  reactor.	  	  (S)-­‐N-­‐Fmoc-­‐1-­‐Naphthylalanine-­‐OH	  (39.4mg,	  90umoles)	  was	  attached	  according	  to	  general	  procedure	  (C)	  using	  HATU	  (34.2mg,	  90umoles),	  NMP	  (450uL)	  and	  DIPEA	  (31.4uL,	  180umoles).	   	   The	   terminal	   Fmoc	  group	  was	   removed	  according	   to	   general	   procedure	   (J)	  using	  20%	  piperidine	  in	  DMF	  (900uL).	  	  	  
Oligomer	  30	   (69.4mg,	   90umoles)	  was	   coupled	   according	   to	   general	   procedure	   (G)	   using	  PyAOP	  (46.9mg,	  90umoles),	  NMP	  (450uL),	  and	  DIPEA	  (31.4uL,	  180umoles).	  	  The	  terminal	  Fmoc	  group	  was	  removed	  according	  to	  general	  procedure	  (J)	  using	  20%	  piperidine	  in	  DMF	  (900uL).	  
























































piperidine	  in	  DMF	  (900uL).	  	  Exposure	  to	  the	  deprotection	  solution	  was	  extended	  to	  2	  hours	  to	  enable	  complete	  diketopiperazine	  closure.	  
The	   Alloc	   group	   was	   removed	   according	   to	   general	   procedure	   (K)	   using	  borane:dimethylamine	   complex	   (10.6mg,	   180umoles)	   in	   DCM	   (450uL)	   and	  tetrakis(triphenylphosiphine)palladium(0)	   (10.4mg,	   9umoles)	   in	  DCM	   (450uL).	   	   Boc-­‐Gly-­‐OH	   (15.8mg,	   450umoles)	   was	   coupled	   according	   to	   general	   procedure	   (F)	   using	   HATU	  (34.2mg,	  90umoles),	  NMP	  (450uL),	  and	  DIPEA	  (31.4uL,	  180umoles).	   	  The	   terminal	   IvDde	  group	   was	   removed	   according	   to	   general	   procedure	   (L)	   using	   2%	   Hydrazine	   in	   DMF	   (	  900uL).	  
Oligomer	  30	   (69.4mg,	   90umoles)	  was	   coupled	   according	   to	   general	   procedure	   (G)	   using	  PyAOP	  (46.9mg,	  90umoles),	  NMP	  (450uL),	  and	  DIPEA	  (31.4uL,	  180umoles).	  	  The	  terminal	  Fmoc	  group	  was	  removed	  according	  to	  general	  procedure	  (J)	  using	  20%	  piperidine	  in	  DMF	  (900uL).	  
Fmoc-­‐L-­‐Dab(Fmoc)-­‐OH	   (50.6mg,	   90umoles)	  was	   coupled	   according	   to	   general	   procedure	  (F)	  using	  HATU	  (34.2mg,	  90umoles),	  NMP	  (450uL)	  and	  DIPEA	  (31.4uL,	  180umoles).	   	  The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (J)	   using	   20%	  piperidine	  in	  DMF	  (900uL).	  	  Exposure	  to	  the	  deprotection	  solution	  was	  extended	  to	  2	  hours	  to	  enable	  complete	  diketopiperazine	  closure.	  
Oligomer	   30	   (69.4mg,	   90umoles)	  was	   coupled	   according	   to	   general	   procedure	   (G)	   using	  PyAOP	  (46.9mg,	  90umoles),	  NMP	  (450uL),	  and	  DIPEA	  (31.4uL,	  180umoles).	  	  The	  terminal	  Fmoc	  group	  was	  removed	  according	  to	  general	  procedure	  (J)	  using	  20%	  piperidine	  in	  DMF	  (900uL).	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Fmoc-­‐L-­‐Dab(Boc)-­‐OH	  (39.6mg,	  90umoles)	  was	  coupled	  according	  to	  general	  procedure	  (F)	  using	   HATU	   (34.2mg,	   90umoles),	   NMP	   (450uL)	   and	   DIPEA	   (31.4uL,	   180umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (J)	   using	   20%	  piperidine	  in	  DMF	  (900uL).	  	  Exposure	  to	  the	  deprotection	  solution	  was	  extended	  to	  2	  hours	  to	  enable	  complete	  diketopiperazine	  closure.	  
The	   Alloc	   group	   was	   removed	   according	   to	   general	   procedure	   (K)	   using	  borane:dimethylamine	   complex	   (10.6mg,	   180umoles)	   in	   DCM	   (450uL)	   and	  tetrakis(triphenylphosiphine)palladium(0)	  (10.4mg,	  9umoles)	  in	  DCM	  (450uL).	  	  Fmoc-­‐Gly-­‐OH	   (53.5mg,	   180umoles)	   was	   coupled	   according	   to	   general	   procedure	   (F)	   using	   HATU	  (68.4mg,	  180umoles),	  NMP	  (900uL)	  and	  DIPEA	  (62.8uL,	  360umoles).	  	  	  
Bromoacetates	   were	   introduced	   according	   to	   general	   procedure	   (M)	   using	   bromoacetic	  anhydride	   (46.8mg,	   180umoles),	   NMP	   (900uL),	   and	   DIPEA	   (62.8uL,	   360umoles).	   	   The	  linear	   assembly	   of	   spiroligomer	   was	   liberated	   from	   the	   resin	   according	   to	   general	  procedure	  (P)	  using	  95%	  TFA/2.5%	  Tips/2.5%	  Water	  (1.8mL)	  to	  32.	  





























was	  liberated	  from	  the	  resin	  according	  to	  general	  procedure	  (U)	  using	  20mL	  of	  TFA.	   	  The	  residue	   was	   reconstituted	   in	   50%	   MeCN	   in	   water	   (0.1%	   formic	   acid)	   and	   purified	   by	  reverse-­‐phase	  chromatography	  (gradient	  elution	  over	  30	  minutes	  from	  water	  (0.1%	  formic	  acid)	   to	   50%	  MeCN	   in	  water	   (0.1%	   formic	   acid).	   	   Desired	   fractions	  were	   combined	   and	  freeze-­‐dried	  to	  yield	  37a	  as	  a	  white	  powder.	  	  
	  	  




















(3.48uL,	  20mmoles)	  in	  DMF	  (18	  mL).	  	  The	  terminal	  pNZ	  group	  was	  removed	  according	  to	  general	  procedure	  (T)	  using	  the	  4M	  tin	  (II)	  chloride	  solution	  (10mL).	  	  	  Compound	  36f	   (3mmoles)	  was	   coupled	   according	   to	   general	   procedure	   (D)	   using	  HOAT	  (2.45g	  ,	  18	  mmoles),	  1:2	  DMF/DCM	  (54mL),	  and	  DIC	  (468uL,	  3mmoles)	  followed	  by	  DIPEA	  (3.48uL,	  20mmoles)	  in	  DMF	  (18	  mL).	  	  The	  terminal	  pNZ	  group	  was	  removed	  according	  to	  general	   procedure	   (T)	   using	   the	   4M	   tin	   (II)	   chloride	   solution	   (10mL).	   	   The	   spiroligomer	  was	  liberated	  from	  the	  resin	  according	  to	  general	  procedure	  (U)	  using	  20mL	  of	  TFA.	   	  The	  residue	   was	   reconstituted	   in	   50%	   MeCN	   in	   water	   (0.1%	   formic	   acid)	   and	   purified	   by	  reverse-­‐phase	  chromatography	  (gradient	  elution	  over	  30	  minutes	  from	  water	  (0.1%	  formic	  acid)	   to	   50%	  MeCN	   in	  water	   (0.1%	   formic	   acid).	   	   Desired	   fractions	  were	   combined	   and	  freeze-­‐dried	  to	  yield	  37b	  as	  a	  white	  powder.	  
	  










































































	  Figure	  4-­‐12.	  	  HPLC	  of	  Spiroligomer	  37c	  






































Spiroligomer	  37d	  Synthesized	  according	  to	  the	  same	  strategy	  as	  for	  Spiroligomer	  37a	  and	  37b	  using	  15N	  Pro4	  building	  block.	  























































































	  Figure	  4-­‐15.	  	  MS	  of	  Spiroligomer	  37d	  
	  


























































































	  Figure	  4-­‐16.	  	  HPLC	  of	  Spiroligomer	  37e	  


























































































































Oligomer	  37d	  (122.4mg,	  90umoles)	  was	  coupled	  according	  to	  general	  procedure	  (G)	  using	  PyAOP	   (46.9mg,	   90umoles),	   NMP	   (450uL),	   and	   DIPEA	   (31.4uL,	   180umoles).	   	   The	  oligomer’s	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (J)	   using	   20%	  piperidine	   in	  DMF	   (900uL).	   	   Fmoc-­‐Gly-­‐OH	  (49.2mg,	  90umoles)	  was	   coupled	  according	   to	  general	  procedure	  (F)	  using	  HATU	  (34.2mg,	  90umoles),	  NMP	  (450uL)	  and	  DIPEA	  (31.4uL,	  180umoles).	   	   The	   terminal	   Fmoc	  group	  was	   removed	  according	   to	   general	   procedure	   (J)	  using	  20%	  piperidine	  in	  DMF	  (900uL).	  	  	  Oligomer	  37c	  (116.5mg,	  90umoles)	  was	  coupled	  according	  to	  general	  procedure	  (G)	  using	  PyAOP	  (46.9mg,	  90umoles),	  NMP	  (450uL),	  and	  DIPEA	  (31.4uL,	  180umoles).	  	  The	  terminal	  Fmoc	  group	  was	  removed	  according	  to	  general	  procedure	  (J)	  using	  20%	  piperidine	  in	  DMF	  (900uL).	  	  Boc-­‐Gly-­‐OH	  (49.2mg,	  90umoles)	  was	  coupled	  according	  to	  general	  procedure	  (F)	  using	  HATU	  (34.2mg,	  90umoles),	  NMP	  (450uL)	  and	  DIPEA	  (31.4uL,	  180umoles).	  	  	  The	  terminal	  pNZ	  group	  was	  removed	  according	  to	  general	  procedure	  (T)	  using	  the	  4M	  tin	  (II)	   chloride	   solution	   (1mL).	   	   Bromoacetates	   were	   introduced	   according	   to	   general	  procedure	   (M)	   using	   bromoacetic	   anhydride	   (46.8mg,	   180umoles),	   NMP	   (900uL),	   and	  DIPEA	  (62.8uL,	  360umoles).	   	  The	   linear	  assembly	  of	  spiroligomer	  was	   liberated	   from	  the	  resin	  according	  to	  general	  procedure	  (P)	  using	  95%	  TFA/2.5%	  Tips/2.5%	  Water	  (1.8mL)	  to	  32.	  
32	  (4.1mg,	  2umoles)	  was	  cross-­‐linked	  according	  to	  general	  procedure	  [R]	  or	  [S]	  using	  DMF	  (44mL)	  and	  1.5%	  TEA	   in	  DMF	  (88mL/umole)	  or	  50%	  MeCN	   in	  water	  (44mL)	  and	  0.05M	  pH7	   Phosphate	   Buffer	   (88mL).	   	   The	   residue	   was	   reconstituted	   in	   50%	   MeCN	   in	   water	  (0.1%	  formic	  acid)	  and	  purified	  by	  reverse-­‐phase	  chromatography	  (gradient	  elution	  over	  
	  138	  
30	   minutes	   from	   water	   (0.1%	   formic	   acid)	   to	   50%	   MeCN	   in	   water	   (0.1%	   formic	   acid).	  	  Desired	  fractions	  were	  combined	  and	  freeze-­‐dried	  to	  yield	  33	  as	  a	  white	  powder.	  
	  Figure	  4-­‐18.	  	  HPLC	  of	  Fauxtein	  33	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MS	  of	  Fauxtein	  33	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5.0	  Exploration	  of	  Cycloaddition	  Routes	  to	  Bis-­‐Amino	  Acids	  
	  
	   	  
	  
	   	  Chapter	   5	   details	   cycloaddition	   chemistry,	   specifically	   [3+2]	   cycloaddition	   to	  explore	  alternative	  routes	  to	  our	  principle	  building	  block,	  Pro4.	  	  Highlights	  of	  this	  work	  are	  success	  synthesis	  of	  Pro4	  with	  either	  “sr”	  or	  “rs”	  stereochemistry.	   	  This	  synthetic	  route	  is	  complimentary	  to	  the	  current	  synthesis	  from	  trans-­‐hydroxyproline,	  where	  the	  “sr”	  and	  “rs”	  stereochemistry	  are	  the	  minor	  diastereomer	  components.	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PG PG 	  Figure	   5-­‐1.	   	   Retrosynthetic	   analysis	   of	   Pro4	   monomer	   class	   possessing	   additional	  functional	  groups.	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An	  alternative	  approach	  to	  the	  synthesis	  of	  bis-­‐amino	  acids	  is	  utilizing	  a	  convergent	  strategy.	   	   A	   convergent	   strategy	   would	   allow	   complex	   molecules	   to	   be	   made	   in	   shorter	  syntheses	   and	   from	   smaller,	   simpler	   fragment	   that	   can	   be	   synthesized	   in	   parallel,	   while	  introducing	  several	  stereocenters	  at	  once.	   	  A	  convergent	  strategy	  to	  highly	   functionalized	  pyrrolidine	   rings,	   the	   ring	   type	   in	   the	  Pro4	  monomer	   class,	   is	   to	  use	   [3+2]	   cycloaddition	  chemistry.	   	   In	   general,	   [3+2]	   cycloaddition	   chemistry	   reacts	   a	   1,3	   dipole	   with	   a	  dipolarophile.	  [2]	  Several	  different	  dipoles	  and	  dipolarophiles	  exist,	  but	  for	  the	  synthesis	  of	  pyrrolidine	  ring	  systems,	  the	  azomethine	  ylide	  is	  used	  as	  the	  1,3	  dipole	  fragment.	  





































































































5.2	  Results	  and	  Discussion	  	  As	  shown	  in	  Chapter	  1	  and	  2,	  the	  prototypical	  bis-­‐amino	  acid	  design,	  compound	  14	  shown	   in	   Scheme	   5-­‐1.	   	   For	   making	   spiroligomers,	   a	   common	   protection	   scheme	   of	  compound	   14	   is	   a	   free	   acid	   at	   the	   C-­‐2	   position,	   an	   Fmoc	   protected	   amine	   and	   methyl	  esterified	   carboxylate	   at	   the	   C-­‐4	   position,	   and	   the	   pyrrolidine	   amine	   protected	   as	   a	  carbamate.	   	   Cbz	   and	   Boc	   are	   most	   frequently	   utilized	   but	   the	   Alloc	   group	   has	   been	  implemented	   as	   well	   (see	   Chapter	   2).	   	   A	   [3+2]	   cycloaddition	   route	   to	   Pro4,	   shown	   in	  Scheme	  5-­‐1,	   required	  synthesizing	   two	   fragments:	  a	  glycinate	  (41)	  and	  a	  dehydroalanine	  (40)	   component.	   	   The	  previously	   shown	   literature	   examples	  demonstrate	  use	  of	   a	   chiral	  auxiliary	   in	   either	   fragment.	   	   Retrosynthetically,	   the	   use	   of	   a	   chiral	   auxiliary	   on	   the	  glycinate	   fragment	   (41)	   was	   of	   greater	   advantage.	   	   The	   (S)	   and	   (R)	   enantiomers	   of	   α-­‐methylbenzylamine	  were	   implemented	   as	   the	   source	   of	   chirality.	   	   Both	   enantiomers	   are	  cheap	   and	   commercially	   available	   and	   they	   can	   easily	   be	   used	   to	   make	   N-­‐substituted	  glycinates.	   	   A	   tert-­‐butyl	   ester	  was	   chosen	   for	   the	   glycinate	   ester	   for	   its	   ease	   of	   removal,	  similar	  to	  the	  existing	  Pro4	  synthesis	  (see	  Chapter	  1).	  	  The	  azomethine	  ylide	  was	  generated	  
in	  situ	  by	  the	  condensation	  of	  the	  glycinate	  and	  paraformaldehyde.	  	  In	  consideration	  of	  the	  dipolarophile	  fragment	  (40),	  the	  Fmoc	  group	  would	  not	  tolerate	  the	  reaction	  conditions	  of	  the	   cycloaddition	  and	  would	  need	   to	  be	   installed	   later	   in	   the	   synthesis.	   	   Instead,	   the	  Boc	  group	   was	   used	   to	   protect	   the	   amine	   of	   the	   dehydroalanine	   and	   the	   methyl	   ester	   was	  installed	  on	  the	  dehydroalanine	  prior	  to	  the	  cycloaddition	  step.	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9a$ 9b$ 9c$ 9d$
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g)	   and	   the	   remainder	   of	   the	   synthesis	   was	   carried	   out.	   	   However,	   we	   could	   not	   assign	  stereochemistry	  at	  this	  intermediate.	  
	  Figure	  5-­‐5.	  	  1H	  and	  Cosy	  NMR	  of	  cycloadduct,	  compound	  39X.	  	  	  With	   both	   chiral	   centers	   of	   the	   cycloadduct	   (39X)	   set,	   the	   chiral	   auxiliary	   was	  removed	  and	  replaced	  with	  an	  allyl	  carbamate	  in	  two	  steps,	  using	  Pd(OH)2/C	  in	  THF	  under	  H2(g)	  followed	  by	  Alloc-­‐Cl	  and	  DIPEA	  in	  THF,	  shown	  in	  Scheme	  5-­‐3.	  	  The	  Boc	  and	  tert-­‐butyl	  esters	   were	   cleaved	   with	   TFA	   in	   DCM.	   	   Finally,	   the	   C-­‐4	   amine	   was	   protected	   with	   a	  fluorenylmethyl	  carbamate	  using	  Fmoc-­‐OSu	  and	  DIPEA	  in	  DCM	  to	  yield	  compound	  42X.	  

















The	   absolute	   stereochemistry	   was	   determined	   by	   derivatizing	   compound	  42X	   by	  attachment	  and	  DKP	  closure	  of	  an	  amino	  at	   the	  C-­‐4	  quaternary	  amino	  acid,	   illustrated	   in	  Scheme	  5-­‐4.	   	   Compound	  42X	  was	   attached	   to	  Trityl	   resin	  using	  DIPEA	   in	  DCM.	   	  The	  C-­‐4	  Fmoc	   group	  was	   cleaved	   using	   1:4	   piperidine	   in	   DMF	   followed	   by	   attachment	   of	   Fmoc-­‐Tyr(tBu)-­‐OH	   using	   HATU	   and	   DIPEA	   in	   NMP.	   	   The	   Tyr	   Fmoc	   group	   was	   cleaved	   and	  accompanied	   by	   spontaneous	   DKP	   formation.	   	   The	   Alloc	   group	   was	   cleaved	   using	  (PPh3)4Pd	  and	  BH3:DMA	  in	  DCM	  and	  compound	  43X	  was	  liberated	  from	  the	  solid	  support	  using	  TFA.	   	  To	  assist	   in	  determining	   the	  absolute	  stereochemistry	  of	   compound	  43X,	   the	  four	   known	   stereoisomers	   of	   Pro4	   were	   derivatized	   in	   the	   same	   manner	   to	   provide	  compounds	  43ss,	  43sr,	  43rr,	  and	  43rs.	  
	  Scheme	  5-­‐4.	  	  Synthesis	  of	  Pro4	  derivative	  for	  stereochemistry	  analysis.	  	  a)	  Pro4	  monomer,	  DIPEA,	   DCM;	   b)	   1:4	   piperidine/DMF;	   c)	   Fmoc-­‐Tyr(tBu)-­‐OH,	   HATU,	   DIPEA,	   NMP;	   d)	  (PPh3)4Pd,	  BH3:DMA,	  DCM;	  e)	  48:1:1	  TFA/TIPS/H2O.	  	  	  NMR	  analysis	  of	  the	  5-­‐member	  library	  provided	  the	  stereochemistry	  of	  compounds	  


























































profound	  when	  viewing	  the	  Cosy	  spectra	  of	  compound	  43X	  on	  top	  of	   the	  Cosy	  spectra	  of	  the	   known	   stereoisomers,	   Figure	   5-­‐6.	   	   Much	   like	   fingerprints,	   subtle	   differences	   were	  observed	   except	   of	   one	   perfect	   match	   for	   the	   unknown.	   	   According	   to	   the	   NMR	   data,	  compound	  43X	  is	  the	  same	  as	  43rs.	  
	  	  Figure	  5-­‐6.	   	  Cosy	  NMR	  of	  compound	  43X	  overlaid	  with	  compounds	  43ss,	  43sr,	  43rr,	  and	  





	  Figure	  5-­‐7.	   	  Cosy	  NMR	  of	  compound	  43Y	  overlaid	  with	  compounds	  43ss,	  43sr,	  43rr,	  and	  
43rs.	   	  	  





5.4	  Experimental	  Details	  	  
Solution	  Synthesis:	  	  
	  	  	  










































	  	  	  
(S)-­‐tert-­‐butyl	  2-­‐(1-­‐phenylethylamino)acetate	  (ent-­‐41):	  	  To	  a	  stirring	  solution	  of	  (S)-­‐1-­‐phenylethanamine	  (1.3mL,	  10.1mmoles)	  in	  THF	  (20mL)	  was	  added	   tBuOAcBr	   (1.5mL,	   10.1mmoles,	   1equiv)	   followed	   by	   a	   dropwise	   addition	   of	   TEA	  (2.8mL,	  20.2mmoles,	  2equiv)	  in	  THF	  (20mL).	   	  The	  reaction	  mixture	  was	  stirred	  overnight	  then	   diluted	   with	   EtOAc.	   	   The	   solution	   was	   washed	   with	   sat.	   NaCl	   (aq)	   x	   3,	   dried	   over	  Na2SO4,	   filtered,	   and	   concentrated	   under	   reduced	   pressure	   yield	   as	   colorless	   oil	   (2.3g,	  9.77mmoles,	   97%).	   1H	  NMR	   (500	  MHz,	   rt,	   CDCl3):	  δ	   7.31	   (m,	   5H),	   3.80	   (q,	   J=7.1	  Hz,	   1H),	  3.21	  (q,	  J=17.7	  Hz,	  15.9	  Hz,	  2H),	  2.03	  (br	  s,	  1H),	  1.44	  (s,	  9H),	  1.38	  (d,	  J=7.1,	  3H);	  13C	  NMR	  (125MHz,	  rt,	  CDCl3):	  δ	  172.0,	  144.9,	  128.5,	  127.2,	  126.8,	  125.9,	  81.1,	  57.8,	  49.8,	  28.1,	  24.4.	  	  	  
	  	  	  
Methyl	  2-­‐(tert-­‐butoxycarbonylamino)acrylate	  (40):	  


















































































was	  washed	  with	   sat.	  NH4Cl	   (aq)	   x	   3,	   sat.	  NaCl	   (aq)	   x	   2,	   dried	   over	  Na2SO4,	   filtered,	   and	  concentrated	   under	   reduced	   pressure.	   	   The	   residue	   was	   dissolved	   in	   DCM	   (40mL)	   and	  cooled	  to	  0oC	  in	  an	  ice/water	  bath.	  	  MsCl	  (3.4mL,	  22mmoles,	  1.1equiv)	  was	  added	  followed	  by	  a	  dropwise	  addition	  of	  TEA	  (8.4mL,	  60mmoles,	  3equiv)	   in	  DCM	  (20mL).	   	  The	  reaction	  mixture	  was	  stirred	  overnight	   then	  diluted	   in	  EtOAc.	   	  The	  solution	  was	  washed	  with	  sat.	  NH4Cl	   (aq)	   x	   3,	   sat.	   NaCl	   (aq)	   x	   2,	   dried	   over	   Na2SO4,	   filtered,	   and	   concentrated	   under	  reduced	   pressure	   yield	   as	   orange	   oil	   (4.1g,	   19.9mmoles,	   99%).	   	   1H	   NMR	   (500	   MHz,	   rt,	  CDCl3):	  δ	  5.48	  (br	  s,	  1H),	  4.38	  (br	  s,	  1H),	  3.97	  (dd,	  J=3.7	  Hz,	  7.3	  Hz,	  1H),	  3.91	  (dd,	  J=3.7	  Hz,	  7.3	  Hz,	  1H),	  3.78	  (s,	  3H),	  1.48	  (s,	  9H),	  4.08	  (s,	  3H);	  13C	  NMR	  (125MHz,	  rt,	  CDCl3):	  δ	  171.3,	  155.8,	  80.4,	  63.6,	  55.8,	  52.7,	  28.3.	  	  	  
	  	  	  
2-­‐tert-­‐butyl	  4-­‐methyl	  4-­‐(tert-­‐butoxycarbonylamino)-­‐1-­‐((R)-­‐1-­‐phenylethyl)pyrrolidi-­‐










































(2.6g,	  5.8mmoles,	  58%).	  	  	  1H	  NMR	  (500	  MHz,	  rt,	  CDCl3):	  δ	  7.33	  (m,	  5H),	  6.25	  (t,	  J=5.81	  Hz,	  1H),	  4.02	  (q,	  J=6.8	  Hz,	  1H),	  3.76	  (s,	  3H),	  3.32	  (m,	  3H),	  3.08	  (d,	  J=17.4,	  1H),	  1.44	  (s,	  9H),	  1.37	  (d,	   J=6.2,	   3H);	   13C	   NMR	   (125MHz,	   rt,	   CDCl3):	   δ	   172.3,	   170.9,	   165.1,	   143.3,	   129.4,	   127.6,	  127.0,	  81.1,	  81.0,	  60.4,	  52.7,	  52.3,	  48.7,	  28.3,	  19.2;	  LRESIQMS	  calcd	  for	  C24H36N2O6	  (M	  +	  H+)	  449.2573,	  measured	  449.4.	  	  	  
2-­‐tert-­‐butyl	  4-­‐methyl	  4-­‐(tert-­‐butoxycarbonylamino)-­‐1-­‐((S)-­‐1-­‐phenylethyl)pyrrolidi-­‐	  
ne-­‐2,4-­‐dicarboxylate	  (39Y):	  	  To	  a	  stirring	  solution	  of	  ent-­‐41	  (2.3g,	  9.77mmoles)	  and	  40	  (2.0	  g,	  10mmoles)	  in	  PhMe	  (100mL)	  was	  added	  CH2O(n)	  (600mg,	  20mmoles,	  2equiv).	  	  The	  reaction	  mixture	  was	  fitted	  with	  a	  Dean-­‐Stark	  trap	  and	  heated	  to	  reflux.	  	  The	  reaction	  mixture	  was	  stirred	  overnight	  then	  chromatographed	  on	  silica	  (gradient	  elution	  over	  16	  column	  volumes	  from	  0-­‐50%	  EtOAc	  in	  Hexanes).	  	  The	  desired	  fractions	  were	  combined	  and	  concentrated	  to	  yield	  as	  yellow	  oil	  (2.5g,	  5.6mmoles,	  56%).	  	  	  	  1H	  NMR	  (500	  MHz,	  rt,	  CDCl3):	  δ	  7.33	  (m,	  5H),	  6.25	  (t,	  J=5.8	  Hz,	  1H),	  4.02	  (q,	  J=6.8	  Hz,	  1H),	  3.76	  (s,	  3H),	  3.32	  (m,	  3H),	  3.08	  (d,	  J=17.4,	  1H),	  1.44	  (s,	  9H),	  1.37	  (d,	  J=6.23,	  3H);	  13C	  NMR	  (125MHz,	  rt,	  CDCl3):	  δ	  172.3,	  170.9,	  165.1,	  143.3,	  129.4,	  127.6,	  127.0,	  81.1,	  81.0,	  60.4,	  52.7,	  52.3,	  48.7,	  28.3,	  19.2;	  LRESIQMS	  calcd	  for	  C24H36N2O6	  (M	  +	  H+)	  449.2573,	  measured	  449.4.	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4-­‐(((9H-­‐fluoren-­‐9-­‐yl)methoxy)carbonylamino)-­‐1-­‐(allyloxycarbonyl)-­‐4-­‐
















3.5mmoles,	  70%).	  	  1H	  NMR	  (500	  MHz,	  365K,	  DMSO-­‐d6):	  δ	  8.49	  (bs,	  1H),	  8.11	  (d,	  J	  =	  7.45	  Hz,	  2H),	  7.92	  (d,	  J	  =	  7.1	  Hz,	  2H),	  7.64	  (t,	  J	  =	  7.3	  Hz,	  7.4	  Hz,	  2H),	  7.56	  (t,	  J	  =	  7.3	  Hz,	  7.2	  Hz,	  2H),	  6.17	  (m,	  1H),	  5.52	  (t,	  J	  =	  16.7	  Hz,	  16.7	  Hz,	  1H),	  5.43	  (dd,	  J	  =	  10.5	  Hz,	  17.9	  Hz,	  10.5	  Hz,	  1H),	  4.77	  (m,	  2H),	  4.54	  (m,	  4H),	  4.29	  (dd,	  J	  =	  11.2	  Hz,	  24.2	  Hz,	  11.2	  Hz,	  1H),	  3.82	  (s,	  3H),	  3.80	  (m,	  1H),	   3.11	   (m,	   1H);	   );	   13C	   NMR	   (125MHz,	   365K,	   DMSO-­‐d6):	   δ	   174.8,	   171.8,	   157.6,	   155.6,	  155.6,	   143.6,	   141.0,	   133.5,	   128.7,	   128.4,	   128.2,	   126.8,	   116.4,	   67.3,	   65.1,	   55.0,	   54.8,	   52.2,	  50.9,	  37.2;	  LRESIQMS	  calcd	  for	  C132H138N10O40	  (M	  +	  H+)	  494.1689,	  measured	  494.2.	  	  
4-­‐(((9H-­‐fluoren-­‐9-­‐yl)methoxy)carbonylamino)-­‐1-­‐(allyloxycarbonyl)-­‐4-­‐
(methoxycarbonyl)	  pyrrolidine-­‐2-­‐carboxylic	  acid	  (42Y):	  	  To	  a	  stirring	  solution	  of	  39Y	  (2.3g,	  5mmoles)	  in	  THF	  (50mL)	  was	  added	  Pd(OH)2	  (75mg).	  	  The	   reaction	  mixture	  was	   then	   degassed	   and	   charged	  with	   H2	   (g)	   and	   stirred	   overnight	  then	  sparged	  with	  Ar	  (g).	   	  To	   this	  solution	  was	  added	  Alloc-­‐Cl	   (530uL,	  5mmoles,	  1equiv)	  followed	  by	  DIPEA	   (1.75mL,	  10mmoles,	   2equiv).	   	  The	   reaction	  mixture	  was	   stirred	   for	  4	  hours	  then	  diluted	  with	  EtOAc.	  	  The	  solution	  was	  filtered	  then	  washed	  with	  sat.	  NH4Cl	  (aq)	  x	   3,	   sat.	   NaCl	   (aq)	   x	   2,	   dried	   over	   Na2SO4,	   filtered,	   and	   concentrated	   under	   reduced	  pressure.	  	  The	  residue	  was	  dissolved	  in	  DCM	  (20mL).	  	  To	  this	  reaction	  mixture	  was	  added	  TFA	   (10mL)	   and	   the	   reaction	  mixture	   was	   stirred	   for	   4	   hours	   then	   concentrated	   under	  reduced	  pressure.	   	   The	   residue	  was	   diluted	  with	   PhMe	   and	   concentrated	   under	   reduced	  pressure	   and	   further	   dried	   overnight	   under	   high	   vacuum.	   	   The	   residue	  was	   dissolved	   in	  DCM	   (50mL)	   and	   DIPEA	   (1.75,	   10mmoles,	   2equiv)	   was	   added	   followed	   by	   Fmoc-­‐OSu	  (1.69g,	   5mmoles,	   1equiv).	   	   The	   reaction	  mixture	  was	   stirred	  overnight	   then	  diluted	  with	  EtOAc.	   	  The	   solution	  was	  washed	  with	   sat.	  NH4Cl	   (aq)	  x	  3,	   sat.	  NaCl	   (aq)	  x	  2,	  dried	  over	  Na2SO4,	   filtered,	   and	   concentrated	   under	   reduced	   pressure.	   The	   residue	   was	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chromatographed	  on	  silica	  (gradient	  elution	  over	  16	  column	  volumes	  from	  0-­‐5%	  MeOH	  in	  DCM).	  	  The	  desired	  fractions	  were	  combined	  and	  concentrated	  to	  yield	  a	  yellow	  solid	  (1.7g,	  3.5mmoles,	  70%).	  	  1H	  NMR	  (500	  MHz,	  365K,	  DMSO-­‐d6):	  δ	  8.49	  (bs,	  1H),	  8.11	  (d,	  J	  =	  7.5	  Hz,	  2H),	  7.92	  (d,	  J	  =	  7.1	  Hz,	  2H),	  7.64	  (t,	  J	  =	  7.3	  Hz,	  7.4	  Hz,	  2H),	  7.56	  (t,	  J	  =	  7.30	  Hz,	  7.20	  Hz,	  2H),	  6.17	  (m,	  1H),	  5.52	  (t,	  J	  =	  16.7	  Hz,	  16.7	  Hz,	  1H),	  5.43	  (dd,	  J	  =	  10.5	  Hz,	  17.9	  Hz,	  10.5	  Hz,	  1H),	  4.77	  (m,	  2H),	  4.54	  (m,	  4H),	  4.29	  (dd,	  J	  =	  11.2	  Hz,	  24.2	  Hz,	  11.2	  Hz,	  1H),	  3.82	  (s,	  3H),	  3.80	  (m,	  1H),	   3.11	   (m,	   1H);	   );	   13C	   NMR	   (125MHz,	   365K,	   DMSO-­‐d6):	   δ	   174.8,	   171.8,	   157.6,	   155.6,	  155.6,	   143.6,	   141.0,	   133.5,	   128.7,	   128.4,	   128.2,	   126.8,	   116.4,	   67.3,	   65.1,	   55.0,	   54.8,	   52.2,	  50.9,	  37.2;	  LRESIQMS	  calcd	  for	  C132H138N10O40	  (M	  +	  H+)	  494.1689,	  measured	  494.2.	  
	  	  
Solid	  Phase	  Synthesis	  	  
General	  procedure	  (A):	  Attachment	  to	  Trityl	  resin	  	  To	   a	   solution	   of	   the	   amino	   acid	   (10	   equivalents	   based	   on	   resin	   loading)	   in	   DCM	  (3mL/mmole	  of	  amino	  acid)	  was	  added	  DIPEA	  (5	  equivalents	  based	  on	  resin	  loading).	  The	  reaction	  mixture	  was	   added	   to	   a	   portion	   of	   resin	   in	   a	   solid	   phase	   reactor.	   The	   reaction	  mixture	  was	  stirred	   for	  4	  hours.	  The	  resin	  was	   filtered	  and	  washed	  with	  DMF,	  DCM,	   IPA,	  DCM	  and	  DMF.	  	  
General	  procedure	  (B):	  HATU	  coupling	  	  To	  a	  solution	  of	  amino	  acid	  (3	  equivalents	  based	  on	  resin	  loading)	  and	  HATU	  (3	  equivalents	  based	   on	   resin	   loading	   in	   NMP	   (5mL/mmole	   of	   amino	   acid)	   was	   added	   DIPEA	   (6	  equivalents	  based	  on	  resin	  loading).	  The	  reaction	  mixture	  was	  agitated	  for	  5	  minutes	  then	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added	  to	  a	  pre-­‐swelled	  (with	  DMF)	  portion	  of	  resin	  in	  a	  solid	  phase	  reactor	  and	  stirred	  for	  45	  minutes.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  IPA,	  DCM	  and	  DMF.	  	  
General	  procedure	  (C):	  Fmoc	  deprotection	  	  A	  solution	  of	  20%	  of	  piperidine	  in	  DMF	  (15mL/mmole	  based	  on	  resin	  loading)	  was	  added	  to	   a	   pre-­‐swelled	   (with	  DMF)	   portion	   of	   resin	   in	   a	   solid	   phase	   reactor	   and	   stirred	   for	   15	  minutes.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  IPA,	  DCM	  and	  DMF.	  
General	  procedure	  (D):	  Alloc	  deprotection	  	  A	   solution	   of	   borane:dimethylamine	   complex	   (6	   equivalents	   based	   on	   resin	   loading)	   in	  DCM	   (10mL/mmole	   based	   on	   resin	   loading)	   was	   added	   to	   a	   pre-­‐swelled	   (with	   DMF)	  portion	   of	   resin	   in	   a	   solid	   phase	   reactor	   and	   stirred	   for	   5	  minutes.	   To	   this	   solution	  was	  added	   a	   solution	   of	   tetrakis(triphenylphosphine)palladium	   (0)	   (0.1	   equivalents	   based	  on	  resin	   loading)	   in	  DCM	   (10mL/mmole	   based	   on	   resin	   loading).	   The	   reaction	  mixture	  was	  stirred	  for	  1	  hour.	  The	  resin	  was	  filtered	  and	  washed	  with	  DMF,	  DCM,	  IPA,	  DCM	  and	  DMF.	  	  
General	  procedure	  (E):	  Liberation	  from	  Trityl	  resin	  	  A	   solution	  of	  5%	  TIPS	   and	  5%	  water	   in	  TFA	   (25	  mL/mmole	  based	  on	   resin	   loading	  was	  added	   to	   a	   portion	   of	   resin	   (successively	   washed	   with	   DCM	   and	  MeOH,	   and	   thoroughly	  dried	  under	  vacuum)	  and	  stirred	  for	  4	  hours.	  The	  resin	  was	  filtered	  and	  rinsed	  with	  TFA.	  The	  filtrate	  was	  concentrated,	  reconstituted	  in	  50%	  MeCN	  in	  water	  (0.1%	  formic	  acid)	  and	  freeze-­‐dried.	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  a)	   Pro4	   monomer,	   DIPEA,	   DCM;	   b)	   1:4	   piperidine/DMF;	   c)	   Fmoc-­‐Tyr(tBu)-­‐OH,	   HATU,	  DIPEA,	  NMP;	  d)	  (PPh3)4Pd,	  BH3:DMA,	  DCM,	  48:1:1	  TFA/TIPS/H2O.	  	  
43X	  	  Trityl	  resin	  (100mg,	  100umoles	  loading)	  was	  placed	  in	  a	  4mL	  solid	  phase	  reactor.	  	  42X	  was	  attached	   according	   to	   general	   procedure	   (A)	   using	   DCM	   (4.5mL)	   and	   DIPEA	   (116uL,	  750umoles).	   	  The	   terminal	  Fmoc	  group	  was	  removed	  according	   to	  general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  



























































The	   Alloc	   group	   was	   removed	   according	   to	   general	   procedure	   (D)	   using	  borane:dimethylamine	   complex	   (53mg,	   900umoles)	   in	   DCM	   (2.5mL)	   and	  tetrakis(triphenylphosiphine)palladium(0)	  (17mg,	  15umoles)	  in	  DCM	  (2mL).	  	  	  
	  
43X	  was	  liberated	  from	  the	  resin	  according	  to	  general	  procedure	  (E)	  using	  3.75	  mL	  of	  the	  cleavage	  cocktail.	  	  The	  residue	  was	  reconstituted	  in	  50%	  MeCN	  in	  water	  (0.1%	  formic	  acid)	  and	   purified	   by	   reverse-­‐phase	   chromatography	   (gradient	   elution	   over	   30	   minutes	   from	  water	   (0.1%	   formic	   acid)	   to	   50%	  MeCN	   in	  water	   (0.1%	   formic	   acid).	   	   Desired	   fractions	  were	  combined	  and	  freeze-­‐dried	  to	  yield	  a	  white	  powder.	  
	  
43Y	  	  Trityl	  resin	  (100mg,	  100umoles	  loading)	  was	  placed	  in	  a	  4mL	  solid	  phase	  reactor.	  	  42Y	  was	  attached	   according	   to	   general	   procedure	   (A)	   using	   DCM	   (4.5mL)	   and	   DIPEA	   (116uL,	  750umoles).	   	  The	   terminal	  Fmoc	  group	  was	  removed	  according	   to	  general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  
	  Fmoc-­‐Tyr(tBu)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	   (B)	  using	   HATU	   (171mg,	   450umoles),	   NMP	   (2.25mL),	   and	   DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL)	  and	  the	  reaction	  time	  was	  extended	  to	  2	  hour.	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The	   Alloc	   group	   was	   removed	   according	   to	   general	   procedure	   (D)	   using	  borane:dimethylamine	   complex	   (53mg,	   900umoles)	   in	   DCM	   (2.5mL)	   and	  tetrakis(triphenylphosiphine)palladium(0)	  (17mg,	  15umoles)	  in	  DCM	  (2mL).	  	  	  
	  
43Y	  was	  liberated	  from	  the	  resin	  according	  to	  general	  procedure	  (E)	  using	  3.75	  mL	  of	  the	  cleavage	  cocktail.	  	  The	  residue	  was	  reconstituted	  in	  50%	  MeCN	  in	  water	  (0.1%	  formic	  acid)	  and	   purified	   by	   reverse-­‐phase	   chromatography	   (gradient	   elution	   over	   30	   minutes	   from	  water	   (0.1%	   formic	   acid)	   to	   50%	  MeCN	   in	  water	   (0.1%	   formic	   acid).	   	   Desired	   fractions	  were	  combined	  and	  freeze-­‐dried	  to	  yield	  a	  white	  powder.	  
	  
43ss	  	  Trityl	  resin	  (100mg,	  100umoles	  loading)	  was	  placed	  in	  a	  4mL	  solid	  phase	  reactor.	  	  Pro4SS	  (1)	   was	   attached	   according	   to	   general	   procedure	   (A)	   using	   DCM	   (4.5mL)	   and	   DIPEA	  (116uL,	   750umoles).	   	   The	   terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  
	  Fmoc-­‐Tyr(tBu)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	   (B)	  using	   HATU	   (171mg,	   450umoles),	   NMP	   (2.25mL),	   and	   DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL)	  and	  the	  reaction	  time	  was	  extended	  to	  2	  hour.	  	  	  
	  
43ss	  was	  liberated	  from	  the	  resin	  according	  to	  general	  procedure	  (E)	  using	  3.75	  mL	  of	  the	  cleavage	  cocktail.	  	  The	  residue	  was	  reconstituted	  in	  50%	  MeCN	  in	  water	  (0.1%	  formic	  acid)	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and	   purified	   by	   reverse-­‐phase	   chromatography	   (gradient	   elution	   over	   30	   minutes	   from	  water	   (0.1%	   formic	   acid)	   to	   50%	  MeCN	   in	  water	   (0.1%	   formic	   acid).	   	   Desired	   fractions	  were	  combined	  and	  freeze-­‐dried	  to	  yield	  a	  white	  powder.	  
	  
43sr	  	  Trityl	  resin	  (100mg,	  100umoles	  loading)	  was	  placed	  in	  a	  4mL	  solid	  phase	  reactor.	  	  Pro4SR	  (2)	   was	   attached	   according	   to	   general	   procedure	   (A)	   using	   DCM	   (4.5mL)	   and	   DIPEA	  (116uL,	   750umoles).	   	   The	   terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  
	  Fmoc-­‐Tyr(tBu)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	   (B)	  using	   HATU	   (171mg,	   450umoles),	   NMP	   (2.25mL),	   and	   DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL)	  and	  the	  reaction	  time	  was	  extended	  to	  2	  hour.	  	  	  
	  
43sr	  was	  liberated	  from	  the	  resin	  according	  to	  general	  procedure	  (E)	  using	  3.75	  mL	  of	  the	  cleavage	  cocktail.	  	  The	  residue	  was	  reconstituted	  in	  50%	  MeCN	  in	  water	  (0.1%	  formic	  acid)	  and	   purified	   by	   reverse-­‐phase	   chromatography	   (gradient	   elution	   over	   30	   minutes	   from	  water	   (0.1%	   formic	   acid)	   to	   50%	  MeCN	   in	  water	   (0.1%	   formic	   acid).	   	   Desired	   fractions	  were	  combined	  and	  freeze-­‐dried	  to	  yield	  a	  white	  powder.	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43rr	  	  Trityl	  resin	  (100mg,	  100umoles	  loading)	  was	  placed	  in	  a	  4mL	  solid	  phase	  reactor.	  	  Pro4RR	  (3)	   was	   attached	   according	   to	   general	   procedure	   (A)	   using	   DCM	   (4.5mL)	   and	   DIPEA	  (116uL,	   750umoles).	   	   The	   terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL).	  	  	  
	  Fmoc-­‐Tyr(tBu)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	   (B)	  using	   HATU	   (171mg,	   450umoles),	   NMP	   (2.25mL),	   and	   DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL)	  and	  the	  reaction	  time	  was	  extended	  to	  2	  hour.	  	  	  
	  
43rr	  was	  liberated	  from	  the	  resin	  according	  to	  general	  procedure	  (E)	  using	  3.75	  mL	  of	  the	  cleavage	  cocktail.	  	  The	  residue	  was	  reconstituted	  in	  50%	  MeCN	  in	  water	  (0.1%	  formic	  acid)	  and	   purified	   by	   reverse-­‐phase	   chromatography	   (gradient	   elution	   over	   30	   minutes	   from	  water	   (0.1%	   formic	   acid)	   to	   50%	  MeCN	   in	  water	   (0.1%	   formic	   acid).	   	   Desired	   fractions	  were	  combined	  and	  freeze-­‐dried	  to	  yield	  a	  white	  powder.	  
	  
43rs	  	  Trityl	  resin	  (100mg,	  100umoles	  loading)	  was	  placed	  in	  a	  4mL	  solid	  phase	  reactor.	  	  Pro4RS	  (4)	   was	   attached	   according	   to	   general	   procedure	   (A)	   using	   DCM	   (4.5mL)	   and	   DIPEA	  (116uL,	   750umoles).	   	   The	   terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	  procedure	  (C)	  using	  20%	  piperidine	  in	  DMF	  (2.25mL).	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  Fmoc-­‐Tyr(tBu)-­‐OH	  (211mg,	  450umoles)	  was	  coupled	  according	   to	  general	  procedure	   (B)	  using	   HATU	   (171mg,	   450umoles),	   NMP	   (2.25mL),	   and	   DIPEA	   (156uL,	   900umoles).	   	   The	  terminal	   Fmoc	   group	   was	   removed	   according	   to	   general	   procedure	   (C)	   using	   20%	  piperidine	  in	  DMF	  (2.25mL)	  and	  the	  reaction	  time	  was	  extended	  to	  2	  hour.	  	  	  
	  
43rs	  was	  liberated	  from	  the	  resin	  according	  to	  general	  procedure	  (E)	  using	  3.75	  mL	  of	  the	  cleavage	  cocktail.	  	  The	  residue	  was	  reconstituted	  in	  50%	  MeCN	  in	  water	  (0.1%	  formic	  acid)	  and	   purified	   by	   reverse-­‐phase	   chromatography	   (gradient	   elution	   over	   30	   minutes	   from	  water	   (0.1%	   formic	   acid)	   to	   50%	  MeCN	   in	  water	   (0.1%	   formic	   acid).	   	   Desired	   fractions	  were	  combined	  and	  freeze-­‐dried	  to	  yield	  a	  white	  powder.	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6.0	  Concluding	  Remarks	  	  	   This	   dissertation	   details	   the	   efforts	   to	   the	   progress	   towards	   a	   class	   of	   synthetic	  molecules	  with	   the	  eventual	  goal	   to	   serve	  as	  an	  alternative	   to	  natural	  proteins.	   	  Proteins	  possess	   a	   structural	   hierarchy	   of	   sequence	   (primary	   structure),	   local	   environments	  (secondary	   structure),	   global	   environments	   (tertiary	   structure)	   that	   are	   all	   require	   for	  protein	  function.	   	  Following	  this	  dogma	  we	  have	  created	  a	  series	  of	  chiral	  building	  blocks	  that	  carry	  chemically	  relevant	  functional	  groups.	   	   	  We	  can	  assemble	  these	  building	  blocks	  into	  rod-­‐like	  oligomers	  that	  position	  small	  collections	  of	  functional	  groups	  in	  3-­‐dimensional	  space	   for	   diverse	   applications.	   	   	   To	   increase	   our	   effectiveness	   to	   discovering	   useful	  functional	  molecules,	   we	   have	   gained	   access	   to	   our	   principle	   building	   block	   (Pro4	   class,	  based	  on	   the	  5-­‐membered	   ring	  heterocycle)	   through	  means	  of	   reaction	  optimization	  and	  scale	  up	  to	  600	  millimoles.	  	  We	  are	  continuing	  to	  modify	  and	  optimize	  a	  general	  solid	  phase	  synthesis	   strategy	   for	   making	   the	   oligomers.	   	   Our	   current	   strategy	   has	   allowed	   for	   the	  concurrent	  synthesis	  of	  6	  oligomers	  and	  has	  been	  demonstrated	  effective	  on	  scales	  up	  to	  2	  millimoles	   for	   each	   oligomer.	   	   With	   these	   oligomers,	   we	   have	   demonstrated	   competent	  modeling	   strategies	   for	   hypothesis	   driven	   application	   development	   toward	   electron	  transfer	   processes,	   catalysis,	   and	  molecular	   recognition,	   all	   three	   important	   functions	   of	  natural	   proteins.	   	  We	   have	   expanded	   on	   these	   principles	   to	   create	   larger,	   3-­‐dimensional	  assemblies	   by	   utilizing	   the	   oligomers	   as	   intermediate	   building	   materials.	   	   We	   have	  developed	   strategies	   to	   selectively	   cross-­‐link	   2	   and	   3	   oligomers	   together	   to	   create	  something	  more	  protein-­‐like.	  	  We	  are	  just	  now	  actualizing	  the	  first	  macromolecules	  of	  this	  kind,	   which	   we	   call	   “Fauxteins”.	   	   We	   are	   currently	   concerned	   with	   understanding	   their	  structures	  and	  have	  developed	  tools	  to	  characterize	  them,	  principally,	  the	  implementation	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of	  the	  NMR	  active	  15N	  isotope	  of	  nitrogen.	   	   	   	  Once	  we	  gain	  information	  of	  the	  structure	  of	  these	   large	  macromolecules,	   we	  will	   develop	   them	   for	   the	   recreation	   of	   protein	   binding	  surfaces	   and	   enzyme	   active	   sites.	   	   Successful	   development	   and	   execution	   of	   “Fauxteins”	  would	  mark	   a	   gigantic	   leap	   into	   the	   chemical	   space,	   which	   up	   until	   now,	   has	   only	   been	  accessible	  via	  proteins.	  
